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Abstract
The purpose of this experimental research was to determine whether using delta-MELD
as a criterion for the liver transplant patient selection process could improve the U.S. liver
allocation system. This research closed a gap in current literature on the utility of deltaMELD for liver transplant patient selection. The frameworks of systems theory, the
analytic hierarchy process, and the Kalman filter contributed to the development of 2
simulation models of the liver allocation system: one that used delta-MELD and one that
did not use delta-MELD. The research question examined whether using delta-MELD
could improve the liver allocation system by reducing the number of patients dropping
off the wait list and lowering the average MELD score. Statistical t tests of 2
independent scenarios (allocation with and without delta-MELD), each with 70 runs of
180 simulated days on the liver allocation wait list, did not indicate a significant
improvement to the liver allocation system by using delta-MELD for liver allocation.
However, observations made from the simulation experiment, such as the median patient
wait time being 11 months and delta-MELD being more variable at the end-stage of liver
diseases, provided insights into how to improve the model of the liver allocation process.
In addition, observations made from the status 1 patient subgroup (patients in ICU with
about 7 days to live), which were excluded from this research, suggested including status
1 patients and expanding the simulation timespan from 180 to 360 days to better capture
the delta-MELD variability from patients at the end-stage of liver disease. This research
provides empirical evidence on the applicability of the delta-MELD criterion for nonstatus 1 patients, and yields recommendations to include status 1 patients in an improved
simulation of the donor liver system while using delta-MELD as criterion.

Using the Delta-Model for End-Stage Liver Disease to Improve the Decision-Making
Process for the Donor Liver System

by
Joanne Chin

MS, Hofstra University
BS, New York University

Dissertation Submitted in Partial Fulfillment
of the Requirements for the Degree of
Doctor of Philosophy in
Applied Management and Decision Science

Walden University
August 2015

Acknowledgement
The UNOS STAR database is the largest and most comprehensive organ
transplant database for research in the United States. My dissertation reference of the
UNOS STAR database is supported by the U.S. Department of Health and Human
Services: Health Resources and Services Administration contract 234-2005-370011c.
In full gratitude, I would like to acknowledge and thank my dissertation
committee for guiding me through my dissertation process to completion, Dr. McAllister,
Dr. Spencer, and Dr. Kilmer. I have been fortunate to have Dr. McAllister as my
dissertation chair, who since the beginning of my program, has encouraged, mentored,
and assisted me through my KAM and dissertation writing. I thank Dr. Spencer for his
KAM and dissertation guidance. I thank Dr. Kilmer for his dissertation feedback.
I am blessed to have the constant encouragement, inspiration, support, and
patience from my husband Steve, our family and friends, that helped me focus on my
research and reach my program goals.

Table of Contents
Chapter 1: Introduction ........................................................................................................1
Definitions......................................................................................................................3
Background ....................................................................................................................7
Problem Statement .........................................................................................................9
Purpose.........................................................................................................................10
Framework ...................................................................................................................11
Research Questions ......................................................................................................13
Nature of Study ............................................................................................................15
Significance of Research..............................................................................................16
Implications for Social Change ....................................................................................17
Scope and Delimitations ..............................................................................................18
Assumptions.................................................................................................................19
Limitations ...................................................................................................................20
Acknowledgement .......................................................................................................21
Conclusion ...................................................................................................................22
Chapter 2: Literature Review .............................................................................................24
The MELD Era ............................................................................................................25
MELD Variable .................................................................................................... 25
MELD and MELD-based Models ......................................................................... 31
Delta-MELD: Debate and Gap in Literature ........................................................ 36
Literature Review on Time Series Analysis Method ...................................................42
i

Kalman Filter ........................................................................................................ 42
Kalman State Space, Prediction, and Estimation .................................................. 46
Kalman Error Management................................................................................... 49
Trends in the Liver Allocation System ........................................................................51
MELD Era Objectives........................................................................................... 51
Expanded Criteria Donor and Donor Risk Index .................................................. 55
Increased MELD Scores and Extended Intensive Care Unit Stays ...................... 60
Decision-Making of Multiple Objectives: Urgency, Utility, and Survival ........... 65
Literature on Multiple Criteria and Objective Decision-Making ................................71
Analytic Hierarchy Process / Analytic Network Process ..................................... 71
AHP Background and Applications ...................................................................... 73
AHP Decision-Making with delta-MELD for Simulation .................................... 77
Conclusion ...................................................................................................................79
Chapter 3: Research Method ..............................................................................................81
The Research Design ...................................................................................................82
Research Questions and Hypotheses .................................................................... 83
Research Process and Steps .................................................................................. 84
Simulation Overview ...................................................................................................85
Variables and Parameters in this Research ........................................................... 85
Data Collection through Secondary Data ............................................................. 92
Data Organization for the Simulation ................................................................... 93
Internal and External Validity of the Simulation Components............................. 98
ii

The Simulation Model ...............................................................................................103
Waitlist Entry ...................................................................................................... 104
Donor Liver Arrival ............................................................................................ 104
Disease Progression ............................................................................................ 107
Waitlist Patient Management .............................................................................. 108
Simulation Inputs and Processing ..............................................................................108
Input Data............................................................................................................ 108
Input Data for Simulation without delta-MELD ................................................. 109
Input Data for Simulation with delta-MELD ...................................................... 110
Simulation Outputs ....................................................................................................114
Experiment and Sample Size .....................................................................................114
Hypothesis Testing.....................................................................................................116
Pilot Testing and Scenario Runs ................................................................................120
Summary ....................................................................................................................121
Chapter 4: Simulation Results and Analysis ....................................................................124
Research Questions and Hypotheses .........................................................................124
Pilot Testing and Verification of the Simulation Model ............................................126
Waitlist Entry and Waitlist Patient Management Processes ............................... 128
Disease Progression Process ............................................................................... 131
Donor Liver Arrival Process ............................................................................... 134
Weekly Reports ................................................................................................... 137
Statistics from One Simulation Run ................................................................... 138
iii

Experimental Outcome ..............................................................................................139
Results ........................................................................................................................143
Research Question One ....................................................................................... 144
Research Question Two ...................................................................................... 144
Summary ....................................................................................................................144
Chapter 5: Research Conclusion ......................................................................................146
A Summary of the Research ......................................................................................146
Explanation of Simulation Results.............................................................................148
Recommendations for Future Studies ........................................................................151
Conclusion .................................................................................................................157
References ........................................................................................................................159
Appendix A: Kalman Filter and Error Ellipse .................................................................168
Appendix B: Analytic Hierarchy Process (AHP) ............................................................174
Appendix C: Simulation Programming Notes .................................................................182
Appendix D: Statistics Notes ...........................................................................................199

iv

List of Tables
Table 1. Research Process and Steps ................................................................................ 84
Table 2. Donor Risk Factors ............................................................................................. 88
Table 3. Recipient Risk Factors ........................................................................................ 89
Table 4. Hazard Ratios based on MELD ........................................................................ 108
Table 5. AHP Weights and Ranking without delta-MELD ............................................ 110
Table 6. AHP Weights and Ranking with delta-MELD ................................................. 111
Table 7. Number of Region 9 Liver Transplants from Deceased Donors ...................... 113
Table 8. Simulation Variables and Parameters ............................................................... 127
Table 9. Waitlist Entry and Waitlist Patient Management Processes Verification......... 129
Table 10. Disease Progression Process Steps for Verification ....................................... 131
Table 11. Donor Liver Arrival Process Steps for Verification ....................................... 134
Table 12. MELDmean without delta-MELD ..................................................................... 141
Table 13. MELDmean with delta-MELD .......................................................................... 141
Table B1. Paired Comparison: Value-Description ......................................................... 176
Table B2. AHP Table of Weights of the Criteria............................................................ 176
Table B3. AHP Table of Weights of Alternatives according to MELD ......................... 178
Table B4. AHP Table of Weights of Alternatives according to Blood Type ................. 179
Table B5. AHP Table of Weights of Alternatives according to Body Structure ............ 180
Table B6. AHP Table Ranking of Alternatives .............................................................. 181
Table D1. Chi-square Goodness of Fit test for Normality .............................................. 203

v

List of Figures
Figure 1. Hierarchy of MELD levels for liver allocation ..................................................98
Figure 2. Analytic hierarchy process structure of objectives and criteria........................102
Figure 3. Donor liver processing based on liver quality ..................................................106
Figure 4. Overview of simulation data processing ..........................................................112
Figure 5. Waitlist Entry and Waitlist Patient Management processes .............................130
Figure 6. Disease Progression process-1 .........................................................................132
Figure 7. Disease Progression process-2 .........................................................................133
Figure 8. Donor Liver Arrival process-1 .........................................................................135
Figure 9. Donor Liver Arrival process-2 .........................................................................136
Figure 10. Weekly reports: Disease progression .............................................................137
Figure 11. Statistics from one simulation run .................................................................138
Figure 12. Experimental outcome ....................................................................................140
Figure C1. Initialize data panel .......................................................................................182
Figure C2. Setup scenario(s) panel .................................................................................185
Figure C3. Run scenario(s) panel.....................................................................................187
Figure C4. View disease progression panel .....................................................................191
Figure C5. View liver arrival panel .................................................................................193
Figure C6. View t tests of two independent populations’ parameters panel ...................194
Figure C7. Simulation progress panel .............................................................................197
Figure D1. Goodness of fit-test for normality .................................................................202

vi

1
Chapter 1: Introduction
Due to dissatisfaction with the existing liver allocation system and to improved
predictive models, the U.S. liver allocation system was revised in 2000 in an effort to
better balance the urgency and utility tradeoffs (Freeman, 2009). Bernardi, Gitto, and
Biselli (2011) found that the model for end-stage liver disease (MELD) scoring system
was originally developed by the Mayo Clinic in Rochester, Minnesota to predict the risk
of death in patients undergoing liver transplant and was validated as a reproducible and
reasonably accurate predictor of mortality in patients with chronic liver disease. From an
urgency point of view, the MELD score offered multiple advantages for prioritizing
waiting liver transplant candidates. Freeman (2009) further explained that outside of the
liver allocation role which the MELD score supports, many liver transplant researchers
have reported that changes in the MELD score over time (delta-MELD) have been
associated with increased waiting list mortality. However, the most significant changes
tend to occur very late in the course of the disease, which could limit the prognostic
usefulness of the delta-MELD measurement. On the other hand, Foxton et al. (2006) and
Young et al. (2006) suggested that the current system can further be refined by the use of
delta-MELD, the change in MELD score over time. However, there have been
limitations regarding how delta-MELD should be interpreted and computed as a predictor
of disease progression and waiting list death.
In this research, I investigated the utility of the delta-MELD parameter for
refining the MELD-based allocation system. Currently, the MELD scores can be used
consistently across all types of patients with chronic liver diseases regardless of the
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country or region, and regardless of the biases clinical observers may have in assessing
liver disease severity. Hence, any improvement to the existing MELD-based scoring
system would tend to be MELD-based (Bernardi et al., 2011).
Bambha et al. (2004) described the MELD score as a formula of three parameters
to indicate the level of liver disease severity. The MELD score is calculated using serum
creatinine, serum total bilirubin, and the international normalized ratio (INR) according
to the following formula as is currently used by the United Network for Organ Sharing
(UNOS) organization.

= 9.57 ∗

+ 3.78 ∗

+ 11.20 ∗
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)
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Bambha et al. (2004) also provided the definition of delta-MELD as the
difference between the current-MELD score and the lowest of all serial-MELD scores in
the preceding 30-day window. Thus, delta-MELD is defined as the maximum change in
MELD score over a 30-day period. Current-MELD is defined as the most recent MELD
score available for each patient. The timing of the current-MELD score depends upon
the time lag used in the model. Bambha et al. concluded that the predictive value of
delta-MELD is limited, and that further studies based on prospectively collected
laboratory data in which the frequency of MELD measurements are controlled could
address this issue more definitively. However, other researchers have suggested that
delta-MELD can be beneficial towards the improvement of the MELD system (for
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example Foxton et al., 2006; Young et al., 2006). This is the conflict and gap that was
investigated in this research.
In Chapter 1, I describe the background, problem statement, purpose, theoretical
framework, research questions, and nature of study of this research. The limitations,
assumptions, and social implication of this research are also provided. Chapter 1 also
contains a content description of Chapter 2 and Chapter 3.
In Chapter 2, I provide the literature review with explanations of the investigation
of the delta-MELD parameter, background on the objectives of the liver allocation
system, data collection methods, and decision-making methods that would address the
research questions. The literature review contains an evaluation of multiple objectives of
the liver allocation system, the criteria for each of the objectives, and the statistical and
decision-making methodologies proposed for the simulation model.
In Chapter 3, I describe the implementation of the simulation model, the
simulation experiment, the data to be collected, the computations, and the meaning of the
output data. Furthermore, in Chapter 3, I provide details of the analytic hierarchy process
(AHP) parameters and the AHP decision process, and the functions behind the four
processes of the research simulation. I also provide description on the reliability and
validity of the research data collection, data processing, and data analysis of the
simulation scenarios with and without delta-MELD as a decision-making criterion.
Definitions
ABO: A, B, AB, and O blood types and their subtypes when used for allocation
(Organ Procurement and Transplantation Network, 2014).
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Analytic hierarchy process (AHP): A structured technique for organizing and
analyzing multiple criteria for decision-making based on mathematics and psychology
(Saaty, 1996).
Acute liver failure (ALF): Acute liver failure is a medical condition that includes
the rapid loss of liver function, in a matter of days or weeks, usually in a person with no
pre-existing liver disease (O’Grady, 2012).
Cold ischemic time (CIT): Cold ischemic time is the amount of time, usually
about 12–18 hours, after a donor liver is harvest for transplantation. Reducing the cold
ischemia time would improve the quality of the transplanted liver and CIT can be
lowered by lowering the logistical and transportation time (Burr & Shah, 2010).
Current-MELD: The most recent MELD score available for each patient (Bambha
et al., 2004).
Delta-MELD: The calculated difference between the current-MELD score from
the lowest of all serial-MELD scores in the preceding 30-day window. Thus, deltaMELD is defined as the maximum change in MELD over the 30-day period (Bambha et
al., 2004).
Donor risk index (DRI): Donor risk index is a measurement of the donor liver
quality based on nine factors (Foxton et al., 2010).
Expanded criteria donor (ECD): Organ Procurement Organizations consider
certain conditions of a donor to be expanded criteria donor (ECD) for a liver transplant
and the patient has to give informed consent to accept the liver. These conditions may
include a donor’s age of 70 years or above, a donor who is age 60 years with significant
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medical history, or a donor with a history of hepatitis B or hepatitis C (Rodrique, Hanto,
& Curry, 2011).
Graphical user interface (GUI): Graphical user interface is the interface that
provides text-based or graphical information to the user via a computer interface.
Hepatocellular carcinoma (HCC): Hepatocellular carcinoma is a liver cancer and
it is also known as malignant hepatoma.
Model for end-stage liver disease (MELD): Model for end-stage liver disease
score is used to quantify the severity of end-stage liver disease for liver transplant
planning (Bernardi, 2011).
Organ Procurement Organization (OPO): Organ Procurement Organization is an
organization accepted as a Member and is authorized by the Centers for Medicare and
Medicaid Services (CMS) to procure organs for transplantation. For each OPO, CMS
defines a geographic procurement territory within which the OPO concentrates its
procurement efforts. No OPO is limited to or granted exclusive procurement right to
procure organs in its territory (Organ Procurement and Transplantation Network, 2014).
Organ Procurement and Transplantation Network (OPTN): Organ Procurement
and Transplantation Network is an organization governed by the U.S. Department of
Health and Human Services and is formed by multiple committees to develop organ
transplantation policies (Organ Procurement and Transplantation Network, 2014).
Pediatric end-stage liver disease (PELD): PELD score is the pediatric version of
the MELD score for the purpose of liver transplant planning (Organ Procurement and
Transplantation Network, 2014).
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Scientific Registry of Transplant Recipients (SRTR): Scientific Registry of
Transplant Recipients is a national database of transplant statistics. (Scientific Registry
for Transplant Recipients, 2012).
Serial-MELD: The MELD scores collected over the 30 day window serially
(Bambha et al., 2004).
Standard criteria donor (SCD): Standard criteria donor liver comes from a
decease donor who is brain dead, but still has a beating heart, albeit may be supported by
a respirator. Unless the donor liver has been evaluated to have certain risk factors, it is a
SCD liver for liver transplant (Rodrique et al., 2011).
Survival outcomes following liver transplantation (SOFT): SOFT score is based
on the MELD score and other risk factors for assessment of overall survival outcomes in
order to consider waitlist mortality against posttranplant mortality (Rana, et al., 2008).
Transplant center: A hospital that is a member in which transplants are
performed. It is the responsibility of the transplant surgeon of the transplant center
receiving the organ to offer the surgeon’s candidate to ensure medical suitability of donor
organs for transplantation into the potential recipient according to the candidate’s blood
type and subtype (Organ Procurement and Transplantation Network, 2014).
Transplant program: A transplant center, or hospital, may have one or more
transplant programs. Each program oversees transplantation of one or more organ types
(Organ Procurement and Transplantation Network, 2014).
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United Network for Organ Sharing (UNOS): United Network for Organ Sharing
is a private, non-profit organization that manages the nation’s organ transplant system,
under contract with the federal government (United Network for Organ Sharing, 2014).
Waiting list: This list is a computerized list of candidates who are waiting to be
matched with specific donor organs in hopes of receiving transplants. Waiting list
candidates are registered on the Waiting list by member transplant centers. The
candidate’s transplant program would be responsible for ensuring the accuracy of
candidate ABO data on the waiting list (Organ Procurement and Transplantation
Network, 2014).
Background
Malinchoc et al. (2000) from the Mayo Clinic in Rochester, Minnesota, devised a
mathematical model to prioritize patients for liver transplantation based on medical
urgency, named the Mayo end-stage liver disease score. This model was proved to
accurately predict the probability of death within three months after the procedure.
Subsequently, the model name was changed from Mayo end-stage liver disease to model
for end-stage liver disease (MELD) and it was successfully validated in patients with
different liver disease severity. Bernardi et al. (2011) explained that because of this, the
time has come for a sickest-first policy to be reliably fulfilled, and the MELD score
became the means to allocate donor livers for medical transplant in the United States
from February 2002. Bernardi et al. further explained that MELD has several features of
an ideal prognostic model to predict the probability of survival. It incorporates objective
variables readily determined in all laboratories and each of these variables is weighted
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according to the influence on prognosis.
Bernardi et al. (2011) further elaborated that the MELD score is not a timedependent model, because it is computed by a single measurement of laboratory
parameters. In an attempt to weigh the time-related changes, the delta-MELD which is
defined as the difference between the MELD score calculated at two time points has been
proposed. Bernardi et al. noted that studies showed this new score was able to predict the
mortality risk of patients more accurately than standard MELD score alone. However,
Bernardi et al. also noted that there have also been other studies debating its usefulness in
predicting survival on the waiting list.
Having a time-dependent variable as a criterion could be beneficial to the liver
allocation system because a time-dependent parameter such as delta-MELD could help
align the MELD scores more accurately when assessing patients’ status upon an arrival of
donor liver. This is because pretransplant patients would not have the same time-stamps
of their latest MELD scores, and their MELD scores could vary due to liver deterioration
when an actual donor liver is made available.
Young et al. (2006) acknowledged that the allocation of donor livers through the
MELD score, implemented in the United States on February 2002 by United Network for
Organ Sharing (UNOS), has resulted in a fall in waiting list deaths in the United States.
In addition, liver transplant centers in the United States are able to transplant a sicker
population of patients with no deterioration in results. Foxton et al. (2006) suggested that
the current system can further be refined by the use of delta-MELD, the change in MELD
score over time. However, there have been limitations regarding how delta-MELD
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should be interpreted as a predictor of disease progression and waiting list death.
Young et al. (2006) also concluded that there is value in using delta-MELD score
for decision-making regarding the allocation of donor livers. However, there has been a
problem calculating delta-MELD due to the various collections of MELD data. Hence,
the data collected and studied by Young et al. has been considered biased. Young et al.
concluded that a study designed to minimize data collection bias was needed to fully
clarify the role of delta-MELD in liver allocation. Young et al. also concluded that using
MELD and delta-MELD in allocation decision-making could possibly improve overall
outcomes by allocating livers more efficiently to reduce waiting list deaths.
Rahman and Hodgson (2001) divided acute hepatic failure (AHF) into three
categories, which are hyperacute, acute, and subacute. Hyperacute is when
encephalopathy is developed within 7 days after the onset of jaundice. Acute is when
encephalopathy is developed in 8 to 28 days after the onset of jaundice. Subacute is
when encephalopathy is developed in 5 to 26 weeks after the onset of jaundice. These
classifications of hepatic failure suggest that not all liver diseases deteriorate at the same
rate or that the MELD score alone is an indicator of the most urgent patient in need of a
liver transplant. In the current donor liver system, when multiple matching recipients
have the same MELD scores, the patient who waited longest rather than the patient with
the faster deteriorating disease, will get the transplant.
Problem Statement
While there has been elaborate research on the MELD-based topic, there is a
gap in scholarly literature clarifying whether the delta-MELD parameter used as a
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recipient criterion in addition to the MELD score, together as primary criteria, could
refine the liver allocation system. Specifically, no research has been conducted in current
literature to analyze how using the delta-MELD parameter in addition to the MELD score
as a liver transplant selection criterion would affect the number of liver patients saved by
liver transplants. Overcoming a data collection bias of delta-MELD, as described by
Young et al. (2006), through statistical time series analysis techniques can depict an
accurate account of disease progression and in predicting patient waiting list outcomes.
Purpose
The purpose of this research was to address the lack of scholarly understanding
about the utility of the delta-MELD criterion by investigating whether using the deltaMELD criterion can improve and refine the liver transplant patient selection process of
the U.S. liver donor allocation system. Cholangitas and Burroughs (2012) stated that an
ideal donor liver allocation model should not only be able to allocate according to the
highest probability of dying before liver transplant, but also be able to predict which
patients have the lowest post-liver transplant mortality in order to improve utility (i.e. a
survival benefit system). In this research, I investigated whether the utilization of the
delta-MELD parameter could help reduce patients from dropping off of the waiting list
due to being too sick to undergo liver transplant as well as reduce the average MELD
score among pretransplant patients waiting for liver transplant.
O’Grady (2012) noted that patients undergoing liver transplantation with more
advanced MELD scores are more likely to have acute liver failure and have longer stays
in intensive care environments. Although this may not affect the outcome of post liver
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transplant, O’Grady noted that it is still an important medical transplant practice to
understand the different patterns of disease progression and to be able to assess prognosis
based on recognized prognostic models. For this reason, this research refers to deltaMELD that is based on the Kalman estimation reflecting MELD progression.
There has been a problem in calculating delta-MELD due to the various collection
methods of MELD data (Foxton et al., 2006; Young et al., 2006). Overcoming a data
collection bias of delta-MELD through statistical time series analysis techniques could
depict a real-life account of disease progression as well as predict patients’ waiting list
MELD outcomes.
Framework
The theoretical frameworks that shaped the simulation model and framed the
research questions were based on multi-criteria decision-making techniques of the
operations research discipline, and time series forecasting and estimation methods from
mathematical statistics. The research framework also has the objective of the U.S.
Federal law that mandates a sickest first system that would be employed for ranking
candidates for liver transplantation based on medical urgency (Freeman et al., 2009).
These methods, techniques, and objective were the conceptual and theoretical
frameworks for determining whether the liver allocation system could be improved upon.
They are mentioned here and discussed in greater detail in Chapter 2 and Chapter 3.
A multi-criteria decision-making tool for the selection of the most suited and
sickest patient was useful because there would be multiple objectives and criteria to
weigh in the selection consideration among the many patients waiting for a donor liver.
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Winston (2004) described that multi-criteria decision-making could be a complex process
because when multiple objectives are important to a decision-maker, it could be difficult
to choose among the many alternatives. By using a multi-criteria decision-making tool,
the AHP, the simulation would be an ideal method for reflecting the selection of the most
suitable patient.
Time series analysis is an arm of mathematical statistics that provides tools useful
for estimation and forecasting of time series values. Box, Jenkins, and Reinsel (2008)
explained that an intrinsic feature of a time series is that, typically, adjacent observations
can be dependent. The nature of this dependence among observations of a time series is
of considerable practical interest. Time series analysis is concerned with techniques for
the analysis of this dependence. This research applies time series analysis techniques to
determine and predict patients’ MELD and delta-MELD parameters.
Kalman filter is a technique for forecasting and estimating time series values and
it has its strength in the observability and controllability of time series data (Brockwell &
Davis, 2006). Asemoto (2010) described the Kalman filter as a statistical algorithm that
enables certain computations to be carried out for a model cast in state space form. The
Kalman filter is also known for its simplicity and straightforwardness of its algorithm.
This research employed a time series prediction of liver disease progression in order to
aid in the simulation model in computing the delta-MELD parameter for the selection of
compatible transplant recipients.
In summary, the theoretical frameworks that shaped the simulation model and
framed the research questions were the AHP technique and the Kalman filter. And the
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conceptual framework was to meet the objective of the U.S. Federal law that mandates a
sickest first system that would be employed for ranking candidates for liver
transplantation based on urgency (Freeman et al., 2009). These methods contributed to
the development of a simulation experiment to determine whether the current liver
allocation system could be improved upon.
Research Questions
Gotthardt et al. (2009) argued that their study was not only an analysis of the
number of deaths on the waiting list but also an analysis of the number of removals from
the waiting list due to patients’ poor condition. These combinations of numbers more
accurately reflect the natural history of liver diseases. Gotthardt et al. also stated that
while their data do not argue against the use of MELD scores to be taken to prioritize
patients during the initial period on the waiting list, their study showed that for patients
with longer times on waiting list, additional factors for assessment of patient prognosis
could assist in the development of a new scoring system for allocation. Hence, the
following were the research questions for this research.
1. Does a simulation model using the additional parameter of delta-MELD as a
patient selection criterion reduce the number of pretransplant patients who
dropped off of the waiting list?
The null and alternative hypotheses are as follows for the first research question:
Ho: There is no difference in the number of patients who dropped off of the
waiting list between simulation models with and without delta-MELD along with the
MELD score as primary criteria for patient selection in donor liver allocation.
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Ha: There is a difference in the number of patients who dropped off of the
waiting list between simulation models with and without delta-MELD along with the
MELD score as primary criteria for patient selection in donor liver allocation.
Quante, Benckert, Thelen, and Jonas (2012) stated that the implementation of the
MELD score system in Europe affected a change not only by the reduction in waitlist
mortality among pretransplant patients, but also in the average MELD score that
increased among pretransplant patients. This trend is also reflected in the Eurotransplant
Annual Report 2010, which describes a 24% increase in the number of high-MELD
recipients within the total population of liver-graft recipients in 2010 compared with
2009. Hence, the null and alternative hypotheses are as follows for the second research
question.
2. Does a simulation model using the additional parameter of delta-MELD as a
patient selection criterion lower the average MELD score among pretransplant
patients?
Ho: There is no difference in the average MELD score among pretransplant
patients between simulation models with and without delta-MELD along with the MELD
score as primary criteria for patient selection in donor liver allocation.
Ha: There is a difference in the average MELD score among pretransplant patients
between simulation models with and without delta-MELD along with the MELD score as
primary criteria for patient selection in donor liver allocation.
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Nature of Study
This quantitative simulation experiment investigated the utility of the deltaMELD parameter for decision-making in liver transplant patient selection. This research
used a simulation model that was unlike any previous research on the study of the deltaMELD parameter because of its unique approach to compute part of the MELD scores
based on the Kalman estimation. The Kalman filter was also used to generate and
simulate the disease progression of patients that are on the waiting list for a donor liver.
In addition, the technique of AHP was used to simulate the decision-making process of
the existing and proposed patient selection criteria of the liver allocation according to
OPO hierarchy of priority.
The experiment simulated two scenarios, one that would reflect the current
system’s utilization of the MELD score as a primary criterion, and another scenario that
utilized both MELD and delta-MELD scores as primary criteria in determining medical
urgency. The two scenarios, utilizing and not utilizing delta-MELD as criterion, counted
the number of patients who dropped off of the waiting list and computed the average
MELD over a 180-day period. This quantitative study generated the values of patients
removed and average MELD from the two scenarios for statistical comparison.
The data used in this simulation model include secondary data from the United
Network of Organ Sharing Organization’s Standard Transplant Analysis and Research
(UNOS STAR) database. The data consisted of both patient and donor liver data. Patient
data included age group, gender, race, primary cause of disease, transplant history, blood
type, MELD scores, date of MELD scores, time on wait list, and status. Donor liver data
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included donor age, donor height, donation after cardiac death donors, split liver donors,
race, donor’s cause of death from cerebrovascular accident, regional sharing, local
sharing, and cold ischemia time. Patient data supported the patient and disease
progression simulation portion of the scenarios. Multiple and sequential MELD scores
records taken over time determined the patients’ delta-MELD scores.
The simulation model is a software program that is comprised of four components
or processes. These four components included patient waitlist entry, donor liver arrival
which performs scoring processing for liver recipient selection, patient disease
progression, and waitlist patient management.
This quantitative study addressed the research questions by formulating a time
series estimation of patients’ illness based on known and estimated MELD, and deltaMELD scores. This research applied a multi-criteria decision-making process consisting
of the proposed new criterion, and performed statistical t tests of two independent
populations for comparison of the system utilizing delta-MELD scenario against the
existing system’s scenario.
The elements crucial to the simulation included MELD and delta-MELD patient
data. I performed t tests of two independent populations (with and without delta-MELD
criterion) to determine whether the delta-MELD parameter is useful for patient selection.
Significance of Research
In this research, I investigated the delta-MELD parameter as a transplant patient
selection criterion. The delta-MELD parameter was helpful for its predictive attributes
when assessing pretransplant patients’ prognosis because it helped to align and predict
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patients’ health statuses upon the arrival of an available donor liver. Gotthardt et al.
(2009) stated that an effort that could improve the MELD system would involve
analyzing the change in MELD scores over time, bearing in mind that this dynamic
variable would reflect the dynamic of the disease. Gotthardt et al. further explained that
several attempts have been made where some studies concluded that the delta-MELD
score had better prediction ability for mortality than the baseline MELD score, while
other studies concluded that delta-MELD was not as predictive compared to the most
updated MELD score. This suggested that an in-depth study still needs to be conducted
but with different supporting methodologies. This research could potentially improve
upon the current allocation system by including the use of the delta-MELD parameter as
a criterion for patient selection in order to reduce the number of patients from dropping
off of the waiting list and to reduce the average MELD score of waiting list patients.
Strategies used in this study are a methodology for forecasting and estimating liver
disease progression and the use of a multi-criteria decision-making process, while
incorporating the multiple processes of the liver allocation system. This research
provided further understanding on the usefulness of the delta-MELD parameter.
Implications for Social Change
The implication of positive social change is the potential of saving more lives
through an improved decision-making system for allocating donor livers to transplant
patients. Time series prediction technique could be applied to other areas of health care
for better control and management of disease progression. This research helped to
promote using knowledge of disease progression into the decision-making refinements
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for the donor liver allocation system.
Quante et al. (2012) noted that, in December 2006, the MELD score system was
implemented as the basis for new liver allocation system in many countries within the
Eurotransplant area. Cholongitas and Burroughs (2012) also noted that the MELD
system adopted by Eurotransplant helped to allocate organs in seven countries of central
Europe: Austria, Belgium, Croatia, Germany, Luxemburg, the Netherlands, and Slovenia.
Since then, there was a significant reduction in waiting-list mortality in Europe. This
affected a social change in the reduction in waiting-list mortality among pretransplant
patients. A potential refinement to the liver donor system by including delta-MELD to
patient selection criteria could benefit the transplant community in the United States and
in Europe in two ways. The donor allocation system could be more effective in achieving
the sickest first policy, and thus, would provide a more fair system for the recipients.
Scope and Delimitations
This research was limited to the investigation of the delta-MELD. Although the
donor risk index (DRI) was considered in the multi-criteria decision-making, and this
research referenced the DRI, the DRI values were the same for both before and after
(utilizing delta-MELD) simulation scenarios. The delta-MELD was the sole interest of
this study. The prediction of MELD scores was limited only to supporting the simulation
and was not meant to be used for prognosis. The propagated MELD scores used in the
simulation were intended to project the MELD scores in future time and in accordance
with secondary data.
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In this research, I included data from the UNOS STAR database. I used a
simulation model to simulate and fill in additional MELD scores that were estimated
MELD scores in order to support a sequence of MELD scores so that the derivation of
delta-MELD values was possible. This was done because secondary data may not have
enough MELD values to formulate delta-MELD values throughout a 180-day timeline.
The 2010 American Association for the Study of Liver Diseases guidelines
advised against the use of prognostic models in an individual patient (Siciliano et al.
2012). The simulation used de-identified patient and donor liver data. The simulation’s
processing and output data of MELD average and number of patients dropped from
waitlist cannot be used to single out any individual patient. In addition, the research was
limited to adult liver donations, adult transplant patients, non-HCC patients, and nonstatus 1 patients.
This research limited the use of the UNOS STAR database for the simulation to
data from the recent five years of 2008-2012, and from one region, Region 9. The
purpose for this was to limit the simulation’s scope from the need to concern with cold
ischemia time and the varying MELD averages of additional regions, by focusing solely
on one region from the recent five years, 2008-2012. Region 9 is confined to the area of
New York state and western Vermont.
Assumptions
Massie et al. (2011) explained that although MELD was adopted to estimate the
short-term (90-day) risk of waitlist mortality, it is believed to underestimate such risk for
certain patients with non-normative conditions. Some diseases have low risk of short-
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term mortality, but require transplant before progression to the point of irreversible
complications. For such cases, additional MELD points can be granted, and these
patients receive priority based on the exception MELD rather than the calculated MELD.
The Organ Procurement and Transplantation Network (OPTN) policies originally
allowed exception points for certain recognized exceptional diagnoses such as
hepatocellular carcinoma (HCC) and hepatopulmonary syndrome (HPS).
The two categories of liver diseases are cholestatic and noncholestatic. The
assumption is that the exception points are already incorporated in the patient data for the
noncholestatic disease of HCC. It is known that HCC patients receive exception MELD
points that are not derived from the MELD formula. This research filtered out HCC
patients for the simulation to allow the MELD scores to be comparable to other MELD
scores without the concern of how the exception points were applied.
Limitations
Simulation limitations, such as using the simulation sampling intervals of 180-day
instead of 360-day in duration, along with using a limited data sampling from the OPO
Region 9, may have masked the true effect of delta-MELD, and prevented the t tests from
producing a significant outcome. This may be because while OPO Region 9 has many
liver transplant patients, it is also a region of many organ donors. This could be the
predominant factor for keeping the waitlist MELD averages low, and possibly reducing
the occurrence of waitlist patients from having sizable delta-MELDs in this limited data
sample. The delta-MELD values usually have more variability near the end-stage of
patients’ liver disease (Freeman, 2009), and the simulation model may not have used a
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duration that was long enough to allow the patients’ disease progression to follow its
course to completion in order to encounter the variability in delta-MELD values.
Finally, the simulation employed two main theoretical frameworks, the Kalman
estimation for simulating disease progression, and the AHP for simulating decisionmaking. The AHP was used for its sophistication and straightforwardness in applying the
same decision criteria to all patients. However, in actuality, the selection of patients is
likely based on physicians’ medical experience, expertise, and knowledge of patients’
medical history (Bernardi et al., 2011), while weighing other factors in addition to the
AHP criteria. Many times, transplant physicians are knowledgeable of their patients’
medical history, allowing them to see subtle changes to their patients’ conditions
(Schiano, 2012), which this simulation model or any simulation model may not be able to
replicate, given only the UNOS STAR database to work with.
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Conclusion
The supporting methodologies of this research, AHP and Kalman filter, may be
new to the health care field and may be new to the donor liver allocation scoring system.
The research question was to determine whether the parameter of delta-MELD should be
used, in addition to the MELD score together as primary criteria, for patient selection. As
a patient selection criterion, delta-MELD could potentially improve the liver allocation
system by reducing the number of pretransplant patients from dropping off the waiting
list and by lowering the average MELD score among pretransplant patients.
The conceptual framework included the delta-MELD and MELD being primary
criteria for patient selection decision-making process for selecting the most urgent patient
in need of a liver transplant. The underlying theoretical frameworks for the simulation
were applying the Kalman filter and the AHP technique into the scenarios of the existing
and proposed liver allocation system.
By using the conceptual and theoretical frameworks, the decision-making process
could potentially be refined and equitably judged among the patients waiting for a liver
transplant. An additional strategy for the simulation was taking a systems perspective of
the liver allocation system.
In Chapter 2, I present a literature review to explain why the investigation of the
delta-MELD parameter is needed and how the chosen methodologies could bring further
understanding regarding delta-MELD. In the literature review, I examine and conclude
the need to bring forth a different set of methodologies which include statistical
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prediction, criteria and decision-making development, and a systems perspective into the
simulation to address the research problem.
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Chapter 2: Literature Review
In this introduction, I outline and describe the structure of the literature review. In
the first section, I describe the MELD of the donor liver allocation system, its problem
and gap in research, and the methodology that was used in the simulation model to
determine whether the MELD system could be refined. The similarities and differences
of various MELD-based models are presented. Among the MELD-based models, the
delta-MELD is discussed as a potential donor liver allocation criterion. In the literature
review, I reveal an unresolved problem of delta-MELD being a viable criterion for donor
liver allocation. Kalman filter is a statistical methodology that could provide MELD
estimations in order to establish consistently measured delta-MELDs. The Kalman filter
can provide MELD data based on existing MELD values in order to compute deltaMELD.
In the second section of the literature review, I evaluate the decision-making
process of the donor allocation system that meets the objectives of urgency (sickest first),
utility, and survivability. The DRI and the expanded criteria donor (ECD) are also
evaluated. The survival outcomes following liver transplantation (SOFT) scoring system
is reviewed which meets both urgency and utility objectives. The AHP model for
multiple criteria and objectives was proposed for decision-making of the liver allocation
system. In the literature review, I evaluate the usefulness and flexibility of AHP for
analyzing the delta-MELD parameter as an additional criterion for donor liver allocation.
The literature search was based on reviewing liver transplant topics through the
journals of American Journal of Transplantation, Liver Transplantation, Journal of
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Hepatology, and BMC Gastroenterology. These peer-reviewed journals are either open
access or are on-line journals accessible via the internet. Subsequently, the references
used by these articles led to other peer-reviewed journals such as Langenbecks Archive of
Surgery, International Journal of Hepatology, Transplant International, and Hepatology
International. As the search developed, other medical, health, and management journal
databases were referenced. Initially, the key words used to search these articles were
liver allocation, liver transplant, liver procurement, waitlist, MELD, and liver donation.
In the literature review, I conclude by summarizing the major points of the
literature review and describe the purpose of the research simulation. The simulation
model includes the patients entering and exiting the waitlist, the progression of patients’
illnesses, the arrival of available livers, and the selection of a compatible recipient
reflected by theoretical frameworks of the Kalman filter and AHP.
The MELD Era
MELD Variable
In this first section of the literature review, I define the MELD, provide
background and history of the MELD as it relates to the liver allocation system, identify
and review the MELD-based models where the studies have been concluded, and identify
and review the MELD-based models where the studies were inconclusive due to
conflicting findings. In this literature review section, I also summarize how the MELD
had positively impacted but also provided limitations to the liver allocation system, and
review the effect of MELD in the transplant community of the United States, Europe, and
Brazil. In the next section of the literature review, I reveal the trends of the MELD
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system and discuss how the objective of attending to the sickest first policy (urgency)
further led to the implementation of urgency, utility, and survivability objectives for
decision-making on donor liver allocation. Bernardi et al. (2011); Teixeira de Freitas et
al. (2010); Bahra and Neuhaus (2011); and Quante et al. (2012) acknowledged the
advantages of the MELD system in the United States, Europe, and Brazil, particularly for
shortening the waiting list and wait time for available donor livers.
In 2000, Malinchoc et al. (2000) from the Mayo Clinic in Rochester, Minnesota,
devised a mathematical model to predict the probability of death within three months
after the procedure. The model name was called MELD and it was successfully validated
in patients with different liver disease severity, and from different geographical and
temporal origin. Bernardi et al. (2011) explained that what made MELD an ideal
prognostic model is its reliability in predicting the probability of survival.
Bernardi et al. (2011) further noted that MELD possessed predictive
characteristics, the ability to provide a continuous ranking of disease severity, and the
characteristic of being independent from the etiology of the liver disease. The impact of
the MELD-based liver allocation policy had been impressive. New registrations on the
waiting list suddenly dropped and the removal rate for death or disease progression also
steadily declined.
Bernardi et al. (2011) explained that the adoption of the MELD to select and
prioritize patients for liver transplantation represented a turning point in donor liver
allocation. Prioritization of transplant recipients had switched from time accrued on the
waiting list to the principle of “sickest first” (p. 1297). The simplicity of the MELD
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score is in the incorporation of three laboratory parameters, serum creatinine, bilirubin,
and INR for prothrombin time. Patients are also then stratified according to the disease
severity in an objective and continuous ranking scale. Further advantages associated with
implementing the MELD was a decrease in the median waiting time to transplant. Yet,
the MELD limitations are related to the variability of the parameters and in the inability
to predict mortality accurately in specific settings. Bernardi et al. discussed that these
limitations of the MELD include not properly accounting for factors related to certain
liver diseases where their progression are not weighted into the MELD scores such as
with HCC.
While Bahra and Neuhaus (2011) also noted that MELD is limiting when scoring
patients with HCC, Bahra and Neuhaus introduced the definitions of MELD-based
allocations, labMELD, and a MELD-based concept called matchMELD which is a
modification of the calculated MELD. The calculated MELD, or labMELD, was
developed primarily for viral or ethyltoxic liver cirrhosis. In cases of HCC, the
labMELD fails to indicate the urgency for liver transplantation. In this case, the MELD
score will increase after implementing a defined criterion of standard exceptions.
Bahra and Neuhaus (2011) further noted that in the pre-MELD era, organ
allocation was usually center-based, which meant that waiting list management was in the
hands of the transplant center. The transplant center has the opportunity to decide which
patient on the waiting list would receive the next available organ. Factors such as patient
priority, clinical conditions of the recipient, donor organ quality, donor age, and other
logistic aspects are included in the decision. The criteria of this allocation system
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included patient urgency, blood group similarity, length of time a patient has been
waiting for a transplant, size, other compatibility, and geographic location of the recipient
hospital with regard to the donor hospital. In addition, a byproduct of the MELD
allocation system was that good quality organs were usually preferentially allocated to
patients with high morbidity (comparable to patients with MELD > 30). Bahra and
Neuhaus questioned whether this allocation system was always fair. However, currently,
there is a general consensus that organs with a high DRI should not be allocated to a high
MELD scoring patient because of a significant increase in chance of posttransplant
complication and death.
Bahra and Neuhaus (2011) argued that patients with HCC would usually achieve
their matchMELD scores only through standard exceptions. Those patients usually have
a labMELD score of less than 20, leading to a decreased rate of patients requiring
intensive care after liver transplantation. Patients with matchMELD of 37 are not
comparable to patients with labMELD of 37. Bahra and Neuhaus believed that this is a
reflection of how the MELD system has some significant weaknesses compared to the
diagnosis of a team of experienced physicians.
Teixeira de Freitas et al. (2010) likewise confirmed that end-stage liver disease is
considered one of the major causes of death in the United States and its treatment is a
major health dilemma. Teixeira de Freitas et al. explained that the MELD was introduced
in Brazil for organ allocation in 2006. MELD score would help assess the severity of
cirrhosis and predicted mortality. It would help provide priority to candidates waiting for
liver transplants with more severe diseases. It also would help prioritize patients with
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HCC. Before the MELD was introduced, organ allocation was based mainly on
chronological waiting time.
Texiera de Freitas et al. (2010) explained that in one Brazilian center, after the
introduction of MELD score as priority criterion for liver transplantation, there was an
increase in the number transplants for patients with HCC. In the pre-MELD era 16.0% of
receptors had HCC and in the MELD era 37.5%. There was no difference in the general
MELD score of patients with HCC in the two eras. Excluding the cases of HCC, the
transplants were performed in patients with more advanced cirrhosis. Furthermore, there
were no increases in the indicators of worse prognosis or complications after the
transplantations and there were no changes in the 3-month and 1-year posttransplant
survival rate.
Teixeira de Freitas et al. (2010) also revealed that the MELD scores of patients
without hepatocellular carcinoma was 18.2 ± 6 in the MELD era, which is similar to the
study of Bahra and Neuhaus (2011), and this value was higher in the MELD era than the
MELD score in the pre-MELD era which was 15.8 ± 4. Texiera de Freitas et al.
explained that in Brazil, patients with cirrhosis and hepatocellular carcinoma were listed
for liver transplantation with MELD exception points as according to the Milan criteria.
This means that for one nodule of less than 5m in diameter or a maximum of 3 nodules is
deemed safe, where each of the nodules is less than 3 cm in diameter. To avoid tumor
growth beyond the Milan criteria while the patient is on the waiting list, extra points
could be added to the MELD score. Therefore, some patients with HCC would be
transplanted earlier in the evolution of cirrhosis. According to Brazilian legislation,
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patients with HCC would initially receive 20 extra points to their MELD scores.
Quante et al. (2012) explained that the MELD was implemented on December
16th, 2006 as the basis for new allocation system in many countries within the
Eurotransplant area. The MELD model provided a prediction of 3-month mortality
without liver transplantation. Quante et al. similarly noted that there are many different
possible underlying diseases that despite chronic liver decompensation, often have only a
modest impact on laboratory results, and standard exceptions to the MELD system with
adjustment of the score, have been defined. For example, patients suffering from HCC
are given an adjustment in their MELD score because of the underlying malignancy and
the consequent anticipated tumor growth during the waiting period. In addition to HCC,
there are other risk factors that may not be reflected by laboratory results.
Quante et al. (2012) noted a few significant findings regarding waitlist mortality
and MELD score at time of organ allocation and donor graft quality. In their center, there
was a significant reduction in waiting-list mortality from 18% in the year before to 10%
in the year after the MELD was introduced. Other single-center results within Europe
have also confirmed a reduction in waitlist mortality since the introduction of MELD.
Quante et al. also noted that after the MELD was implemented, there was a significant
increase in the mean MELD score at the time of liver allocation, reflecting the intention
to give priority to sicker patients on the waiting list. In their center, the mean MELD
score increased from 16.3 points in the year before to 22.4 points in the year after MELD
introduction. Since then, there has been a steady increase in mean MELD score within
the Eurotransplant area, especially in Germany. In 2010, a mean MELD score of 34
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points for standard liver allocation, without standard exceptions and without highurgency status, was reported in Germany. In addition, Quante et al. detailed that this
resulted in worse posttransplant outcomes in the group of high-MELD recipients, which
in 2010 represented 43% of all liver graft recipients in Germany.
In addition to providing exception MELD points for patients with HCC, recent
literature revealed how the MELD was compared against the Child-Turcotte-Pugh (CTP)
model, which was previously applied in the United States, and how the MELD is
considered a better prognostic model. Recent literature also revealed the outcomes of
various MELD-based studies. Finally, a deeper look into the literature would identify
and detail the various limitations, strengths, and benefits of MELD-based models.
MELD and MELD-based Models
Bernardi et al. (2011) explained that the impact of MELD scoring on the donor
liver transplant allocation system had such an impact, that the period following the
implementation of the MELD system is referred to as the "MELD era" (p. 1298).
However, MELD has its weaknesses and many attempts had been underway to improve
the applicability and reliability of the MELD formula with specific conditions. These
attempts were based on the original MELD score as the original MELD is such that it can
be employed in many settings. An analysis in the literature review of Huo et al. (2008)
and Biselli et al. (2010) provided a comparison of multiple MELD-based models. This
literature review details the benefits of the various MELD-based models.
Huo et al. (2008) and Biselli et al. (2010) both introduced, evaluated, and assessed
various MELD-based models. Regarding the analysis of MELD-based models, Huo et al.
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(2008) analyzed four MELD-based models by comparing and contrasting their risk of
mortality prediction at 3 and 6 months. The four MELD-based models included MELD,
MELD-Na, iMELD, and MESO index scores. Huo et al. explained that the MELD has
been shown to be more accurate in predicting survival than the Child-Turcotte-Pugh
(CTP) classification for patients with cirrhosis awaiting liver transplantation in the United
States.
According to Huo et al. (2008), the MELD-Na, iMELD, and MESO index
formulas are as follows (p. 838):
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Huo et al. (2008) compared the short-term prognostic ability of the four models,
MELD, MELD-Na, iMELD, and MESO index, to determine which MELD-based system
have a better predictive accuracy in patients with cirrhosis. The criteria to select eligible
patients included an initial Child-Pugh score of 6 or higher, with no coexisting
hepatocellular carcinoma or human immunodeficiency virus infection, and a known
initial MELD score at the time of evaluation and survival status at follow-up after 6
months.
Huo et al. (2008) explained that the iMELD tended to have the highest scores and
that was followed by the MELD-Na, MELD, and MESO index at the time of initial
evaluation. With the c-statistic and 3- and 6- month mortality as the endpoint, the
estimated Area Under Curves (AUCs) for the four prognostic models in predicting
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mortality were graphed. Of all patients, 83 patients or 10.1% of patients died at 3 months
of follow-up, and 162 patients or19.6% of patients died at 6 months of follow-up. At 3
months, the iMELD had the highest AUC (0.807), and that was followed by the MELDNa (0.801), MESO (0.784), and MELD (0.773). At 6 months, the iMELD still had the
highest AUC (0.797), and was followed by the MELD-Na (0.778), MESO (0.747), and
MELD (0.735).
Huo et al. (2008) concluded that to further improve the MELD-based liver
allocation system, their studies have found that serum sodium (Na) is an important
additional predictor of waitlist mortality. Hyponatremia is associated with severe
complications of cirrhosis, including ascites, hepatorenal syndrome, and liver-related
mortality. It has been suggested that Na should be incorporated into the MELD to further
enhance the model's prognostic ability, and so a mathematical equation based on both
MELD and Na known as the MELD-Na, has been developed to predict the 6-month
mortality in patients with cirrhosis awaiting liver transplantation.
Huo et al. (2008) further concluded that the utilization of MELD has been
demonstrated to have an equal or better ability in short-term or intermediate-term
outcome prediction over the CTP system. In addition, the application of the MELD
system has been shown to be a useful model in predicting the outcome of patients with
cirrhosis undergoing surgical procedures for hepatocellular carcinoma and nonhepatocellular carcinoma conditions. Huo et al. noted that a potential limitation of their
study is that the majority of the patients had chronic hepatitis B, were older with more
males, and were taken from Taiwan’s Taipei Veterans General Hospital (p. 843). The
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study results indicated that incorporation of Na into the MELD could enhance the
prognostic accuracy of MELD for outcome prediction.
Similarly, Biselli et al. (2010) analyzed the results of six MELD-based score
systems by comparing and contrasting the risk of mortality prediction. These six MELDbased parameters were MELD, UKELD, iMELD, MELD-Na, uMELD, and mCTP. At
present, the MELD score is widely used for donor liver allocation, but it has shown some
limitations. MELD is not directly influenced by other complications of cirrhosis
associated with poor survival, such as persistent ascites and hyponatremia. For this
reason, many recent studies have evaluated the effects of incorporating other variables
into the model, such as serum sodium and age.
According to Biselli et al. (2010), the formulas of UKELD, iMELD, MELD-Na,
and uMELD are as follows (p. 965).
/0

= [(5.395 ∗ ln($%&)) + (1.485 ∗ ln(

+ (3.13 ∗

(

= (81.565 ∗
=

(% ) =

+ (

(% ,

,4

,4

/ ))

/ ))

/ )] + 435

(5)

∗ 0.3) – (0.7 ∗ % ) + 100

– % – [0.0225 ∗

= 1.266 ∗ ln(1 +

+ 0.939 ∗ ln(1 +

+ 1.658 ∗ ln(1 + $%&)

,

∗ (140– % )] + 140

,

/

)

/

)

(6)
(7)

(8)

Biselli et al. (2010) explained that survival was calculated from the time of listing
to drop-out, liver transplant, or end of the observation period. Drop-outs included

35
patients being removed from the list because of either death or worsening of their disease
up to the point that they were too sick to undergo a liver transplant. Biselli et al. noted
that at 6 months, the best calibrated score was iMELD. Furthermore, an iMELD cutoff of
39 identified listed patients with a worse prognosis more reliably than standard MELD of
15, whereas no significant difference was found with respect to standard MELD of 18.
Similar to the study of Huo et al. (2008), at 3 months the iMELD had the highest AUC,
showing an excellent diagnostic accuracy, followed by MELD-Na, but the comparison
between AUCs showed that only MELD-Na had a better prognostic power than the
standard MELD because of a very small standard error in the difference between the
areas. At 6 months, the comparison between AUCs showed that only iMELD and
MELD-Na had a better prognostic power than the standard MELD.
Biselli et al. (2010) explained that their study was a comparison of the short-term
and intermediate-term prognostic ability of the standard MELD with respect to five
alternative scoring models. The performance of these scoring models in relation to the
varying severity of cirrhosis was specifically assessed by calibration analysis. The
utilization of the MELD has been demonstrated to have an equal or better ability in shortterm or intermediate-term outcome prediction in comparison with the CTP system. In
addition, Biselli et al. similarly found that the application of the MELD system has been
shown to be a useful model in predicting the outcome of patients with cirrhosis
undergoing surgical procedures for hepatocellular carcinoma and non-hepatocellular
carcinoma conditions. The studies of both Bisseli et al. (2008) and Huo et al. (2008)
conclusively determined that the MELD-based models could be used to refine the

36
decision-making of liver allocation, particularly the iMELD and MELD-Na models.
In addition to providing exception MELD points for patients with HCC, Biselli et
al. (2010) and Huo et al. (2008) revealed that when the MELD was compared against the
CTP model, the MELD was considered a better prognostic model over CTP. Recent
literature also included MELD-based studies that studied the delta-MELD. Bambha et al.
(2004) defined the delta-MELD as the calculated difference between the current-MELD
score from the lowest of all serial-MELD scores in the preceding 30 day window. Thus,
delta-MELD is defined as the maximum change in MELD over the 30 day period. DeltaMELD was covered in several studies and was hypothesized to have prognostic
predictive value (Cholongitas et al., 2006; Foxton et al., 2006; Gotthardt et al., 2009; and
Young et al., 2006). However, these delta-MELD studies revealed that there are research
problems regarding how delta-MELD was computed and interpreted.
Delta-MELD: Debate and Gap in Literature
The research of Bambha et al. (2004), Foxton et al. (2006), Young et al. (2006),
Gotthardt et al. (2009), and Cholongitas et al. (2006) were reviewed on how delta-MELD
can help refine the MELD system. These studies also focused on waitlist mortality while
searching for a refinement for the MELD scoring system. A summary of their studies
regarding the delta-MELD would reveal the conflict and inconsistency on the data
collection for delta-MELD. Also, a methodology is presented and suggested regarding
MELD estimation for the derivation of delta-MELD values.
The studies of Cholongitas et al. (2006), Bambha et al. (2004), Young et al.
(2006), and Foxton et al. (2006) not only included MELD-based models, their studies

37
included the analysis of delta-MELD. Cholongitas et al. acknowledged that the MELD is
now used for allocation of donor livers, and it has successfully replaced the ChildTurcotte-Pugh (CTP) model. However, there are still debates on whether the MELD is
really superior to the CTP model in predicting mortality in patients with cirrhosis on the
liver transplant waiting list and after liver transplant. Cholongitas et al. found from
multiple studies, that only 4 of 11 showed MELD to be superior to CTP in predicting
short-term mortality. In addition, two of three studies evaluating the changes in MELD
score, delta-MELD, had shown that the delta-MELD had better prediction for mortality
then the baseline MELD score. Finally, Cholongitas et al. also noted that several studies
have shown that the predictive ability of MELD score increases by adding clinical
variables, such as hepatic encephalopathy, ascites, and laboratory sodium parameters.
Cholangitas et al. (2006) evaluated the change in MELD, delta-MELD, in large
cohorts of candidates on the liver transplant waiting list. In this evaluation, the deltaMELD score had better prediction for mortality than the baseline MELD score. For
example, an increase of 5 points in delta-MELD during a 30-day period predicts a
significantly increased risk of death. Cholangitas et al. also suggested that delta-MELD
score be a tiebreaker for patients on the waiting list with identical MELD scores. When
Cholangitas et al. explained how the delta-MELD, baseline MELD, and CTP were
compared, the c-statistic showed that delta-MELD at 6 and 12 months was significantly
better predictors compared to baseline MELD and CTP. Although it was found that
MELD was significantly better than CTP in 4 of 11 studies, whereas 7 studies showed no
statistical difference, there were no studies that showed MELD to be statistically inferior
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to CTP scores.
Gotthardt et al. (2009) argued that an effort to improve the MELD system should
involve analyzing the change in MELD scores over time while bearing in mind that this
dynamic variable would reflect the dynamic of diseases in patients. When Gotthardt et
al. analyzed a study of delta-MELD of 60 patients, the delta-MELD scores had better
prediction for mortality than the baseline MELD score.
On the other hand, Bambha et al. (2004) explained that their research was focused
on monitoring waiting list mortality and refining the MELD scoring system. Using an
institutional liver transplantation database of serial MELD measurements for each
patient, Bambha et al. found that the most recent MELD score for a patient awaiting liver
transplantation was significantly associated with waitlist mortality. Bambha et al. also
found that increasing MELD score, estimated by the slope of the line representing the
changes of MELD scores over the 30-day period preceding the most recent MELD,
conferred to an increased mortality risk on the waiting list, while decreasing MELD could
be associated with a decrease in mortality.
However, Bambha et al. (2004) noted that an increasing MELD score may simply
represent an intrinsic, irreversible component of the death process rather than being
predictive of death in the future. For example, patients in the terminal phase of their
disease may be expected to have increasing daily MELD scores during the last few days
of life due to progressive organ failure. Bambha et al. further elaborated that when
collecting laboratory data for calculation of delta-MELD scores, the potential for
detection bias exists. For example, patients with acute liver illnesses, regardless of the
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status of their liver disease, will undergo frequent laboratory tests producing multiple
observations of MELD scores.
Foxton et al. (2006) explained that the MELD score is based on a methodology to
predict poor survival in patients undergoing a liver transplantation. Foxton et al. also
explained that MELD has been validated among multiple groups with liver disease and
was shown to retain a high concordance with 3-month mortality. Foxton et al. noted that
a change in MELD score, delta-MELD, while awaiting transplant has not only been
suggested as a method of refining liver allocation, but delta-MELD should be examined
for its impact on patient survival and intensive care stay. Foxton et al. found that using
delta-MELD could subsequently help to improve overall outcomes. Foxton et al. found
that delta-MELD over a period of 30 days was predictive of waiting list mortality and
was significantly better than MELD score at the time of listing. Foxton et al. calculated
delta-MELD by simply taking the MELD at transplant minus the initial listing MELD.
Foxton et al. explained that various researchers may vary on how they calculate the deltaMELD value.
Young et al. (2006) also explained that the usefulness of MELD can be enhanced
if it could also predict posttransplant outcomes. Predicting posttransplant outcome is
important, as this would enable a more rational utilization of scarce resources to achieve
their maximum benefit. The MELD score has been validated as an accurate tool for
predicting 3-month mortality in different groups of patients with end-stage liver disease.
Young et al. further explained that while MELD uses three readily measurable and
objective parameters of bilirubin, creatinine, and INR in a logarithmic formula to produce
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a score between 6 and 40, the wider range of MELD values when compared with CTP
values can more easily allow the sickest patient to be prioritized. In addition, Young et
al. similarly found delta-MELD and hyponatreamia to be significant parameters for
predicting which patients would be placed on the waiting list and would not proceed to
undergo a liver transplant. Young et al. noted that while a move to allocating donor liver
solely by MELD is not justified for the U.K. allocation system, there is value in using
MELD, delta-MELD, and hyponatreamia at predicting which patients should be placed
on the waiting list and which would not proceed to transplant.
Young et al. (2006) confirmed in their study that hyponatreamia was highly
significant in predicting which patients would not get a liver transplant. And deltaMELD has been studied before but until now has not been shown to be of significant
value in determining allocation or predicting outcomes. Young et al. postulated that by
identifying those patients who are hyponatreamic and who had large delta-MELD scores,
it may be possible to prioritize them earlier and so have them liver transplanted before
they become too sick to transplant. Hyponatreamia and delta-MELD, however, were not
shown to be significant predictors of posttransplant outcome. By transplanting this group
of patients sooner should not result in posttransplant outcomes that are worst off, but
could even result in improved overall outcomes. Finally, data revealed that matching a
poor quality organ with a sicker recipient will lead to much worse outcomes. Therefore,
to allocate solely based on disease severity may sometimes discourage the use of
marginal organs due to bad outcomes.
Young et al. (2006) concluded that one of the problems with delta-MELD is that
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previous studies were biased due to the various collection method of the MELD data.
Young et al. sought to minimize this bias by using the MELD scores at entry and exit
from the waiting list. However this reasoning is flawed as this assumed a linear
progression of MELD serial values while on the waiting list which is unlikely. Young et
al. explained that in the study of Bambha et al. (2004), it was suggested that delta-MELD
may be of limited value due to having too short a lead time to play a role in decisionmaking. On the contrary, Young et al. explained that it has been shown that despite
relatively short waiting times, MELD can increase considerably prior to a liver transplant.
A large prospective study designed to minimize collection bias is needed to fully clarify
the role of delta-MELD in allocation. In conclusion, Young et al. noted that there is
much data supporting MELD as a valuable tool in assessing potential liver transplant
recipients in the U.K. Young et al. suggested that by using MELD and delta-MELD
combined with a measure of hyponatreamia may improve the overall outcomes of
allocating donor livers with more efficient and optimized timing to transplant while
reducing waiting list deaths.
Even though Young et al. (2006) mentioned that a large prospective study should
be designed to remove collection bias and to fully clarify the role of delta-MELD in liver
allocation, there was no further research to either disregard or accept the delta-MELD as
a valid criterion for determining a donor liver recipient for transplant. Furthermore,
while Foxton et al. (2006) had calculated delta-MELD as the transplant MELD minus the
listing MELD, Young et al. had calculated delta-MELD differently and as dxMELD,
which is calculated by dividing delta-MELD by the time spent on the waiting list. While
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the formula of dxMELD given by Young et al. seems to be more accurate, the time spent
on the waiting list, the divisor, could be different among patients and the formula of
dxMELD is different from the formula of delta-MELD given by Bambha et al. (2004).
To refine the concept of the sickest first policy based on a delta-MELD criterion,
a methodology is needed for the consistent computation of delta-MELD prior to
incorporating a multiple criteria decision-making model for analysis. A time series
methodology can provide consistent estimation of data for delta-MELD computation.
Huth et al. (2010) had suggested a methodology for tracking cell progress by the
technique of the Kalman filter. The Kalman filter was used as a methodology for
estimating data for the consistent computation of delta-MELD values.
Literature Review on Time Series Analysis Method
Kalman Filter
Not only was there a need for a methodology to estimate MELD values in a
consistent manner based on patient MELD values, but a simulation was also needed to
progressively track the MELD scores, stratify the groups of MELD values, and keep
inventory of the patients on the waitlist. A simulation was needed to advance the study
of delta-MELD in order to determine whether delta-MELD would be a useful criterion
for donor liver allocation.
In this section, Kalman Filter, I examine the theoretical framework of the Kalman
estimation and forecasting for the purpose of removing bias of delta-MELD computation.
In the next section, Kalman State Space, Prediction, and Estimation, I examine the
literature review of Asemoto (2010), Huth et al. (2010), Baker, Poskar, and Junker
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(2011), and Zhou and Hu (2010) who demonstrated and highlighted the modeling of state
space, estimation and prediction, and error management with Kalman filter.
Asemoto (2010) explained that the traditional time series analysis is primarily
directed towards univariate data. The Kalman filter is a statistical algorithm that enables
certain computations to be carried out for a model cast in state space form. Asemoto
mentioned that even though the Kalman filter algorithm was proposed as far back as
1960, many statisticians are still unaware of the simplicity and succinctness of this
methodology.
Asemota (2010) noted that state space models and the state-space representation
of data are important tools for modeling time series data. State space models of random
processes are based on the Markov property which implies the independence of the future
of the process from its past, given the present state. In other words, the state of a Markov
process summarizes all the information from the past that is necessary to predict its
future. A state space model consists of two equations: the state equation, which is also
called the transition or system equation, and the observation equation, which is also
called the measurement equation. The measurement equation relates the observed
variables or data, and the unobserved state variables, while the transition equation
describes the evolution of the state variables (p. 7).
Asemoto (2010) explained that in a Kalman filter formulation, one can let Yt, Yt-1,
..., Y1 be denoted as the observed values of an endogenous variable of interest at times t,
t-1, ... 1 which depends on the unobservable quantity βt and exogenous variable Xt, Xt-1, ...
X1 (which may be either scalars or vectors) through the following relationship:
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(9)
(10)

where βt is a vector of unobserved state variable, Xt is a vector of exogenous or
predetermined observed variables.
The observation error εt and state error Vt are assumed to be Gaussian white noise
sequences with zero mean and a covariance matrix. The covariance matrix is for the
vector X of dimension n x 1 is defined to be an n x n matrix that contains the ijth elements
that is the covariance between the ith and jth components of X. Equation (9) is known as
the observation equation, and (10) is known as the state, system or transition equation.
The system of equations (9) and (10) with their assumptions is called the state-space
model. The essential difference between the state-space model and the conventional
linear model representation is that in the state-space model, the dynamic nature of state is
not assumed to be constant but may change with time. This dynamic feature is
incorporated in the transition equation. The overall objective of the state space analysis
is to study the development of the state over time using the observed values of the series
(p. 7).
Zhou and Hu (2010) explained that a complementary Kalman filter differs from
other similar work by adopting a refined noise model which could lead to an efficient
computation of the Kalman filter. Zhou and Hu proposed a strategy consisting of four
components, a prediction model, an error model, a standard Kalman filter, and a
correction model. Zhou and Hu compared results by using a Kalman filter with those not
using a Kalman filter, which only used a direct integration algorithm, and a kinematic
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model to reconstruct the trajectories of joints from their studies. The results showed that
a Kalman filter can significantly reduce errors in the orientation estimates when
compared with the models in which no Kalman filter was used.
Huth et al. (2010) similarly explained that a method through the tracking of
positions of individual cells over time, marked in consecutive images, through the use of
the Kalman filter was compared to the migratory behavior of cells through the use of
time-lapse microscopy. Huth et al. explained that the tracking of the positions of
individual cells through the technique of Kalman filter was markedly improved and
accurate over the technique of a tracking procedure that is commonly performed
manually through a point and click imaging systems. In addition to being laborintensive, a point and click method is highly susceptible to user-dependent errors
regarding both the selection of subsets of cells for analysis as well as the manual
determination of cell centroids serving as measuring points for cell positions.
Baker et al. (2011) explained that the focus of systems biology is to study the
dynamic, complex, and interconnected functionality of living organisms. To have a
systems-level understanding of these organisms, it is necessary to integrate experimental
and computational techniques to form a dynamic model. Baker et al. elaborated that a
Kalman filter designed for inference in a linear dynamic system can subsequently result
in inaccurate results when applied to nonlinear systems. Instead, a number of extensions
to the Kalman filter have been proposed to deal with nonlinear systems such as the
extended Kalman filter (EKF) and the unscented Kalman filter (UKF).
In addition to establishing a state space model consisting of two equations that
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contain both the state and the observation equations, the observed variables or data and
the unobserved state variables need to be either collected or computed, while the
transition equation describes the evolution of the state variables.
Kalman State Space, Prediction, and Estimation
Asemoto (2010), Huth et al. (2010), Baker et al. (2011), and Zhou and Hu (2010)
applied the Kalman filter by setting their time series data into a state space model,
performing prediction using the dynamic data of their systems, and using a correction
model to reduce errors once their observed data are made available. These state space
models were set up to achieve better cell tracking, positional estimation, and error
reduction of time series data.
Asemoto (2010) also demonstrated how the Kalman filter recursive method can
be applied to a model cast in state space form. The main advantage of the state space
model is that it is based on a structural analysis of the problem that includes trend,
seasonal, cycle, explanatory variables, and interventions that are put together into the
state space model. The state space models are based on modeling the observed structure
of the data.
Zhou and Hu (2010) explained that by including an error model in their study, a
Kalman filter considers a state space representation and models the relation between the
errors in the estimated orientation angle and the errors in an inclination predicted by the
model. And by including a correction model, the error or noise can be reduced at a later
stage.
Huth et al. (2010) demonstrated that systems represented as state space with the
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Kalman filter can produce objective and highly reproducible measurements,
outperforming manual tracking procedures. Huth et al. further explained that the
precision of automated cell identification and centroid placement was very high, resulting
in cell detection rates ranging from 96% to 99%. For the subsequent tracking of
individual cell centroids through image sequences, Kalman filtering, commonly
employed in multi-target tracking systems in military radar surveillance applications was
utilized. Kalman filters are a set of mathematical equations allowing state ahead
predictions of object positions as well as the estimation of optimized object states in
noisy environments.
Baker et al. (2011) similarly noted for a nonlinear function of random variables,
the use of the UKF is a technique that gives more accurate results than analytical
linearization techniques, such as Taylor series linearization, as it considers the spread of
the random variables. UKF is itself an extension of the unscented transform, a
deterministic sampling technique which implements a native nonlinear transformation to
derive the mean and covariance of the estimates. This transformed mean and covariance
are then supplied to the Kalman filter equations to estimate the state variables.
These state space models were set up to achieve better cell tracking, positional
estimation, and error reduction of time series data. This was made possible by knowing
the observed data in order to refine the estimation of optimized object states in noisy
environments. For the MELD data, the literature review provided insights on how to
compute estimated MELD data when there are not enough MELD data available.
Asemoto (2010), Huth et al. (2010), Baker et al. (2011), and Zhou and Hu (2010)

48
discussed estimation and prediction techniques for their state space model. Estimation or
prediction is only a part of their Kalman filter’s iterative process. Their state space
models were set up for the computation of not only predictions of the time series data, but
for the estimation of errors and covariances.
Zhou and Hu (2010) explained that their prediction model included predictions of
acceleration or gyroscope data that were generated based on previous estimates and
sensor readings. The predicted estimates of the angular velocity at any time can be
expressed as the summation of angular velocity estimate (world coordinate) and
measurement errors which vary over time. Zhou and Hu then defined their estimated and
their predicted estimate. Zhou and Hu explained that their correction model included
error or noise reduction. Before proceeding to the correction model, Zhou and Hu needed
to know the predicted estimates based on the prediction and error models. Zhou and Hu
computed angular velocity error and acceleration error which were used as intermediate
variables. Zhou and Hu explained that evaluation was performed during the iteration.
The inclination difference was first minimized by the Newton method for the inclination
difference. This was followed by optimizing using the proposed Kalman filter until the
discrepancy is smaller than a fixed threshold.
Similarly, Huth et al. (2010) explained that the applied discrete Kalman filter
algorithm consists of two alternating steps, which were repeated for each iteration and
each new frame, prediction and correction. In the prediction step, the filter makes an
assumption (prediction) about the future state of the observed object. In the correction
step, an optimized state estimate was computed using a weighted difference between the
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a priori state and an actual or noisy measurement. Huth et al. further explained that the
weighting term was updated iteratively according to the quality of the previous
prediction. If the prediction was good, the weighting term will suppress the influence of
the measurement in the next iteration and show more weight in the state ahead prediction
than in the measurement. If the prediction was poor, the weights are applied to the
measurement more heavily in the next iteration while suppressing the influence of a
predicted estimate.
Baker et al. (20111) argued that at the core of the UKF is the unscented
transformation, which operates directly through a nonlinear transformation, instead of
relying on analytical linearization of the system. Overall, the UKF has been found to be
more robust and converges faster than the EKF due to increased time update accuracy
and improved covariance accuracy. Baker et al. further noted that parameter estimation
is highly dependent on the availability and quality of the measurement data. It could be
difficult to obtain reliable estimates of unknown kinetic parameter values. Baker et al.
found that in order to compare the parameter estimation methods, the nonidentifiable
parameter was fixed to known values. In general, however, these parameters would not
be known beforehand.
Kalman Error Management
Error management plays an important role in the processing of the Kalman filter.
Asemoto (2010), Huth et al. (2010), Baker et al. (2011), and Zhou and Hu (2010)
discussed their error reduction techniques for their state space models. Error reduction is
a major part of the Kalman filter’s iterative process.
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Asemoto (2010) explained that the Kalman filter considers the mean square error
(MSE) as the covariance matrix of the unobservable quantity minus a computed optimal
estimator. Once current values become available, inference about the unobservable
quantity on the basis of the observation, the MSE of the prediction can be computed. The
prediction error in the state space model consists of two parts. These two parts include
the prediction error due in making an inference about the unobservable quantity and the
error in random shock of the observed values.
Zhou and Hu (2010) explained that their error model consisted of a state space
representation and models the relation between the errors in the estimated orientation
angles. The difference between the estimated and the corrected orientation angle and
error was the difference between the gyroscope and accelerometer inclination estimates.
Zhou and Hu compared the results of the Kalman filter with those not using a Kalman
filter, a direct integration algorithm and a kinematic model, to reconstruct the trajectories.
The result of Kalman filter significantly reduced errors in the orientation estimates.
Huth et al. (2010) managed the quality of the data set by taking an automatically
generated track that was only regarded as valid if it followed one cell (and only one)
through all frames in which the cell was visible. This stringent criterion was violated if a
track failed to initialize, was prematurely terminated, or swapped between two cells.
Huth et al. suggested that to simplify mitosis detection and track initialization /
termination, backward tracking of the system was taken, meaning that cells were
followed from the last to the first frame.
According to Baker et al. (2011), the UKF is more consistent throughout and in
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estimating both larger and smaller values with a more consistent standard deviation.
Baker et al. summarized that one of the benefits in integrating estimation and
identifiability is the reuse of the variance generated by the UKF for the step size in the
calculation and for the sensitivity coefficient for identifiability. The UKF is thus able to
overcome one of the major bottlenecks in biological modeling, a lack of experimentally
measured parameters.
MELD data can be set up into a state space model for reference, prediction, and
error reduction. The methods reviewed are useful for estimating MELD data evenly and
consistently for delta-MELD calculations. Kalman filter is useful in the estimation of
MELD values into evenly time-spaced intervals that would be equivalent among all
patients in order to compute consistently measured delta-MELD values. This would be
an important aspect for removing bias that is described in the delta-MELD literature.
Some of the techniques suggested in literature review of the Kalman filter included
taking all the MELD values to compute estimated MELD data thresholds, backtracking
data from the transplant time to the entry time of waitlist for better estimation of observed
MELD, and error reduction by placing more weight to the observed MELD when
estimating MELD values. These were all useful techniques for the simulation model.
Trends in the Liver Allocation System
MELD Era Objectives
The MELD era had brought on a major impact to the reduction of waitlist time
and waitlist deaths while waiting for an available donor liver for liver transplant
recipients without changing the overall outcomes of post liver transplants. The sickest
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first policy has fulfilled its objective that was based on urgency (Bernardi et al., 2011).
In order to simulate a decision scoring system to test whether delta-MELD would be a
valid criterion, further literature review of the liver allocation system was reviewed. The
following recent literature review would reveal a trend of not one objective but three
objectives, urgency, utility, and survival, to refine the liver allocation system. In
addition, the concepts of ECD and DRI were introduced. Additional trends were
analyzed, such as increased age, MELD scores, and intensive care unit and hospital
length of stays of transplant recipients. These literature reviews provided understanding
on the objectives, criteria, and limitations of the liver allocation system that is
informative for the simulation model.
Asrani and Kim (2010) acknowledged that the implementation of the MELD
system has led to a reduction in waitlist registration and waitlist mortality. The MELD
score had been useful in patient management, as well as providing an accurate gauge of
liver disease severity. Asrani and Kim concluded that a future beyond MELD could be in
updating the coefficients, adding terms that are better determinants of liver and renal
functions, focusing on better donor-recipient matching, and updating the currently used
urgency-based objective with the additional utility-based objective.
Weismuller et al. (2009) concluded that the prioritization of patients with higher
labMELD scores for liver transplantation was followed by an increase in the mean
MELD since the implementation of the Eurotransplant criteria in 2006. However, a
decrease of post-liver transplantation survival was also observed. This led to the
investigation of recipient and donor associated factors capable of determining outcome
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after liver transplantation in the MELD-based allocation system, and thus provided
insights to the variables influencing survival. Wiesmuller et al. also explained that in the
United Kingdom, analyses indicated that delta-MELD and hyponatremia parameters were
found to predict patients on the waitlist that did not reach transplantation. However, the
prediction of posttransplant outcomes based on pretransplant parameters was much more
difficult.
Wiesmuller et al. (2009) compared the graft quality between the two studied eras
of transplant activity and recorded the parameters of donor age, cold ischemia time, split
liver transplantations, gender matching, and ABO matching. In addition, the total time or
duration of transplant surgery as a surrogate parameter for the technical complexity of the
procedure was also reviewed. Wiesmuller et al. noted that the mean recipient age was
found to be higher and the mean MELD rose from 14.3 years to 18.9 years in the MELD
era. Wiesmuller et al. also noted that in addition to INR, bilirubin, and creatinine, there
was an increase of blood urea nitrogen in the post-MELD group, which is an indicator of
more severe renal or nutritional abnormalities. Mortality is also associated with the
complexity of the surgery, along with cold ischemia time, age, and quality of donor graft.
Wiesmuller et al. further noted that while the mean donor graft age did not differ between
the groups, the mean cold ischemia time was significantly reduced in the MELD-era.
However, the mean surgical procedure time was significantly longer. Further analysis
showed that there was a significant correlation of the mean operation time with INR, and
since INR is a component of MELD, also with MELD.
Wiesmuller et al. (2009) further noted that patients with high labMELD have the
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highest probability of receiving a graft but they also exhibited the highest complexity and
severity of disease. MELD encompassed two parameters, creatinine and INR, and in this
analysis, these parameters were associated not only with the prediction of mortality
before transplantation, but appear to be also predictive of 90-day survival. In a recent
study, creatinine was also identified as an independent marker of posttransplantation
survival together with cholinesterase and age. Wiesmuller et al. further noted that INR
was associated with the length of operation time and this was found to also be an
independent variable predicting 90-day mortality. Wiesmuller et al. explained that recent
suggestions to modify the MELD score regarding INR and creatinine were confirmed.
This indicated that the currently employed MELD used for prioritization could be
modified to account for patients with complex morbidity to optimize overall
posttransplantation survival.
Asrani and Kim (2010) similarly explained that the MELD-Na was associated
with a higher risk of mortality independent of the MELD score in patients listed for liver
transplantation. The effect was greater in patients with a lower MELD score. According
to an analysis of 110 patients (23%), the difference between the MELD-Na and MELD
scores was large enough to have affected allocation priority. Asrani and Kim argued that
about 7% of the deaths on the waiting list could have been prevented if MELD-Na had
been used rather than the MELD. Asrani and Kim also similarly explained, in the face of
increasing use of ECD or high risk donors, identifying the right set of donor and recipient
matching characteristics that would lend to a better outcome after liver transplant should
be a significant objective.
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Donor and recipient matching should occur at the time of organ procurement and
transplantation with a substantial emphasis on selection going into accepting a donor
liver. Given the importance of advanced donor age and graft quality, the arithmetic
product of donor age and preoperative MELD (D-MELD) was recently evaluated as a
predictive model (Halldorson et al., 2009).
Expanded Criteria Donor and Donor Risk Index
The MELD era brought along with it not only the conceptual framework of a
sickest first policy for the reduction of time on waitlist to transplant but also the
conceptual framework of optimizing utilization that would be based on how to best match
donors and recipients. Blok et al. (2012) and Halldorson, Bakthavatsalam, Fix, Reyes,
and Perkins (2009) reviewed, analyzed, and discussed the composition and issues of the
DRI regarding donor-recipient compatibility for resource utilization in liver allocation.
Blok et al. and Halldorson et al. also analyzed the risk, concerns, and modeling associated
with DRI and posttransplant outcomes.
Blok et al. (2012) explained that a continuous scoring system for analyzing donor
risk, DRI, has been developed within the OPTN. Blok et al. also validated the use of DRI
in Eurotransplant. This was based on a database analysis of 5,939 liver transplants
involving deceased donors and adult recipients from January 2003 to December 2007.
In addition, Halldorson et al. (2009) explained that recently, two developments
have greatly impacted decision-making in liver transplantation. The first was the
adoption of the MELD to prioritize the sickest patients for transplantation. The second
was the increased use of higher risk donor livers to expand the donor pool and decrease
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time to transplantation. Halldorson et al. argued that since posttransplant patient survival
depends on both preoperative medical condition and donor liver quality, physicians are
often faced with the difficult decision on whether to accept high risk donor liver offers
for high risk patients. Halldorson et al. also elaborated that Feng et al. (2006) identified
nine donor factors predicting graft failure after transplantation (donor age, donor height,
donation after cardiac death donors, split liver donors, race, donor cause of death from
cerebrovascular accident, regional sharing, local sharing, and cold ischemia time). Using
these risk factors, a DRI was developed predicting the isolated and cumulative effects of
these variables on graft survival. While highly informative, a DRI system is not easily
translated into practical usage without making generalizations and extrapolations. In
general, however, donor age is the predominant donor risk factor.
Blok et al. (2012) explained that when these data were analyzed, a significant
correlation was shown between the DRI and outcomes. A multivariate analysis
demonstrated that the DRI was the most significant factor influencing outcomes. Among
all donor, transplant, and recipient variables, the DRI was the strongest predictor of
outcomes. Blok et al. similarly described that with the increased need for liver allografts,
the earlier and very strict criteria for liver donors have slowly become more liberal.
However, the use of donors with additional risk factors may influence outcomes after
liver transplantation. Currently, however, there is no unambiguous definition of what
exactly these donor risk factors are and the extent of these risks, such as donor age, cause
of death (COD), hypernatreamia, donation after cardiac death (DCD) status, and split
liver status.
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Halldorson et al. (2009) hypothesized that D-MELD, being the product of two
continuous variables (donor age and calculated preoperative MELD), would result in an
incremental gradient of risk for postoperative mortality and complications estimated in
hospital LOS. Halldorson et al. also hypothesized that this gradient could then be used to
identify a criterion where donor and recipient risks combined result in inferior outcome.
Blok et al. (2012) similarly noted the criteria used as risk factors for liver
donation. These risk factors include donor age greater than 65 years, an ICU stay greater
than 7 days, a high body mass index, steatosis, hypernatremia, high levels of aspartate
aminotranferase (AST), alanine aminotransferase (ALT), and serum bilirubin. If any of
these apply, a donor is considered marginal. However, Blok et al. argued that most of
these donor criteria have never been validated, and parameters such as donation after
cardiac death (DCD) status and split liver status were not included.
Blok et al. (2012) analyzed the set of factors contributing to DRI, which was
developed by Feng et al. (2006) with OPTN data, into a continuous scoring system.
These factors were based on only donor and transplant parameters found to significantly
influence outcomes after liver transplantation in a multivariate analysis of a large cohort
(20,023 transplants) from the Scientific Registry of Transplant Recipients (SRTR)
database. Blok et al. noted these factors to be the donor's age, race, height, COD, split
liver donation status, DCD status, type of allocation (local, regional, or national), and
cold ischemia time.
Blok’s et al. (2012) analysis showed that more than 48% of all transplants were
from donors 47.6 ±16.5 years old. Fifty-three point eight percent of all transplants were
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performed with livers recovered from male donors. Most donors died from
cerebrovascular accident (CVA) (63%), only a little more than one-quarter died from a
traumatic injury (27%). The DCD rate was 2.1% and the split liver donation rate was
4.4%. Among all donors, 0.9% was positive for hepatitis C core antibodies, and 5.8%
were positive for hepatitis B core antibodies. Blok et al. also noted the differences
between donor and transplant characteristics in OPTN/UNOS and Eurotransplant. The
mean donor age was much higher in Eurotransplant versus UNOS (48 versus 39 years).
The COD was more often CVA in Eurotransplant versus UNOS (63% versus 40.9%) and
was less often trauma in Eurotransplant versus UNOS (26.7% versus 41.9%). The DCD
and split liver donation rates were higher in Eurotransplant versus UNOS, and organs
were more often allocated regionally than outside their regions in Eurotransplant versus
UNOS. This resulted in a much higher mean DRI within Eurotransplant versus UNOS
(1.71 versus 1.45). Similarly, Blok et al. (2012) noted that in Eurotransplant, 57.6% of
all donors had a DRI > 1.5. This was the OPTN limit for twice as many discarded organs
in comparison with donors with a DRI ≤ 1.1.
Halldorson et al. (2009) similarly noted that patients with MELD ≥ 30 and
patients who received a donor liver aged ≥ 60 were analyzed as subgroups of the whole
population and then studied as a population. Both MELD ≥ 30 and donor age ≥ 60
subgroups demonstrated worse survival when compared to the population as a whole. DMELD was calculated as the simple product of donor liver age and laboratory-based
MELD score capped at 40. The D-MELD scores were divided into groups of 400 and a
D-MELD cutoff of 1,600 was found to best differentiate survival. Survival was
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improved in both high risk groups if D-MELD was limited to less than 1,600. In the
MELD ≥30 group, D-MELD < 1,600 demonstrated a 4-year survival of 71.3% versus
63.8% if D-MELD was 1,600 or greater. Halldorson et al. further noted that in all
subgroups, with and without hepatitis C, survival was superior if D-MELD was limited to
less than 1,600.
Blok’s et al. (2012) analysis also showed that the outcome was strongly
influenced by recipient factors. The recipient's age and the cause of liver disease were
important factors influencing the outcome as well. The mean laboratory MELD score at
transplantation was 20.3, and the mean age was 51.0 years. Halldorson et al. (2009)
similarly explained that various donor and recipient risk factors influence patient and
graft survival after liver transplantation. A major recipient risk factor is preoperative
MELD score. The most influential donor risk factor is age. Halldorson et al.
demonstrated that the product of these two factors, D-MELD, stratifies survival and LOS
after liver transplantation. Halldorson et al. further noted that currently, liver allocation
based on the MELD system is urgency which is based without regard for posttransplant
survival. The merits of this current system lie in its simplicity, objectivity, and accuracy
in predicting waitlist mortality. The downside was facing a dilemma in which centers in
low donor to recipient ratio regions compete for organs by transplanting the sickest
(highest MELD) patients or accepting the highest risk donor livers.
Blok et al. (2012) and Halldorson et al. (2009) did not only reviewed and
identified the risk factors of donor livers, their studies analyzed the composition of DRI
and established that the model D-MELD (Halldorson et al., 2009) can provide more
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definitive measurements on the outcomes of recipient and donor matches based on donor
age and recipient MELD score. The D-MELD measurement was the initial attempt to
fulfill the objectives of sickest first and resource utilization.
Increased MELD Scores and Extended Intensive Care Unit Stays
Dutkowski et al. (2011) and Foxton et al. (2010) noted that the MELD era not
only resulted in a higher mean MELD score, but also resulted in extended ICU stay,
hospital LOS, and overall health care cost. Both Dutkowski et al. and Foxton et al.
analyzed posttransplant data outside of the United States, although their results mirrored
the trends of the United States.
Dutkowski et al. (2011) explained that there is currently an intense debate about
whether liver grafts should be offered directly to a patient (the sickest one) or rather to a
transplant center with the freedom to use an organ for the patient of their choice. In the
United States, allocation of donor livers through the MELD system resulted in a
substantial decrease in median time to transplant from 981 days in 2002 to 306 days in
2006 (p. 675). Dutkowski et al. described that despite this change leading to sicker
patients at the time of transplantation, an initial analysis showed an excellent one-year
survival after liver transplantation in the MELD era.
Foxton et al. (2010) similarly explained that liver allocation for transplantation
worldwide has undergone dramatic change within the last 5 years, particularly with the
introduction of the MELD. This policy change occurred because of increasing demand
for liver transplant and increasing waitlist mortality. Foxton et al. explained that the
MELD system removed the time variable on the waitlist as a discriminating factor in
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allocation and mandated that organs are allocated to the sickest patients first. This has
successfully resulted in a decrease in waitlist mortality with no corresponding worsening
of mortality after liver transplantation.
Dutkowski et al. (2011) studied cost analysis of liver transplants that refers to all
costs accumulating from the time of hospital admission prior to surgery until first
posttransplant discharge. Dutkowski et al. further explained that as expected,
introduction of the MELD policy increased the laboratory median MELD score of
recipients from 13.5 to 20. One third of the transplanted patients, 32%, had a MELD
score > 25 compared to only 14% in the pre-MELD era. Correspondingly, the
preoperative incidence of hepatorenal syndrome increased in the MELD era from 14% to
35%. Significantly more patients in this group had to be hospitalized prior to liver
transplant, 18% versus 35%.
Dutkowski et al. (2011) further noted that despite sicker transplant candidates in
the MELD era, the proportion of patients with MELD ≥ 36 remained similar in both
groups (4% versus 10%). Dutkowski et al. also noted in 6 months after liver transplant,
the number of patients requiring renal replacement therapy was comparable and low in
both groups. In addition, the median serum creatinine was not different in both groups
after 6 months. Dutkowski et al. described that the median ICU and hospital LOS were 2
and 6 days longer during the MELD era, respectively. Also, the recipient MELD score
correlated significantly with hospital LOS. Dutkowski et al. tallied the median
cumulative cost per single case, which was from the time of admission to first discharge
after liver transplant, and confirmed an increase in cost from U.S. $81,967 during the pre-
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MELD era to U.S. $127,453 per case in the MELD era. Cost correlated strongly with the
individual MELD score.
Foxton et al. (2010) similarly noted that the median cost associated with the ICU
stay was U.S. $5,800 (IQR = U.S. $2,900 - $14,600). Forty-seven patients (11.7%) were
admitted to ICU more than once following their liver transplant. Their median MELD
score at transplant was 16. This was compared to a median MELD score of 14 for those
who did not require ICU readmission. The need for renal replacement therapy (RRT)
was associated with an ICU stay greater than 3 days. The median ICU cost of those
receiving RRT was U.S. $52,812, whereas in those who did not require RRT post-liver
transplant, the cost was U.S. $5,800. Foxton et al. explained that DRI was not associated
with increased cost, whereas the MELD score was associated with increased cost. Also,
when dividing DRI into groups, there was no correlation of any DRI group with
increased health care cost or prolonged ICU stay.
Dutkowski et al. (2011) further compared the overall outcome of transplantation
in a pre-MELD and MELD era. Previously, the number of patients with MELD > 25 at
the time of listing was very low at 8%. Probably due to the fact that sick patients had no
chance to receive a liver graft while waiting, and at that time, some end-staged candidates
were not even placed on the waitlist. And it can be hypothesized that the true death rates
were much higher in the pre-MELD era. Dutkowski et al. found that the number of
patients requiring renal replacement therapy in the post group exceeded the number of
comparable cases in the pre-group. However, 6 months after liver transplants, most
kidneys recovered in both groups. Dutkowski et al. noted that countries with very low
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donation rates are under higher pressure to use grafts from ECD. Dutkowski et al. found
the price of MELD allocation to be an increase in postoperative morbidity, resulting in
longer hospital stay, temporary renal complications, and higher health care cost.
Foxton et al. (2010) similarly found that their study demonstrated that ICU costs
associated with liver transplantation increased with increasing MELD score particularly
where MELD > 24. Recipient age, alcohol-related liver disease, and the severity of liver
disease prior to transplantation, in the form of UNOS status or CTP score, have been
shown to have significant impact on resource utilization according to the study of 711
patients who underwent liver transplantation in 3 U.S. transplant centers. Foxton et al.
explained that in their study, they were not able to identify recipient age or alcoholic liver
disease as factors that were associated with higher costs, although alcoholic liver disease
was associated with a prolonged ICU stay.
Foxton et al. (2010) iterated Feng’s et al. (2006) DRI formula as follows (p. 669).
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Dutkowski et al. (2011) concluded that the MELD system addresses the goal of
urgency and hence fairness the best. Despite the expected higher postoperative efforts, it
still appears to be the most reliable tool for selecting liver transplant candidates. Foxton
et al. (2010) likewise concluded that the group of patients with the highest MELD score,
≥24 points, also has the highest health care cost, reflecting significant increase in ICU
costs and therefore overall transplant costs. However, patients with MELD score ≥24
represented only 8% of the cohort. Foxton et al. also showed that there is a significant
increase in DRI over time which reflects the trend of transplant centers using more
marginal grafts. This finding mirrored the responses to organ shortage that was
experienced nationally and internationally. Foxton et al. noted that in practice, there was
a clear attempt to match better organ quality with patients of higher MELD scores. This
likely reflected appropriate matching of donor organs to recipients by experienced
surgeons in an attempt to optimize outcomes and maximize donor organ utility. Foxton
et al. also concluded that DRI failed as a predictor in determining total liver transplant,
pretransplant, or posttransplant cost.
Although Foxton et al. (2010) and Dutkowski et al. (2011) did not establish a
model fulfilling a liver allocation objective, per se, they showed the trends of the MELD
era with higher median MELD scores and that higher MELD scores correlated with
higher health care cost, longer ICU stays, and longer hospital LOS. Along with higher
MELD scores, there was more liberal criteria of accepting ECD livers, and hence the
need to stratify donor livers according to their DRI scores.
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Decision-Making of Multiple Objectives: Urgency, Utility, and Survival
The literature review of Rana et al. (2008) and Rodrique, Hanto, and Curry (2011)
did not only provide modeling and behavior perspectives of the ECD in liver allocation,
but the perspective of patients’ consent and feedback on accepting an ECD liver. This
helped to shape the simulation model to meet the multiple objectives of urgency, utility,
and survival with the possibility that an available liver is an ECD liver. The simulation
model not only simulated the delta-MELD as being a criterion, it also simulated the liver
allocation system realistically to the existing system, including the incorporation of ECD
livers.
Rana et al. (2008) argued that because recipient factors alone were not predictive
of survival following transplantation, a new model was required to accurately predict
posttransplant survival. The lack of consideration of donor risk factors is one limitation
of the existing standard, which is transplanting patients with a MELD greater than 15.
Rana et al. explained that recently, the DRI has been proposed as a method to stratify
outcomes associated with graft selection. However, the lack of recipient factors gave the
DRI alone poor predictive value. In their analysis, Rana et al. combined both donor and
recipient risk factors to construct the survival outcomes following liver transplantation
(SOFT) score to accurately predict recipient posttransplant survival at 3 months. This
score would allow clinicians to balance waitlist mortality at 3 months as predicted by the
MELD score against 3-month mortality following liver transplantation as predicted by
the SOFT score to determine which patients should undergo liver transplantation.
Rodrique et al. (2011) noted that despite notable efforts to increase rates of
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deceased organ donation and living liver donation, the supply of livers has not kept pace
with the growing demand for transplantation. Increased utilization of livers from higher
risk deceased donors is one strategy to overcome the severe organ shortage, although
there is no uniformly accepted definition for what constitutes an ECD liver. Rodrique et
al. explained that a DRI has been developed and can be used to assess the relative risk for
a potential graft and the relative risk for a specific recipient. Rodrique et al. further
argued that the decision to utilize an ECD liver for transplantation is complex where
patient's disease severity, comorbidities, and survival without transplantation are
considered. During the pre-liver transplant period, patients are informed of ECD versus
standard criteria donor (SCD) transplantations. Rodrique et al. explained that patients
would need to provide explicit consent for ECD liver transplants. This may be a
challenging decision for some patients, who must balance the risks and benefits of an
earlier ECD liver transplant versus the risks and benefits of waiting for a SCD liver
transplant at a time when their emotional, physical, and cognitive resources are likely
compromised.
Rana et al. (2008) explained that their risk score was actually two different risk
scores, the preallocation score to predict survival outcomes following liver
transplantation (P-SOFT), and the score to predict survival outcomes following liver
transplantation (SOFT). Rana et al. formulated two distinct scores. The P-SOFT is
designed to evaluate patients on the waitlist and the SOFT includes both donor and
recipient factors to evaluate transplant outcome at the time of transplantation. Rana et al.
explained that since MELD has been proven to be an accurate predictor of 3-month
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waitlist mortality, Rana et al. constructed the SOFT score to complement the MELD
score by predicting 3-month posttransplant mortality. The SOFT score along with the
MELD score would allow clinicians to make a more definitive decision on whether to
accept a particular allograft. Rana et al. argued that the SOFT score can also be used to
avoid wasteful transplants when predicted survival is below an acceptable standard. As
the critical liver allograft shortage encourages more aggressive practices to utilize
marginal donor allografts, the SOFT score can establish risk limits for particular liver
transplant candidates.
Rana et al. (2008) concluded that candidates with a MELD score ranging from 17
to 19 points should only receive low-risk SOFT transplants. Candidates with a MELD
score of 20-29 points should receive low or low-moderate risk SOFT transplants.
Candidates with a MELD score of 30-39 points should receive low, low-moderate, or
high-moderate risk SOFT transplants. And candidates with the highest waitlist mortality
risk with a MELD score of greater than 40 should receive low, low-moderate, highmoderate, or high-risk SOFT transplants. These recommendations likely do not apply to
patients with hepatic cancers since the benefit of early removal of tumor must also be
considered in addition to the MELD and SOFT scores. Rana et al. emphasized that
transplants in patients with a SOFT score of > 40 are likely futile since the predicted
posttransplant mortality is greater than any waitlist mortality.
Rodrique et al. (2011), on the other hand, studied the willingness of patients
accepting an ECD liver transplant. Transplant hepatologists or surgeons determine
whether a patient is medically eligible to receive an ECD liver transplant and would
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discuss this option with the patient. Eligibility includes the ability to read, speak, and
understand English, and the ability to provide written informed consent. Expanded
criteria donor liver transplant is discussed with patients during their initial visit with the
transplant hepatologist and subsequently during their appointment with the transplant
surgeon. Rodrique et al. noted that patients are also informed that they can pursue live
donor liver transplant at another program or deceased donor liver transplant in another
region, which may reduce the time they would otherwise have to wait for liver transplant
in their current program. Finally, all patients need to attend a 90-minute liver transplant
orientation class, which includes a discussion of ECD liver transplant, multiple listing,
and live donor liver transplants. Rodrique et al. argued that while there is considerable
discussion about the definition, breadth, and outcomes of ECD liver transplants, there
were no studies examining patients' willingness to accept ECD liver transplant. Hence,
the aim of their study was to assess patients' willingness to accept ECD liver transplant,
identify the increase in mortality risk they are willing to assume relative to a SCD liver
transplant, and examine the associations between sociodemographic variables and ECD
liver transplant willingness.
Rodrique et al. (2011) found that patients were significantly less willing to accept
ECD versus SCD liver transplants. Most patients were willing to accept a 1-year ECD
liver transplant mortality risk that is higher than that expected for SCD liver transplant.
Patients with high labMELD scores and patients of the white race were more willing to
accept ECD livers and ECD livers with higher 1-year post-liver transplant mortality risk.
Rodrique et al. found that in more than half of the study, patients reported a low
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willingness to accept an ECD liver transplant, and one-third were unwilling to consider
ECD liver transplant at all. Not surprisingly, patients with higher labMELD scores were
more willing to accept ECD liver transplant and higher 1-year post-liver transplant
mortality risk than those patients associated with SCD liver transplant. Rodrique’s et al.
analysis showed that the rate which patients are willing to accept an ECD liver with
higher 1-year mortality risk was 25%.
Rodrique et al. (2011) hypothesized that since the MELD score is a reflection of
the short-term survival probability without liver transplant, patients with higher MELD
scores may feel a sense of urgency in trying to best balance the ECD liver transplant
mortality risk with their risk of death while waiting for a higher quality SCD organ offer.
One could reasonably hypothesize that patients with hepatocellular carcinoma (HCC),
faced with potential malignancy and tumor progression, would be more willing to accept
an ECD liver than patients without HCC. This study did not support this hypothesis, as
patients with HCC did not differ from patients without HCC in their ECD liver transplant
willingness. Furthermore, MELD score with exception points was not associated with
ECD liver transplant willingness or mortality risk acceptability.
Regarding decision tools, Bernardi et al. (2011) described that an ideal decision
tool should be able to achieve multiple objectives. It should quantify a patient's chances
of survival in the short to medium-term for optimal allocation of patients waiting for liver
transplants. It should classify patients according to their disease stage, while enabling
doctors to determine whether it is too early, appropriate, or too late to perform a liver
transplant. It should also be able to predict outcome regardless of the disease. Finally, it
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should set aside subjective factors influencing the doctors' judgment, such as features of
the transplant center, human resources, and physician's individual expertise.
Freeman, Jamieson, Schaubel, Porte, and Villamil (2009) added that the widening
gap between the demand and supply of donor livers has prompted governments and
medical policy-makers to develop strategies to optimize liver graft allocation. While
realizing that the donor liver pool will never be sufficient to meet the demand, liver
transplant practitioners have tried to expand the criteria that define graft quality
acceptable for transplantation yet recognizing that expanding criteria often come with
risks to transplant recipients. Some of the most difficult decisions have been focused on
determining which patients with acute liver failure should receive transplants since most
will die without transplantation while realizing that only a fraction of these patients will
recover. Freeman et al. discussed that the allocation of liver graft should be based on
patient-based models that consider urgency, utility, and survival benefits, while
considering ECDs, HCC patients, and acute liver failure (ALF) patients.
The model formulas of DRI, D-MELD, P-SOFT, and SOFT were established to
meet the utility and survivability objectives, while accommodating to the current trend of
using ECD livers for liver transplant. Current literature revealed that ECD liver
transplants would require consent from patients acknowledging the risks and awareness
of accepting ECD livers. Hence, a decision-making model would take on multiple
objectives, multiple criteria, and the dependency of patient consent of ECD livers for the
research simulation.
In the next section, I review, evaluate, and assess the literature that is related to
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modeling a multiple criteria and objectives decision-making tool appropriate for the liver
donor allocation system, the analytic hierarchy process / analytic network process
(AHP/ANP). Both AHP and ANP encompass the quantitative measurement of
consolidating multiple objectives and criteria among many alternatives.
Literature on Multiple Criteria and Objective Decision-Making
Analytic Hierarchy Process / Analytic Network Process
The AHP’s usage, purpose, and construction are the focus of the following
literature review. The remaining literature review is based on the research by Parthiban
and Goh (2011), Danner et al. (2011), Ishizaka, Balkenborg, and Kaplan (2011b), Sipahi
and Timor (2010), and Ishizaka, Balkenborg, and Kaplan (2011a) on the use of AHP.
This collection of literature highlights how AHP is flexible, consistent, simple in the
development of pairwise comparisons, and straightforward in incorporating the decisionmaking requirements for the simulation model.
Danner et al. (2011) presented the AHP as a preference elicitation method in
health technology assessment. Their AHP study included two AHP workshops where in
these workshops, both patients and professionals rated their preferences with respect to
the importance of different endpoints of antidepressant treatment by a pairwise
comparison of individual endpoints. These comparisons were performed and evaluated
by the AHP method and relative weights were generated for each endpoint.
Danner et al. (2011) explained that the six most important patient-relevant and
professional-relevant outcome measures resulted in the same outcome for the two
independent groups, and thus validating the consistency of the AHP. These six endpoints
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covered 85% of the overall weights in the patient group and 89% in the professional
group.
Parthiban et al. (2011) proposed that an integrated model consisting of
performance measurements and quality factors measurements can be evaluated by using
the AHP. Parthiban et al. provided a way to identify the current performance of an
organization and a methodology for further improvement. An important contribution of
the AHP model is that it combines both the qualitative and quantitative dimensions of
manufacturing performance measurements. For Parthiban et al., both the objective and
manufacturing quality factors have been converted into consistent dimensionless indices
to measure system performance. Partiban et al. demonstrated that the applicability of the
AHP model can support a manufacturing performance measure where AHP can be used
to calculate the two different manufacturing units using time, cost, and service quality
dimensions.
Ishizaka et al. (2011b) used experimental economics methods to test how well
AHP fared as a choice support system in a real decision problem. Analytic hierarchy
process provided a ranking that can statistically compare with three additional rankings,
given by the subjects in the experiment, one at the beginning, one after providing AHP
with the necessary pair-wise comparisons, and one after learning the ranking provided by
AHP. While these rankings varied widely across subjects, it was observed that for each
individual, all of the rankings were similar. Hence, AHP was able to replicate their
rankings. Furthermore, the AHP ranking helped the decision-makers reformulate their
choices by taking into account suggestions made by AHP.
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Sipahi and Timor (2010) presented a detailed literature review of the recent
applications of the AHP and analytic network process (ANP) group decision-making
methodologies. The findings showed that during the years 2006-2009, the use of the
AHP technique has continued to increase exponentially. Moreover, it is expected that
ANP will gain more popularity in manufacturing, followed by the environmental
management and agriculture field, power and energy industry, transportation industry,
construction industry, and healthcare industry.
Ishizaka et al. (2011a) described a decision problem with an inherent trade-off
between two criteria. For instance, a job may require two unrelated skills and workers
tend not to be adept at both. Ishizaka et al. compared the additive AHP and its variant,
the multiplicative AHP (MAHP), with the utility theory to evaluate the choice among
three alternatives: two extremes and one compromise. The utility theory has a normative
approach and AHP a descriptive or a practical orientation. In this study, Ishizaka et al.
aimed to demonstrate the effects of the aggregation method of local priorities and the
measurement scale of AHP on the selection of a compromise, and hence to the degree of
agreement with the utility theory.
AHP Background and Applications
The experiments among the researchers were varied and the results of their
studies would show that AHP is a valid decision-making tool, which can be integrated
with other tools, and can be used to aid in decision-making processes. In addition, from
the wide amount of research in literature, AHP and ANP are shown to be versatile,
consistent in their technique, and are widely applied into decision problems across
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multiple industrial sectors.
Danner et al. (2011) explained that AHP is an approach where a multi-attribute
decision problem is first structured into a hierarchy of interrelated elements. This
hierarchy is a tree-like structure that is used to decompose the decision problem, moving
from main criteria to more specific sub-and sub-subcriteria. Pairwise comparisons of
these criteria are separately performed at each level of a decision hierarchy from the
lower-level to the upper-level criteria. Important methodological constraints within AHP
regarding the decision hierarchy are the independence and comprehensiveness of criteria
at each level. Danner et al. further explained the matrices of the pairwise comparisons,
Saaty's mathematical algorithm as a key element within AHP allowing the calculations of
an approximation vector representing preference-based weights for each of the decision
criteria. While the preferences in AHP are recorded on a numbered but ordinal scale,
calculation of preference weights is performed by transforming this scale into an
approximation cardinal one. Danner et al. further explained that weights can be
calculated for each endpoint and for each person, and the group geometric mean can be
calculated for a group of individuals taking part in the AHP. In addition, because
reciprocity and transitivity of preferences is required within AHP, AHP allows for
calculation within a measure of consistency for each group of pairwise comparisons.
This measure reflects how logical each pairwise comparison is with regard to the
remainder of comparisons performed by the same individual. This consistency ratio, as a
measure of performance within the AHP, has a threshold of 0.1 that should not be
exceeded.
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Parthiban et al. (2011) demonstrated the steps of AHP using criteria from
performance measures that were classified into objectives and quality factors. A
structured survey was conducted at two organizations, Unit A and Unit B using the same
questions to elicit the performance measure classified into objective and quality factors.
After the AHP was performed, the quality factor measure was then calculated from the
results of AHP, followed by the service factor measure for both locations, A and B. This
yielded a result that Unit A has a lower service factor measure value which meant Unit A
needs improvement more than Unit B. Quality function deployment has been employed
to facilitate this process. This was useful in establishing the priority of actions within the
overall re-engineering strategy.
Sipahi and Timor (2010) reviewed recent literature that was comprised of a
comprehensive literature review of recent applications of AHP and ANP as decision tools
over the period of 2005-2009. Saaty (2001) developed the AHP technique, which
constructed a decision-making problem in various hierarchies as goal, criteria, subcriteria, and decision alternatives. Sipahi and Timor also explained that AHP provides
decision-makers with a way to transform subjective judgments into objective measures.
Due to its mathematical simplicity and flexibility, AHP has been a favorite decision tool
for research in many fields, such as engineering, food, business, ecology, health, and
government. Saaty (2001) also developed another technique, the ANP technique, as a
generic form of AHP that allows for more complex interdependence in relationships, and
feedback among elements in the hierarchy. Sipahi and Timor further explained that ANP
has been used in several decision-making applications in the last decade, especially in the
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study of risk and uncertainty.
Ishizaka et al. (2011b) noted that while the rankings vary widely from individual
to individual, they found, by using a variety of non-parametric statistical tests, that for
each individual the ranking generated by AHP is typically in reasonable agreement with
the rankings provided by each participant. While the study did show that AHP detected a
clear top and least priorities well, the study also found that the other rankings given by
the subjects tend to be closer to each other than they are to the AHP ranking. Ishizaka et
al. also noted that there is evidence that the subjects tend to follow the ranking provided
by AHP and found the experiment showed that AHP is a useful decision tool and that
AHP could be used as a decision aid.
Ishizaka et al. (2011a) elaborated that one of AHP's strengths is the possibility to
evaluate quantitative and qualitative criteria and alternatives on the same preference
scale. In Saaty's AHP, the verbal statements are converted into integers from 1 to 9.
Theoretically there is no reason to be restricted to these numbers. Therefore, other scales
have been proposed. With integers 1 to 9 being local weights, which could be unevenly
dispersed, there could be a lack of sensitivity when comparing elements which are
preferentially close to each other. Using a logarithmic scale could be smoother for these
high values.
Ishizaka et al. (2011a) explained the decision technique of AHP and MAHP.
This study described and discussed the hiring decision problem solved with AHP and
MAHP. All the possible matrix combinations with an acceptable consistency were used
with each preference scale. For the MAHP, four different weight normalizations were
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applied. Then, the results of the AHP and MAHP were compared with the consumer
choice theory. The final position of a compromise in a candidate was selected. Ishizaka
et al. compared the result with the standard consumer theory where the consumer would
prefer a compromise alternative B. The choice of a power or geometric scale excluded
definitely (for AHP) or almost definitely (for MAHP) the compromise alternative. The
MAHP captured the obvious case in which B should win.
AHP Decision-Making with delta-MELD for Simulation
The strength of the AHP method is in its method to reduce the cognitive burden of
decision-making by decomposing a complex decision problem into a limited number of
pairwise comparisons (Ishizaka et al., 2011b). The AHP with its applications of pairwise
comparisons of criteria is shown to be in accordance with human behavior, especially if it
is based on bounded rationality. Saaty's (1996) method of deriving priorities from
pairwise comparisons based on matrix multiplication and the eigenvector calculation is
not only mathematically sophisticated, but it is reflective of human decision-making. The
decision-making of selecting a liver transplant recipient, using an integrated model of
urgency (MELD-based), utility (DRI), and survivability (SOFT) can be set up, modeled,
and constructed by AHP.
The literature review showed that AHP is a powerful decision tool for assessing
decisions of many and various decision situations. Although AHP does not take into
account dependencies and interrelationships among factors, real world problems usually
consist of dependencies or feedback between elements (Sipahi & Timor, 2010). One
such example is in the application of the simulation model where feedback is needed
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from patients to agree on accepting ECD livers for liver transplant. For this reason, ANP
was considered for taking into account patient consent.
To summarize the MELD-based aspect of the literature review, my analysis of
Huo et al. (2008) and Biselli et al. (2010) provided a comparison and assessment of the
MELD-based models of MELD-Na and iMELD with conclusive and known results for
refining the liver allocation system. But the analysis of Foxton et al. (2006), Young et al.
(2006), and Cholongitas et al. (2006) conflicted with Bambha et al. (2004) on the
assessment of the MELD-based delta-MELD for refining the liver allocation system.
These studies did not use AHP for decision-making analysis, but delta-MELD used as a
major criterion in an AHP could help to resolve this conflict in literature regarding the
delta-MELD utility for refining the liver allocation system.
Although Young et al. (2006) mentioned that a study should be designed to
definitively disregard or accept the delta-MELD for refining the liver allocation system,
there was still missing research on the assessment of delta-MELD as a valid criterion for
liver allocation. Gotthardt et al. (2009) argued that an effort to improve the MELD
system should involve analyzing the change in MELD scores, delta-MELD, over time as
this dynamic variable would reflect the progression of disease in patients. AHP appeared
to be an appropriate model to analyze whether the current liver allocation can be
improved upon by taking into account the MELD as primary criterion and then
comparing it to an AHP model with both the MELD and delta-MELDs as primary
criteria.
Meanwhile, a recent trend of the liver allocation system has moved from the
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objective of urgency to include utility and survivability. In addition, since the earlier and
very strict criteria for liver donors have become more liberal, ECD livers have recently
become more widely employed for liver transplant than in the past. This suggests that
these factors needed to be considered for the study on the role of delta-MELD for liver
allocation. A study needed to be conducted to deterministically conclude the utility of
delta-MELD with consideration of the recent trends of the current liver allocation system.
It was conceivable to consider delta-MELD along with the recent trends of the current
liver allocation system in the construction of an AHP model for this study.
Conclusion
The literature review described the MELD and MELD-based development, and
described the history of MELD in the evolution of the liver allocation system. The
MELD-based variable, delta-MELD was defined, its background of its use in research
was evaluated, and its gap regarding it being a viable criterion for liver allocation in
literature was reviewed.
Young et al. (2006) sought to minimize the bias due to various collection method
of the MELD data by using the MELD scores at entry and exit from the waitlist. The
varying duration on the waitlist among patients suggested that a methodology should be
considered to approximate the delta-MELD into consistently measured time intervals.
Young et al. further explained that a study should be conducted to fully clarify the role of
delta-MELD in liver allocation. Since decision-making in liver allocation system has
evolved from the objective of urgency to include utility and survivability, decisionmaking should be multi-objective while integrating with the OPTN liver allocation.
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Also, since ECD livers have recently been more widely employed for liver transplants
than in the past, ECD livers were also considered in the study of delta-MELD for liver
allocation.
In Chapter 3, I describe, outline, and define how the simulation was performed in
two scenarios, with and without delta-MELD being used as criterion. Chapter 3 will
explain how the average MELD scores and number of patients dropping off the waitlist
from the two scenarios were compared. The decision-making technique behind the
simulation was AHP.
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Chapter 3: Research Method
In Chapter 3, I describe the research design, variables, parameters, and instrument
(a simulation model). The simulation was run to determine whether delta-MELD should
be used in addition to MELD as primary criteria in patient selection. As a patient
selection criterion, the delta-MELD could improve the liver allocation system by
reducing the number of pretransplant patients from dropping off the waitlist (Research
Question and Hypothesis 1) and by lowering the average MELD score among
pretransplant patients (Research Question and Hypothesis 2). The experiment utilized a
simulation model of two scenarios which used secondary data from the OPTN/UNOS
Standard Transplant Analysis and Research (STAR) database, additional estimated
MELD values computed through a Kalman filter, and computed delta-MELD values.
The additional MELD values through the Kalman filter supported consistent
measurements of delta-MELD values among all patients on the waitlist. The theoretical
frameworks of Kalman estimation and AHP for patient selection were applied in the
simulation experiment. The simulation model, data collection by Kalman estimation,
decision-making by the AHP technique, and the OPTN liver allocation policy are
elaborated in the sections below.
In Chapter 3, I provide justifications on the validity of the research instrument and
its methodologies. In addition, explanations of how the simulation outputs data for
research summary, analysis, and conclusion are provided. Finally, in Chapter 3, I explain
how the results of the experiment were designed to answer the research questions and
hypotheses.
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The Institutional Review Board (IRB) approval number for this study is 05-01-140175913.
The Research Design
Frankfort-Nachmias and Frankfort (2008) described quantitative research as a
deductive research that deals directly with the operationalization, manipulation of
variables, predictions, and testing. Hence, quantitative research places particular
emphasis on the research methodology, procedures, and their validity. Consequently,
quantitative research design should be arranged to show a clear progression from theory
to operationalization of concepts, a correspondence from the choice of methodology to
the procedures, and the association from statistical tests to findings and conclusions (p.
488). Furthermore, the findings and conclusions would relate and provide answers to the
research hypotheses and questions.
Hillier and Lieberman (2010) outlined the steps that a major simulation study
should contain. These steps include identifying the research problem, collecting the data,
formulating the simulation model, constructing the computational program, planning the
experiments to be performed, conducting analysis of the experiments, and summarizing
and concluding the study. In addition, the research design details how the data are
gathered, processed, and measured, and how the simulation is constructed and used to
influence its outcome.
The description of the research questions and hypotheses, process and steps,
variables, data collection through secondary data, data organization for the simulation,
and simulation model are described below.
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Research Questions and Hypotheses
The research questions and hypotheses below are repeated from Chapter 1.
1. Does a simulation model using the additional parameter of delta-MELD as a
patient selection criterion reduce the number of pretransplant patients who
dropped off the waiting list?
The research hypotheses for the first research question are as follows.
Ho: There is no difference in the number of patients who dropped off of the
waiting list (Total_Patients_Removed) between simulation models with and without
delta-MELD along with the MELD score as primary criteria for patient selection in donor
liver allocation.
Ha: There is a difference in the number of patients who dropped off of the waiting
list (Total_Patients_Removed) between simulation models with and without delta-MELD
along with the MELD score as primary criteria for patient selection in donor liver
allocation.
2. Does a simulation model using the additional parameter of delta-MELD as a
patient selection criterion lower the average MELD score among pretransplant
patients?
The research hypotheses for the second research question are as follows.
Ho: There is no difference in the average MELD score (MELDmean) among
pretransplant patients between simulation models with and without delta-MELD along
with the MELD score as primary criteria for patient selection in donor liver allocation.
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Ha: There is a difference in the average MELD score (MELDmean) among
pretransplant patients between simulation models with and without delta-MELD along
with the MELD score as primary criteria for patient selection in donor liver allocation.
Research Process and Steps
The research process and steps in Table 1 comprise the research design.
Table 1
Research Process and Steps
Research Process and Steps
Step 1

Identify/describe the problem and the plan of study. Describe research
purpose, questions, and hypotheses for simulation.

Step 2

Describe the control factors and response variables.

Step 3

Formulate the simulation model. Describe key pieces of data, processes,
parameters, and events in the model.

Step 4

Ensure the validity of the simulation model. Describe how the theoretical
frameworks are incorporated into the simulation and their construct validity
for the simulation.

Step 5

Test (verify) the simulation model.

Step 6

Plan the simulation experiment to be performed. Organize combinations of
the control factors (inputs to the simulation/experiment) in some form of an
experiment.

Step 7

Conduct the experimental simulation runs and analyze the results. Perform
quantitative analysis on the outputs of the simulation runs by conducting
statistical t tests of two independent populations in order to test the
hypotheses.
Provide analysis, conclusion, and summary of the research questions, based
on the results of the hypothesis tests. Provide explanation of limitations and
recommendations for future studies.

Step 8
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Simulation Overview
The simulation and its computations were implemented by using Microsoft Excel
and C++ programming language with NetBeans’ integrated development environment
(IDE) for the Windows operating system. The simulation generated output data (the
response variables) in two scenarios: (a) using only MELD as primary criterion, and (b)
using delta-MELD and MELD as primary criteria in the simulation scenarios. Hence, the
control factor for the experiment was the presence or absence of delta-MELD as a
simulation parameter.
There were two response variables for this research: the number of pretransplant
patients who dropped off the waitlist (Total_Patients_Removed for Research Question
and Hypothesis 1) and the average MELD score among pretransplant patients (MELDmean
for Research Question and Hypothesis 2). Detailed descriptions of the simulation
variables, parameters, data organization, and validity are explained.
Variables and Parameters in this Research
The MELD and delta-MELD were the primary simulation parameters of interest.
The MELD values were used to compute the delta-MELD parameters, where
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(Young et al., 2006). Regarding the use of delta-MELD, the control factor for the
simulation experiment was indicated by DM for indicating whether or not to reference the
simulation parameter delta-MELD into the AHP decision-making. Therefore, DM was a
categorical variable which assumed one of two values (with delta-MELD, without deltaMELD). The simulation ran two scenarios: one with and one without delta-MELD.
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The simulation model ensured that all patients’ delta-MELD scores can be
uniformly compared from an evenly distributed time series. In order to obtain an evenly
distributed set of MELD values for consistent and unbiased computation of delta-MELD
values, the Kalman estimation was performed. Patient MELD scores were referenced to
support the Kalman estimation for additional MELD values. The MELD score is a
parameter supplied by UNOS that is calculated using serum creatinine, serum total
bilirubin, and the INR according to the following formula as is currently used by the
UNOS organization.
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The MELD data through Kalman estimation for delta-MELD values were derived
data from the UNOS STAR database. This database was requested from the OPTN
organization. The UNOS STAR database, provided by UNOS, contained waitlist,
patient, donor liver, and posttransplantation information on all recipients undergoing liver
transplantation in the United States since 1987 (Northup & Berg, 2004).
The delta-MELD values were computed in order to be used as a primary patient
selection criterion for liver allocation when the indicator DM indicated that the scenario
with delta-MELD is to be run. Patient selection was performed in the simulation by the
AHP processing.
Other simulation parameters of this research included DRI and SOFT parameters.
In addition to the two important and primary parameters used for donor liver allocation,

87
MELD and delta-MELD that were used to fulfill the medical urgency objective, the
parameters DRI and SOFT were used to meet the utility and survivability objectives.
These simulation parameters, DRI and SOFT, were referenced in the patient selection
decision-making. Within the two scenarios with and without delta-MELD, the same
donor liver data were referenced from the UNOS STAR database. The DRI and SOFT
values were not manipulated or varied between the scenarios with and without deltaMELD. In addition, when patient data were retrieved from the STAR database and were
referenced within a 180-day simulation interval, they were the same patient data used in
both scenarios with and without delta-MELD. The computation of the DRI parameter is
expressed using equation (11). The computation of the SOFT parameter is as follows.
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Donor_Risk_Factors and Recipient_Risk_Factors are listed in Table 2 and Table 3.
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Table 2
Donor Risk Factors
Donor Risk Factors

Risk Points

Age > 70

3

COD (anoxia, trauma)

2

Creatinine > 1.5

2

National Procurement

2
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Table 3
Recipient Risk Factors
Recipient Risk Factors

Risk Points

Age > 70

4

BMI > 35

2

Albumin < 2.0

2

Previous Abdominal Surgery

2

Dialysis pretransplant

3

ICU pretransplant

6

Hospitalized pretransplant

3

MELD 30-39

4

MELD ≥ 40

4

Life support pretransplant

9

Encephalopathy at transplant

2

Portal vein thrombosis at transplant

5

Portal bleed within 48 hours pretransplant

6

Ascities pretransplant

3

In each 180-day interval, even with different replications, the simulation used the
same pool of patients against the same pool of livers. With each replication, the same
scenario in each interval was used in both scenarios (two decision-making
criteria). However, even though both scenarios involved identical patients, the model
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was stochastic because in each replication, the livers and their arrival times were
randomly generated. In addition, not only were DRI and SOFT simulation parameters
referenced as decision criteria for patient selection, but the DRI and SOFT parameters
were stochastic since there was no way to know in advance the liver type, liver data, and
the timing that a donor liver would become available for transplant. But the DRI and
SOFT values were from the same liver data in both the scenarios with and without deltaMELD. The MELD and delta-MELD parameters, as well as DRI and SOFT parameters
were referenced for AHP scoring in the simulation for patient selection.
Although the parameters, DRI and SOFT, were referenced in each of the ten 180day simulation scenarios for patient selection, they were both considered to be much
lower in importance compared to the MELD and delta-MELD scores. Subsequently they
were rated (weighted) consistently much lower than MELD and delta-MELD in both
scenarios whether using delta-MELD or not. The trend in literature, as discussed in
Chapter 2, suggested that DRI and SOFT parameters were realistic factors in patient
selection although the MELD and delta-MELD were the primary factors fulfilling the
sickest first objective.
In addition to the MELD, delta-MELD, DRI, and SOFT parameters for decisionmaking within the simulation model, the response variables of Average_MELD and
Patients_Dropped_From_Waitlist were both computed and output by the simulation
model. They were compiled at the end of each simulation week and would subsequently
be summed or averaged within a 180-day interval to compute the response variables that
determined whether the research hypotheses would be accepted or rejected.
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The Patients_Dropped_From_Waitlist parameter was processed from the
simulation’s Disease Progression and Waitlist Patient Management processes.
Patients_Dropped_From_Waitlist was computed by adding all the patients who had
dropped off from the waitlist at the end of each week based on patient data from the
UNOS STAR database. The removal of patients from the waitlist was based on patients’
MELD score, hazard ratios based on MELD scores, and patients who were deemed too
sick to transplant.
The average MELD from the simulation model (dependent variable) was
computed over ten 180-day intervals, producing ten MELDmean values. For each interval,
MELDU
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as there are 26 weeks in one 180-days interval. The total number of patients dropping off
of the waitlist from the simulation model (dependent variable) was also computed over
ten 180-day intervals, producing ten Total_Patients_Removed values. For each interval,
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For both the response variables, MELDmean and Total_Patients_Removed, the
control factor, DM, was postulated to be influential. This was because in addition to the
parameters of MELD, DRI, and SOFT, the simulation model with delta-MELD as a
decision criterion could affect the final decisions of winning patients differently from the
scenario without delta-MELD. The response variable MELDmean relied on
Average_MELD(n=1…26) compiled over weeks on the waitlist, and like the response
variable, Total_Patient_Removed, it could be affected by the choices of winning patients
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which were based on MELD, delta-MELD, DRI, and SOFT. The processing of these
variables and parameters are further elaborated in the sections, Simulation Outputs,
Experiment and Sample Size, and Hypothesis Testing.
Data Collection through Secondary Data
The main source of data collection was through secondary archived data, which
was received upon request from the OPTN and the UNOS organizations. I filled out an
agreement form indicating that this data was not used to pursue contact of any individual
patient. There was a programming fee of $200 for a university researcher not associated
with a liver transplant hospital to use the UNOS STAR database requested from OPTN.
OPTN/UNOS STAR database was received by postal mail which consisted of
patient data and donor liver data from the OPTN/UNOS organizations. Patient data
included age group, gender, race, primary cause of disease, transplant history, blood type,
MELD scores, date of MELD scores, time on wait list, and status. Donor liver data
included donor age, donor height, donation after cardiac death donors, split liver donors,
race, donor’s cause of death from cerebrovascular accident, regional sharing, local
sharing, and cold ischemia time.
In a study by Halldorson et al. (2009), the UNOS STAR national transplant
database was referenced to analyze survival for first-time liver transplant recipients with
chronic liver failure. In this study, following approval by the University of Washington
Institutional Review Board, Halldorson et al. extracted all records of recipients
transplanted for chronic liver disease from UNOS Standard Transplant Analysis and
Research (STAR) files from January 1, 2003 through December 31, 2006. The data were
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referenced to compute the D-MELD parameter. This required the referenced donor liver
data in order to compile the DRI parameter. The DRI parameter consisted of a
computation based on nine risk factors and it was referenced to compute D-MELD for the
study of Halldorson et al. Similar to Halldorson et al., the simulation model referenced
patient data and donor liver data from the UNOS STAR database.
I utilized OPTN data in the four processes of the research simulation. Donor liver
data contained the DRI composition which, according to Feng et al. (2006), included nine
parameters, were needed to compute the DRI parameter. Patient data were needed to
determine compatibility and urgency considerations. Data from the five years of 20082012 were processed by the simulation model. The DRI parameter is expressed using
equation (11).
Rana et al. (2008) developed the SOFT score by combining patients’ MELD and
risks scores. The risks scores come from both donor and recipient risk factors and their
risks points are summarized in Table 2 and Table 3. Finally, the MELD, delta-MELD,
DRI, and SOFT scores were normalized prior to being referenced in the AHP algorithm.
Data Organization for the Simulation
Foxton et al. (2010) explained that liver allocation for transplantation worldwide
has undergone dramatic changes within the last 5 years, particularly with the introduction
of the MELD. Liver allocation policy changed because of increasing demand for liver
transplants and increasing waitlist mortality. Hence, sample data of years 2008-2012
were used as these years are recent. There are 11 Organ Procurement Organization
(OPO) regions in the United States. The data requested were from the one of the most

94
populous yet confined OPO regions, Region 9, of the United States. Region 9 includes
New York state and western Vermont.
Burr and Shah (2010) explained that the United States has 58 OPOs and 11
UNOS regions. Within the regions are multiple OPOs. Furthermore, the OPO
centralizes the patients from the waiting lists of all centers within its coverage area and
assigns them priority based on the MELD score, so that available organs will first be
allocated to patients in descending MELD order within each specific OPO. Organ
allocation is prioritized as local (within the OPO), then regional (within a UNOS region)
and finally, national (p. 134).
Burr and Shah (2010) further explained that the purpose of this allocation is to
reduce cold ischemia time by shipping the organs within a confined region. Reducing
cold ischemia time improves the quality of the transplanted organ. Hence, the simulation
model limited the study to one region, Region 9, and limited the scope outside the need to
concern with cold ischemia time and varying MELD averages of additional regions, by
focusing solely on one region, Region 9, which is confined to the area of New York state
and western Vermont.
The patient and donor liver data from Region 9 were used for simulation input.
However, the patient data were taken from the UNOS STAR database to enter in the
waiting list according to the time interval according to their entry timeframe, but the
donor liver was randomly selected from the UNOS STAR database when simulating the
arrival of a donor liver. The timing of the arrival of donor liver was determined by a
Poisson process. This way, the content of a patient and a donor liver were from real
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patient and donor liver data, while the timing and order of available livers were not based
on any actual occurrences. But the data of patients and the data of donor livers were from
actual data.
MELD projections based on timed intervals. The patient data and donor liver
data received from OPTN/UNOS were organized to accommodate an event driven
simulation. The patient data were organized into one of the 10 simulation interval based
on UNOS’ date of entry. The arrival of an available liver was randomly selected from
the pool of donor livers at the UNOS-based average rate determined by a Poisson
process. This meant that the timing of the actual matching of liver to patient was not
replicated according to the archived data, but by the arrival of livers processed by the
simulation model. Donor livers were randomly selected from the list of donor livers
which were from UNOS STAR of the 2008-2012 timeframe. The intent was to simulate
the same sequence of events in both scenarios, without and with delta-MELD, with the
purpose of comparing their outcomes.
Kalman estimation of MELD values. An additional method of gathering data
was by the computation of additional and estimated MELD values through the Kalman
algorithm. It was through this form of data collection that the simulation was able to
process sufficient MELD values for a steady flow of available and consistently computed
delta-MELD values. The delta-MELD values were used for decision-making in the
simulation model.
The Kalman estimation was used to estimate a steady supply of time series
MELD values for the consistent computation of delta-MELD values. The OPTN
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stratification of MELD scores were applied in the simulation model as described in the
OPTN liver allocation policy section. Steps were taken to use the Kalman estimation for
additional MELD data that were computed from patient MELD scores.
Appendix A illustrates the steps and a basic example of an Extended Kalman
Filter (EKF). The progression of actual disease progression is likely to be non-linear and
hence, in the simulation model, the EKF was used for capturing the series of sequences
that are likely to be non-linear approximations. After the time series of MELD values
were computed, the time series of MELD values were referenced to compute the deltaMELD values. Then, patients were stratified according to their MELD scores in the
following OPTN liver allocation policy levels for patient selection. This was done in the
AHP processing of the simulation. Appendix B illustrated an example of an AHP
processing.
OPTN liver allocation policy. In each OPO, the purpose of allocating livers is to
enable physicians to apply their consensus medical judgment for the benefit of liver
transplant candidates as a group. Each candidate is assigned a status or probability of
candidate death that has been derived from their MELD score reflecting the degree of
their medical urgency. The MELD score is the patients’ mortality risk scores determined
by prognostic factors. Candidates are then stratified by the MELD score and by blood
type similarity (Organ Procurement and Transplantation Network, 2014).
Regarding the hierarchy of decision-making, donor livers are offered to
candidates first with an assigned status of 1A and 1B (highest priority) in descending
point sequence with the candidate having the highest number of points receiving the
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highest priority before being offered for candidates of lower probability rankings. At
each hierarchical level, adult livers are allocated in descending sequence order most
urgent to least urgent in the OPO hierarchy groups as follows.
1. Status 1A / Status 1B candidates in descending point order (local and regional).
2. Candidates with MELD scores ≥35 in descending order of mortality risk MELD
scores with local candidates ranked above regional candidates at each level of
MELD score (local and regional).
3. Candidates with MELD scores 29-34 in descending order of mortality risk MELD
scores with local candidates ranked above regional candidates at each level of
MELD score (local).
4. Liver-intestine candidates in descending order of Status and mortality risk MELD
scores (national).
5. Candidates with MELD Scores 15-28 in descending order of mortality risk
MELD scores (local).
6. Candidates with MELD Scores 15-34 in descending order of mortality risk
MELD scores (regional).
7. Candidates with MELD Scores < 15 in descending order of mortality risk MELD
scores (local first, then regional).
These categorical levels were reflected in the AHP scoring algorithm which
ensured that the OPTN categories were adhered to. In other words, the AHP algorithm
ensured that a candidate in category 3 (with a MELD score of 29-34) would never
supersede a candidate of the same blood type in category 2 (with a MELD score ≥ 35).
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Figure 1 is an illustration of hierarchy which the AHP scoring would adhere to.
Within a hierarchical level, the AHP scoring is ordered according to medical urgency
(sickest first) and blood type, with the consideration of the donor liver quality and
survivability factors.

Status 1A/B
MELD >35 (Local & Regional)
MELD = 29 - 34 (Local)
Liver-Intestinal (National)
MELD = 15 - 28 (Local)
MELD = 15 - 34 (Regional)
MELD < 15 (Local first, then Regional)

Figure 1. Hierarchy of MELD levels for liver allocation.
The priority of the decision-making is to consider patients at the highest MELD
level first. When there are no candidates with a valid match at an existing priority level,
then patients of the next lower priority level are considered.
Internal and External Validity of the Simulation Components
The internal validity of the simulation method lies in using secondary data for the
simulation model to ensure sampling validity, and in the systems perspective of the
simulation to simulate the actual liver allocation system. In addition, the simulation
reflected the objectives and processes of the actual donor liver allocation system.
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According to Frankfort-Nachmias and Nachmias (2008), one kind of validity that is
primarily related to the instrument is the sampling validity. In the Simulation validity
section, the sampling validity is described. The construct validity of the simulation is
described in the sections, Analytic hierarchy process validity and Kalman estimation
validity as it is the premise of these theoretical frameworks that the simulation was built
upon.
Simulation validity. Frankfort-Nachmias and Nachmias (2008) defined research
method validity as three basic types of validity, content validity, empirical validity, and
construct validity. These validities relate to a specific type of evidence and conditions (p.
149). The simulation validity was established by relating the measuring instrument of the
data collected which really was the actual data to the general theoretical framework.
Secondary data were requested and OPTN allocation levels were implemented to reflect
the actual MELD scoring and decision-making of the existing U.S. liver allocation
system. Secondary data were also used to extend the MELD time series with additional
MELD values.
Regarding sampling reliability, OPTN data are open for researchers to use for
research and the OPTN organization is a reliable resource for the research of patient,
donor liver, and waitlist history related to organ transplant. According to Northup and
Berg (2004), the data requested from the OPTN/UNOS organizations is from the most
comprehensive liver transplant reference database presently in existence in the United
States (p. 1648).
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The data pertaining to this research were based on the recent 5 years of 20082012. The simulation time duration was 180 days for each of the 10 intervals where there
are approximately two 180 day intervals per year. Requesting for multiple years of data
ensured that there was enough data to carry out the analysis for a statistical conclusion
and ensured that the sampling sizes were adequate.
Regarding content validity of the simulation program, not only were patient and
donor liver data based on actual data, but the OPTN liver allocation levels were
integrated into the AHP decision-making. Also, the percentage of ECD acceptance was
taken from peer-reviewed literature and it was accounted for in the simulation model.
The objectives of urgency, utility, and survivability, by the measurements of MELD,
DRI, and SOFT normalized scores, were integrated into the AHP algorithm.
Analytic hierarchy processing validity. Regarding the use of AHP as a valid
tool for multi-criteria decision-making, Saaty (1996) explained that it is of high
importance to recognize measurements of various kinds of scales and in particular, the
ratio scales. An ordinal scale is a set of numbers that is invariant under monotone
transformations. In other words, ordinal numbers can neither be multiplied nor added
meaningfully. An interval scale is a set of numbers that is invariant under linear
transformations, specifically, of the form, ax+b, where a>0, b≠0. Different interval
scales cannot be multiplied. However, numbers from the same scale can be added. A
ratio scale, on the other hand, is a set of positive numbers that is invariant under a
positive similarity transformation of the form, ax, where a>0. Different ratios scales can
be multiplied and divided and still give rise to a ratio scale because the invariance of their
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products and quotients is derived from the invariance of each one of these scales.
Numbers from the same scale can also be added. Ratio scales enable us to relate
alternatives of tangible action to criterion and values that are intangible. The ratio scale
of the AHP decision-making scores enabled us to see that our preferences were measured
and compared among different measuring units among all the patients that were subjected
to the same criteria. Finally, the consistency ratio, ensured the transitivity property and
numerical proportions of the AHP decisions are consistent by ensuring it does not exceed
0.1.
The simulation selected the patient with the highest AHP score of matching blood
type. If the donor liver was an ECD or ECD 1-year liver, and the patient has not given
consent and does not wish to proceed to transplant unless the donor liver is a SCD liver,
then the next highest AHP scoring patient was selected. The structure of AHP decisionmaking is shown in Figure 2.
Donor Liver
Allocation

Decision-Making

Objectives

Sickest First

MELD

delta-MELD

Utility

Donor Risk
Index (DRI)

Criteria

Figure 2. Analytic hierarchy process structure of objectives and criteria.

Survivability
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Transplantation
(SOFT)
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The liver allocation decision-making can be translated in its limited range into
meaningful numbers reflecting criteria ranking and patient selection. The liver allocation
selection process via AHP included criteria that were uniformly used among all
pretransplant patients.
Kalman estimation validity. The Kalman filter is the theoretical framework to
model liver disease progression of pretransplant patients for the simulation. Steps were
taken to translate the Kalman filter theory into the simulation model by using patient data
from the OPTN organization and by estimating additional MELD data consistent with
actual MELD data. The main task of Kalman filter was to develop the system model
where the goal is to determine the matrices reflecting the systems dynamics of disease
progression, covariance values, and observation matrices of the observed disease
progression.
The Kalman filter algorithm for the MELD and delta-MELD parameters consisted
of two alternating steps, which were repeated for each iteration and each new frame,
prediction, and correction. In the prediction step, the filter made an assumption about the
future state. In the correction step, an optimized state estimate was computed using a
weighted difference between the prediction state and an actual or averaged measurement.
Hence, this provided a mechanism to ensure optimal MELD estimations. In the
simulation model, estimates of MELD scores were based on actual MELD values and
these values were used to propagate MELD data upon arrival of available donor livers.
An error technique was setup in order to check that Kalman estimations did not exceed
beyond certain thresholds.
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The Simulation Model
This section describes the simulation model and its processing. The model
simulated the liver allocation system by the way it handled available donor livers, the
process of placing patients into the waitlist, and patient disease progression while waiting
for available livers as reflected by the U.S. liver allocation system.
The model simulated four processes and outputs relevant values for analysis. The
four processes included a process for the arrival of donor livers, transplant patient entry
into the waitlist, liver disease progression, and waitlist patient management. These
processes referred to patient and donor liver data.
A stochastic component of the simulation experiments was the interarrival timing
of available donor livers. The available donor livers were randomly selected from the
UNOS STAR database, and hence it was not in accordance to the timing as specified by
the database. The interarrival timing of the liver was set accordingly to a Poisson process
and based on the mean interarrival time from actual data. Also, the random selection of
available liver presented an uncertainty regarding the type of available liver, whether it is
SCD, ECD-1 year, or ECD donor liver.
Each simulation run was conducted over ten 180-day intervals of simulation time.
There were two scenarios for the simulation which defined the values for the control
variables, one not using delta-MELD and one using delta-MELD as a primary criterion
for patient selection. The sequence of the donor liver arrival was the same for both
scenarios, with or without using delta-MELD.
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Waitlist Entry
The management of waitlist entry included processing new patients waiting for an
available liver for transplantation. These patients have undergone a liver medical
assessment and have an initial MELD score with a start date into the waitlist. The
Waitlist Entry process referenced the patient data from OPTN/UNOS. Once a patient had
entered into the waitlist, the Disease Progression process would approximate future
patients’ MELD scores in regular time intervals by Kalman estimation. The Waitlist
Entry’s data included patient’s waitlist start date, patient initial MELD score, and the
number of patients entering into the waitlist.
Burr and Shah (2010) explained that the way the current allocation system worked
is that patients are prioritized on the waitlist according to blood type by descending
MELD order. This would mean that organs are offered to the waitlisted patient with the
highest MELD score and blood type identical to the patient. To avoid an inequitable
distribution of organs, blood type O livers are only assigned to blood type O patients.
The system allows patients with special situations such as very small size adult patients
or AB-type patients to be listed for more than one match of blood types.
Donor Liver Arrival
The events of donor liver arrival were simulated by a Poisson process and the data
were randomly selected to be one of the donor livers from the UNOS STAR database.
The Donor Liver Arrival process selected matching patients from the waitlist according
to patient medical urgency, donor liver’s DRI, and patient-donor SOFT scores. Hence,
the Donor Liver Arrival process computed the AHP scores for all the patients on the
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waitlist. The winning patient was selected as the best scoring patient for the available
donor liver. However, if the available donor liver was an ECD liver, consent needs to be
retrieved from the patient. The chances of the patient accepting an ECD liver was
determined in this process. The Donor Liver Arrival’s output data included the
ECD/SCD status, DRI score, whether a patient consented to accept an ECD liver, patient
MELD and AHP scores, the number of SCD and ECD livers, and the number of patients
transplanted. In Figure 3, processing is shown for handling ECD and SCD livers.
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Figure 3. Donor liver processing based on liver quality.
Upon arrival of an ECD or ECD 1-year liver, the model determined whether a
patient accepted an ECD or ECD 1-year liver, by a random function, with a chance of
25% or 15%, respectively (Rodrique et al., 2011).
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Disease Progression
The Disease Progression process estimated patients’ disease progression by
updating MELD and delta-MELD parameters. The patient’s waitlist status was updated
indicating whether the patient was still on the waitlist awaiting for an available donor
liver, or has dropped off from the waitlist due to being too sick, death, or for other
reasons. The Disease Progression’s output data included patient MELD, delta-MELD,
and waitlist status. In addition, the output data provided the average MELD score of
patients on the waitlist and the count of patients dropping off from the waitlist at the end
of each week.
Unlike the Waitlist Entry, Donor Liver Arrival, and Waitlist Patient Management
processes, which were event-driven, the Disease Progression process was a timer process
that runs continuously at a one second rate. Every instance when the Disease Progression
process runs simulated one day on the waitlist. The timer process ran for 180-days to
fulfill one of ten intervals in a simulation scenario.
In order to simulate and track the occurrence of patients being removed from the
waitlist because the patient was deemed too sick to transplant, the
Patients_Dropped_From_Waitlist parameter was updated at the end of each week. The
survival table based on MELD score and patient risk factors according to the study of
Rana et al. (2008) was referenced as a guide when the weekly average MELD exceeded
the actual Region 9 average MELD of 21. The risks based on patient risk factors are
tallied up and patients with the highest risks are considered for removal based on MELD
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scores and survival rates. The survival rates were based on the hazard ratio according to
MELD scores as follows (Sharma, Schaubel, Gong, Guidinger, & Merion, 2012).
Table 4
Hazard Ratios based on MELD
MELD

15-17

18-20

21-23

24-26

27-29

30-32

33-35

36-37

38-39

40

HR

0.03

0.04

0.08

0.12

0.22

0.39

0.5

0.82

0.98

1

Pvalue

0.0001

0.0001

0.0001

0.0001

0.0001

0.0001

0.0001

0.1

0.89

0.87

Waitlist Patient Management
The Waitlist Patient Management process managed patient disease updates due to
actual MELD scores and removed patients off of the waitlist reported as being too sick to
receive transplant or died while waiting for available liver. These updates were based on
actual patient reports provided by the OPTN data. The waitlist patient output data
included patients’ MELD scores, statuses of removal from the waitlist, as well as the
count of patients dropping off of the waitlist.
Simulation Inputs and Processing
Input Data
The simulation model input data included a control factor, assumptions, and
limitations. From the UNOS STAR database, and similar to the study by Northup and
Berg (2004), recipients listed for liver transplantation with MELD exclusions such as
hepatocellular carcinoma patients, all status 1 (acute hepatic failure) recipients, and
patients with incomplete laboratory or survival data were excluded from the simulation.
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Also, the data set was queried for MELD score on the day of transplant. Patients with
only a single MELD score reported to UNOS or with no MELD scores were excluded
from the analysis. The parameters of DRI and SOFT scores were computed upon the
arrival of a donor liver.
The uncertainties of the process, simulated by the model, included the arrival of
available livers and the type of quality of these donor livers, whether they were SCDs, 1year ECDs, or ECDs. The interarrival times of liver donor were varied according to a
Poisson distribution. The liver and patient data and their arrival times were the same in
both scenarios with and without delta-MELD. The objective was to measure and
compare the scenarios with and without delta-MELD to the same livers, pool of patients,
and their arrival times. Finally, since there were two 180-day intervals in a year, and data
were based on 2008-2012 timeframe, there were 10 different model runs. The entire
experiment ran 7 replications of these model runs, to meet the minimum required sample
size, which was 70, for a t test of two independent populations of means. There was an
equal number of replications for each of the two groups (one group for each level of the
independent variable).
Input Data for Simulation without delta-MELD
In the simulation scenario without delta-MELD, the AHP integrated the OPTN
allocation levels of urgency and played a major part in patient selection. The following
AHP decision tables were initialized for decision-making where the delta-MELD was not
used as a criterion.
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The patient AHP scores were based on the AHP initial values, donor liver DRI,
patient-donor SOFT, and MELD normalized scores. The AHP score was computed as
follows, where the coefficients and multiplier are according to Table 5.
Hb`(cdYe) =
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AHP Weights and Ranking without delta-MELD
Allocation Level

MELD

DRI

SOFT

Status 1A/B

0.570305

0.214847

0.062941

0.320454

≥35 (Loc & Reg)
29-34 (Local)
Liver-Int
(National)
15-28 (Local)
15-34 (Regional)
<15 (Local, Reg)

0.457376
0.347082
0.257338

0.271311
0.347082
0.257338

0.214847
0.326458
0.371330

0.216472
0.149638
0.109904

0.177135
0.122618
0.882129

0.177135
0.122618
0.088212

0.411432
0.438690
0.455893

0.081728
0.065517
0.056284

=

[

g

Multiplier

Input Data for Simulation with delta-MELD
In the simulation scenario with delta-MELD, the AHP integrated the OPTN liver
allocation levels of urgency that also played a major part in patient selection while using
the delta-MELD parameter as a criterion for liver allocation. The following AHP Table 6
contains the weights of the criteria (coefficients), MELD, delta-MELD, DRI, and SOFT,
and the ranking (multiplier) of priority groups for liver allocation used in AHP scoring.
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The patient AHP scores were based on the AHP initial values, delta-MELD,
donor liver DRI, patient-donor SOFT, and MELD normalized scores. The AHP score
was computed as follows, where the coefficients and multiplier are according to Table 6.
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AHP Weights and Ranking with delta-MELD
Allocation Level

MELD

delta-MELD

DRI

SOFT

Multiplier

Status 1A/B
≥35 (Loc & Reg)
29-34 (Local)
Liv-Int (National)

0.363181
0.313835
0.257655
0.204669

0.363181
0.313835
0.257655
0.204669

0.138186
0.186164
0.242344
0.295330

0.136818
0.186164
0.242344
0.295330

0.352108
0.229594
0.150847
0.104031

15-28 (Local)
15-34 (Regional)
<15 (Local, Reg)

0.150480
0.109225
0.081062

0.150480
0.109225
0.081062

0.349519
0.390774
0.418937

0.349519
0.390774
0.418937

0.070833
0.051732
0.040853

=
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The AHP technique for the selection of the most suited and sickest patient was
appropriate for the liver allocation decision-making because there were multiple
objectives and criteria to weigh into the consideration of many patients awaiting a donor
liver. Winston (2004) described that a multi-criteria decision-making process could be
complex because when multiple objectives are important to a decision-maker, it may be
difficult to choose among the many alternatives (patients). The AHP was a tool used for
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the selection of matching patient as it integrated the objectives with the OPTN liver
allocation levels into the decision-making. AHP scores were outputted for analysis from
the donor liver process of the simulation. In addition to AHP, number of patients
dropping out of the waitlist, and average MELD scores were outputted for analysis. In
the Figure 4, an overview of the simulation’s data processing is presented.
(MELDmean1,

Patient
Data

STAR
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2008-2012

MELD

Kalman
Filter
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without
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deltaMELD
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SOFT

Donor
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AHP with
delta-MELD
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Figure 4. Overview of simulation data processing.
Table 7 lists the actual number of liver transplants performed from deceased
donors in the years 2008-2012 according to OPTN (2014). This list indicates that when
considering the limitation of actual patient data used in the simulation due to non-HCC
disease, non-status 1 patients, etc., the simulation processing a unique pool of 100 patient
records and 130 donor liver records within any 180-day simulation interval is feasible.
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Table 7
Number of Region 9 Liver Transplants from Deceased Donors

Year

Number of Region 9 Liver Transplant Patients
from Deceased Donors

2012

313

2011

343

2010

322

2009

403

2008

402

Table 7 shows that the patient sampling within the simulation of 100 patients in
each of the ten 180-day intervals is a feasible sampling size, where the actual patients
from the time spanning 2008-2012 from the UNOS Region 9 database was 1,783. The
simulation sampled 100 patients for each 180-day interval, where there were two 180-day
intervals per year, producing 1,000 patients in ten intervals. The simulation patient
sampling of 1,000 patients compared to the actual population of 1,783 UNOS Region 9
patients represent more than 50% of the actual patient population. This showed that in
each 180-day interval, it was feasible to set up a unique pool of 100 patients and at least
130 donor livers, reflective of actual data from UNOS, for each interval to produce a set
of response variables. Each simulation of 26 weekly reports per 180-day interval was
processed after removing patients with HCC disease, status 1 patients, and patient data
with only one MELD score.
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Simulation Outputs
To summarize the simulation output data, each simulation run generated output
data for analysis for each of the two response variables: MELDmean and
Total_Patients_Removed. But most importantly, the disease progression output data
included patient’s MELD, delta-MELD, as well as the average MELD score of patients
on the waitlist. The simulation output data included the number of patients dropping off
of the waitlist at the end of each week. The average MELD and number of patients
removed from the waitlist from the scenario without delta-MELD was compared against
the average MELD and number of patients removed from the waitlist from the scenario
with delta-MELD.
The response variables from model runs were used to compute MELDmean,
equation (15), and Total_Patients_Removed, equation (16), for each 180-day interval.
Both Average_MELD(n) and Patients_Dropped_From_Waitlist(n) parameters were
output from both scenarios with and without delta-MELD. The only control factor of the
simulation experiment was the DM that indicated the use or non-use of the delta-MELD
as a decision criterion in the simulation.
Experiment and Sample Size
The experiment covered 5 years of data (spanning 2008-2012), measured in 180day intervals for a total of 10 timeframes. For each of these timeframes, the simulation
model ran twice, once for each level of the control factor (once with and once without
delta-MELD). Thus, there were 20 simulation scenario runs (10 timeframes times 2 runs,
with and without delta-MELD). However, the simulation model was stochastic, so I

115
conducted the experiment to run the simulation model multiple times (7 replications) for
each timespan and control factor level. This ensured I met the minimum sample size for t
tests of two independent populations’ means to meet the desired power, effect size, and
confidence.
I computed the minimum experimental sample size using the following
methodology. In determining the minimum experimental sample size, Aczel and
Sounderpandian (2008) provided the following formula for this purpose (p. 243):
Minimum experimental sample size for a t test of two independent and equal
populations is as follows:

= 2 ∗ ijk⁄[ + jm n ∗ σ[ /
[

[

(20)

Z α/2 = the normal distribution critical value for a probability of α/2 in each tail,
Z β = the normal distribution critical value for a probability of β,
σ 2 = population variance, and
E = dσ, the standard error.

I used a 95% confidence interval, hence, Zα/2 is 1.96 (Aczel & Sounderpandian,
2008), and 80% power, hence, Zβ is 0.84 (Gelman & Hill, 2007, p. 441). I ensured a
power of at least 0.8, which is 1 - β, where β is the percentage of Type II error, and Type
II error is the error of not rejecting the null hypothesis when it is false.
For the dependent variables, MELDmean and Total_Patients_Removed, I used
Cohen’s d effect size, where a large effect size is 0.80, a medium effect size is 0.50, and a
small effect size is 0.20 (Cohen, 1992). The standard error, E is rewritten as dσ, as E =
dσ, where I chose a medium effect size, d = 0.5. Cohen (1992) explained that the effect
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size is that measure which can determine whether the null hypothesis may likely be
wrong. For MELDmean and Total_Patients_Removed, I chose a medium effect size since
a MELD score that is off by 1 is a reasonable and noticeable effect size. E = dσ, where σ
= 2 (Figure 11), d = 0.5 times (σ = 2) is 1, a medium effect size. Similarly, for
Total_Patients_Removed, one person removed from the waiting list is a reasonable and
noticeable effect size.
Using an effect size, 0.5, the formula for sample size is reduced to the following:
= 2 ∗ ijk⁄[ + jm n ∗ σ[ /
[

= 2 ∗ ijk⁄[ + jm n ∗ σ[ /
[

= 2 ∗ ijk⁄[ + jm n /
[

[

[

(21)

[ [

σ

(22)
(23)

With d = 0.5, α = 0.05, β = 0.80, the sample size is
= 2 ∗ ijk⁄[ + jm n ∗ σ[ /
[

[

= 2 ∗ (1.96 + 0.84)[ /(0.5)[ = 62.72

(24)

n is rounded up to 70. The sample size of 70 required 7 simulation runs as there are ten
180-days intervals (sample units) per simulation (replication). The normality,
homogeneity of variances, and independence of the t tests of two independent
populations were verified (see Appendix D).
Hypothesis Testing
I conducted statistical tests based on output data from the experiment.
Total_Patients_Removed and MELDmean values were hypothesized to vary with changes
in the control factor: without and with delta-MELD. I utilized t tests for two independent
populations, and the experiment was based on the random sampling of arriving livers
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with an UNOS-based average random interarrival time of five days. The experiment
involved two scenarios, one scenario with decision-making not including delta-MELD,
and another scenario with decision-making including the delta-MELD (hence, generating
samples of two different and independent populations). Upon completion of the
simulation experiment, two t tests of two independent populations were performed (one
for each hypothesis) to evaluate the difference in means between the case where deltaMELD is not used as a criterion and the case where delta-MELD is used as a criterion.
Aczel and Sounderpandian (2008, p. 313) provided the formula for the t test of
two independent populations for the case where σ1 and σ2 may be unknown and may be
unequal:

t=

(st <su )<(vt <vu )
wxtu ⁄yt zxuu ⁄yu

(25)

Since the null hypotheses for both dependent variables stated that there is no
difference in their values for both scenarios without and with delta-MELD as criterion,
(μ1 – μ2) is equal to 0. Hence,

t=

(st <su )

wxtu ⁄yt zxuu ⁄yu

(26)

(Aczel & Sounderpandian, 2008, p. 314). The formula for the t test of two independent
populations for MELDmean of the scenarios with and without delta-MELD is as follows.

t(MELDmean) =

(st <su )

wxtu ⁄yt zxuu ⁄yu

(27)

U VW
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)],

(28)

where x1 is the MELDmean average from scenarios without delta-MELD,
x2 is the MELDmean average from scenarios with delta-MELD,
S1 is the standard deviation of MELDmean without delta-MELD,
S2 is the standard deviation of MELDmean with delta-MELD,
N1 is the number of MELDmean in experiment without delta-MELD,
N2 is the number of MELDmean in experiment with delta-MELD.
The t-statistic is positive when the MELDmean in the scenario without delta-MELD
is larger than the MELDmean in the scenario with delta-MELD, and negative when the
MELDmean in the scenario with delta-MELD is larger than the MELDmean in the scenario
without delta-MELD. A similar t test of two independent populations was performed for
Total_Patients_Removed of the scenarios without delta-MELD and the scenarios with
delta-MELD.
Similarly, the t test of two independent populations for the number of patients
removed for scenarios without delta-MELD and with delta-MELD is as follows.

t(PatientsRemoved) =
N

_`

(st <su )

wxtu ⁄yt zxuu ⁄yu

E_&

G

V†‡

= (1⁄70) ∗ ∑ˆY= 7Z ~e [N

(29)
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G
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where x1 is the Total_Patients_Removed mean for scenarios without deltaMELD,
x2 is the Total_Patients_Removed mean for scenarios with delta-MELD,
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S1 is the standard deviation of Total_Patients_Removed without delta-MELD,
S2 is the standard deviation of Total_Patients_Removed with delta-MELD,
N1 is the number of Total_Patients_Removed for scenario without delta-MELD,
N2 is the number of Total_Patients_Removed for scenario with delta-MELD.
Aczel and Sounderpandian (2008) explained that the degrees of freedom for this t
test is computed by

df =

[(xtu ⁄yt )z(xuu ⁄yu )]u
[(xtu ⁄yt )u ⁄(yt <=)] z[(xuu ⁄yu )u ⁄(yu <=)]

(31)

df is then rounded down to the nearest integer. Here N1 and N2 are equal to 70. df is
computed to be 69.

I utilized a two-tailed t test of two independent populations. The scenarios were

treated as two independent samples with different means for the dependent variables that
were compared using a t test. The t-statistic was compared to the critical value of t. The
alpha level was set to 0.05. This means that five times out of a hundred, I will reject a
null hypothesis when I should have failed to reject it (a false positive result, or Type I
error); that is, a difference between the means is in truth due to random variability in the
stochastic process (simulation model) even if no difference exists in reality (Green &
Salkind, 2011). Confidence is the inverse of alpha (1 - α), indicating the confidence I
have that I will avoid incorrectly seeing an effect that is not present in the population.
The power of the test was set to 0.80. The power of a test is 1 - β, where β is the
probability of a false negative (Type II error)—failing to reject a null hypothesis that
should have been rejected (Aczel & Sounderpandian, 2008). Power, therefore, is the
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probability of properly detecting an effect, such as a true difference in population means.
At the end of running the simulation 7 times, there were 70 sets of response
variables, MELDmean and Total_Patients_Removed, for the t tests of two independent
populations. The t-statistic was compared to the critical value of t for 69 degrees of
freedom, 95% confidence, and a two-tailed test. When the experimental t-statistic is
greater than the critical value of t or less than the negative value of the critical t, the null
hypothesis is rejected. The results of statistical tests provided answers to both the
research questions and hypotheses.
Pilot Testing and Scenario Runs
Hillier and Lieberman (2010) explained that after the computer simulation
program has been constructed and debugged, the next key step is to test whether the
simulation would provide valid results for the system it is representing (p. 961). Hillier
and Lieberman suggested some ways to test the simulation model which may include
observing animations and logs of simulation runs as a useful way to check the validity of
the simulation model. Another suggestion provided is to construct and verify a prototype
simulation which is a smaller version of the simulation (p. 962).
The simulation was designed to generate logs from each of the simulation’s four
processes. An important purpose for this was to provide simulation verification based on
a pilot dataset. A pilot dataset was used and generated to run each of the simulation
processes and to review the logs for simulation verification. This verification process
included review of data initialization and data setup of patient, liver, and disease
progression data, as well as the processing verification of Kalman estimation of patients’
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disease progression, AHP scoring for patient selection, removal of patients from the
waitlist, and t test of two independent populations results. More specifically,
verifications of the Waitlist Entry process included checking whether the number of
patients and their entry sequences matched that of actual data. Verifications of the Donor
Liver Arrival process included checking donor liver mean interarrival times, percentages
of SCD, ECD and ECD 1-year liver types accepted by patients, and AHP selection of
patients against actual data and intended processing. Verifications of the Disease
Progression process included checking whether patients were dropping off of the waitlist
according to actual data and intended processing.
Both the pilot and scenario datasets went through the same simulation processing
and similar log review. The log review of pilot runs provided description, understanding,
and verification of simulation steps and output data. The dataset for the pilot simulation
consisted of the first 180-day interval of 2008 in the UNOS STAR dataset with the same
patient and liver sample data in the scenario runs as in the experimental scenario runs.
The log review of scenario runs provided data analysis and interpretation of output results
that was based on the UNOS STAR’s dataset. Descriptions for generating logs for data
analysis and simulation verification are described in Appendix C, Simulation
Programming Notes.
Summary
The research design was formulated to ensure the research questions and
hypotheses can be answered. The research instrument was the simulation, where the
design of the research included the simulation parameters MELD and delta-MELD as the
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primary criteria. The simulation parameters MELD, delta-MELD, DRI, and SOFT were
used to compute a recipient selection by AHP. This operationalization of criteria
included the stratification of MELD scores into OPTN’s categories of MELD levels. The
design of the research also included secondary patient data and donor liver data from the
UNOS STAR database of Region 9 from 2008-2012. However, in the simulation, the
donor liver data were not sequenced according to its archived occurrence, but randomly,
where the donor livers were randomly selected from the database of the same year. The
research experiment included distributions of SCD, ECD-1 year, and ECD donor livers
with varying interarrival times of available donor livers. The random selection of liver
data and interarrival times were the same for both scenarios with and without deltaMELD.
The simulation used the same patient data for the two scenarios (without deltaMELD and with delta-MELD), in multiple replications, and are treated as having two
independently separate sets of patients. With each experimental run, the purpose of the
simulation was to generate the average MELD scores and number of patients removed
from the waitlist over a 180-day interval, for cases with and without using the deltaMELD parameter as a criterion. The experiment’s objective was to determine whether
the delta-MELD parameter would be a viable criterion to refine the current liver
allocation system. I ran the simulation 7 times for each of the 10 intervals in 2008-2012
with delta-MELD and 7 times without delta-MELD. This resulted in a total of 70 model
runs for each scenario (with and without using delta-MELD as a criterion).
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The research methodology described in this chapter was made possible by the
theoretical frameworks of the Kalman filter, AHP, the OPTN liver allocation policy, and
the patient, liver and waitlist history data provided by the OPTN/UNOS organizations. In
this chapter, I explained the theoretical frameworks, policy, and use of the OPTN/UNOS
data regarding how they were applied to the simulation. This information provided the
conceptual framework for the t tests of two independent populations of response
variables, Total_Patients_Removed and MELDmean, where these t tests helped to address
the research questions and hypotheses.
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Chapter 4: Simulation Results and Analysis
The purpose of this research was to investigate whether using the delta-MELD
criterion can improve the liver transplant patient selection process by reducing the
number of patients dropping off the waitlist and lowering the average MELD score. Pidd
(2004) explained that simulation model-building should ideally include four main steps.
These steps include conceptual model-building, computer implementation, validation,
and experimentation (p. 35). Pidd further explained that the conceptual model-building is
an activity in which the analyst tries to capture the essential features of the system that is
being modelled. In the research model, I emphasized the allocation aspect of the donor
liver system to study the effects of having an additional criterion, delta-MELD, for
patient selection. The description of the conceptual model-building and computer
implementation for this simulation was described in Chapter 3. In Chapter 4, I describe
the validation and experimentation results.
Chapter 4 includes four sections, Research Questions and Hypotheses, Pilot
Testing and Verification of the Simulation Model, Experimental Outcome, Results, and
Summary. I utilized t tests of two independent populations to determine if there was a
difference in outcomes of the two scenarios, with and without using delta-MELD for
decision-making.
Research Questions and Hypotheses
The research questions and their respective hypotheses are repeated here from
Chapter 1:
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1. Does a simulation model using the additional parameter of delta-MELD as a
patient selection criterion reduce the number of pretransplant patients who
dropped off the waiting list?
Ho: There is no difference in the number of patients who dropped off of the
waiting list (Total_Patients_Removed) between simulation models with and without
delta-MELD along with the MELD score as primary criteria for patient selection in donor
liver allocation.
Ha: There is a difference in the number of patients who dropped off of the waiting
list (Total_Patients_Removed) between simulation models with and without delta-MELD
along with the MELD score as primary criteria for patient selection in donor liver
allocation.
2. Does a simulation model using the additional parameter of delta-MELD as a
patient selection criterion lower the average MELD score among pretransplant
patients?
Ho: There is no difference in the average MELD score (MELDmean) among
pretransplant patients between simulation models with and without delta-MELD along
with the MELD score as primary criteria for patient selection in donor liver allocation.
Ha: There is a difference in the average MELD score (MELDmean) among
pretransplant patients between simulation models with and without delta-MELD along
with the MELD score as primary criteria for patient selection in donor liver allocation.
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Pilot Testing and Verification of the Simulation Model
As introduced and explained in Chapter 3, the model simulated processes for
Waitlist Entry, Waitlist Patient Management, Disease Progression, and Donor Liver
Arrival. The Waitlist Entry process handled the days which patients enter into the
waitlist within the simulation interval. The Waitlist Patient Management process ensured
that MELD updates were processed for all patients according to the UNOS data. The
Disease Progression process handled the Kalman estimation for all patients’ MELD
scores according to existing UNOS data on days where there were no patient updates.
The Donor Liver Arrival handled the arrival of donor livers according to computer
randomly generated days by a Poisson process. In addition, pilot testing and verification
of the simulation model included weekly reports of the 180-day interval and statistics
from one simulation run which were output for review.
Table 8 highlights the data derived by the simulation as well as data provided by
the UNOS STAR database for simulation processing. Table 8 identifies whether the data
were derived, stochastically generated, or retrieved from the UNOS STAR database. The
simulation data, which were initially described in Chapter 3, are summarized in Table 8.
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Table 8
Simulation Variables and Parameters
Variable / Parameter
MELD

Description
Model for end-stage liver disease retrieved from UNOS
STAR database and derived for patient on waitlist.

Delta-MELD

This derived parameter is the calculated difference between
a current MELD and the previous MELD score divided by
the days between the two MELD scores.

DM

This control parameter is a categorical variable where 1 =
scenario with delta-MELD as criterion, and 0 = scenario
without delta-MELD as criterion.

DRI

The donor risk index is a derived parameter that is a
measurement of liver quality based on nine factors.

SOFT

The survival outcomes following liver transplantation is a
parameter and measurement of survivability based on risk
factors.

AHP

Analytic hierarchy process score is a derived parameter and
measurement of importance or preference among the
alternatives in decision-making.

Patients_Dropped_From

This parameter contains the number of patients dropped

_Waitlist

from the waitlist weekly.
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MELDmean

This is the mean of weekly Average_MELDs for the
simulation scenarios with or without delta-MELD and is
expressed using equation (15).

Total_Patients_Removed

This parameter is expressed using equation (16) and is
computed within each simulation interval.

Average_MELD

Average MELD is compiled weekly from patient waitlist.

I performed a verification process on the simulation’s four processes, Waitlist
Entry, Waitlist Patient Management, Disease Progression, and Donor Liver Arrival. The
purpose of pilot testing and verification was to verify that the features of the simulation
were working as intended and that the simulation input data, which were provided by
UNOS STAR database, were interpreted correctly. I verified these four processes by
running the simulation graphical user interface (GUI), reviewing the outputs against the
UNOS data, and reviewing the GUI panels and logs generated by the simulation. The
data used for pilot testing were the first 180-day interval of 2008. In addition, I verified
weekly reports of one 180-day interval and statistics from one simulation run.
Waitlist Entry and Waitlist Patient Management Processes
Table 9 lists the verification steps and corresponding variables or parameters
being observed for verification of the Waitlist Entry process.
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Table 9
Waitlist Entry and Waitlist Patient Management Processes Verification
Step

Waitlist Entry and Waitlist Patient Management Processes Steps

1

Initialize patient data with valid entry day #, delta-MELD, disease group,
and status.

2

Ensure the interval duration goes from 1 through 180 days.

3

Ensure that both scenarios, one without using delta-MELD and one with
using delta-MELD as decision-making, are processed.

4

Ensure that the delta-MELD derived field is computed properly for every
patient.

The UNOS STAR data contained all patients who were on the waitlist from 1987
to March 2014. The data included all patients and waitlist history of patients from all
regions of the United States, Regions 1 through 11. The UNOS tabbed delimited data
files from the UNOS STAR files were processed in Excel spreadsheets for filtering
patient waitlist data from Region 9, from 2008 to 2012. The data were further filtered to
exclude patients who were status 1 (emergency patients), HCC disease type, and pediatric
end-stage liver disease (PELD) patient type. The Waitlist data included the patient
MELD updates for the Patient ID of the Patient data. The data, Patient and Waitlist data,
were merged into the Patient data for the simulation, joined by Patient ID. More
specifically, the Waitlist Entry process handled the initial patient entry into the waitlist
while the Waitlist Patient Management process handled the updates of patient MELD and
patient statuses through the course of a simulation interval.

130

Figure 5. Waitlist Entry and Waitlist Patient Management processes.
Figure 5 shows the patient data processed into the simulation’s patient file in the
top panel from the raw UNOS STAR patient data. The data on the top panel were
correctly processed by observation against the UNOS liver and patient data on the bottom
panel. The bottom panel contains the UNOS liver and patient data. I selected the first
180-day interval of 2008 for pilot testing but any of the simulation intervals could have
been selected for pilot testing. In actual experimental runs, all 10 intervals are processed
in the simulation.
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Disease Progression Process
The Disease Progression process ran from day 1 through 180 within the
simulation interval. This included processing the Kalman estimation for MELD score
progression, taking weekly reports of MELD averages and the number of patients who
were dropped from the waitlist, and updating any patient records for each day.
Table 10
Disease Progression Process Steps for Verification
Step

Disease Progression Process Steps

1

Ensure that the processing is performed once for the scenario where AHP
would use delta-MELD and once for where AHP would not use deltaMELD.

2

Ensure the processing performs Kalman estimation of disease progression
by propagating the MELD scores properly when computed by Kalman
estimation.

3

Ensure that patients are removed from the waitlist when their statuses
indicate they are too sick or they have died.

4

Ensure that this process proceeds from day 1 through 180.
As shown in Figure 6, verification steps 2 and 3 of Table 10 confirmed that the

Kalman estimation was propagating MELD scores and only patient status of
“WAITING” was processed. In Figure 7, verification steps 1 and 4 of Table 10 were
accomplished by showing that the scenarios, without and with delta-MELD, were
performed with the simulation progressing from day 1 through 180.
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Figure 6. Disease Progression process-1.
Figure 6 shows not only that the initial delta-MELD were computed for patients
as shown on the top panel, but the bottom panel shows the internal daily Kalman
estimated MELD and delta-MELD computed for patients who do not have a waitlist
update record for that day as the scenario progressed from day 1 through 180 of the
scenario. Patients with the status of “WAITING” were filtered for the initial setup and
the internal Kalman estimation were performed for patients with “WAITING” statuses
only.
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Figure 7. Disease Progression process-2.
Figure 7 shows the highlighted line on the top panel indicating the beginning of
the Liver Patient match processing using delta-MELD as criterion. In the panel’s
previous lines, the processing was performed without delta-MELD. The liver arrivals
were determined by a Poisson process with a computed UNOS-based average interarrival
time of 5 days. Once a patient match was determined, the patient status was changed
from “WAITING” to “TRANSPLANTED”. The parameters of DRI and SOFT logged
on the bottom panel were confirmed against data retrieved from patient and liver data.
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Donor Liver Arrival Process
The Donor Liver Arrival process verification method includes steps shown in
Table 11.

Table 11
Donor Liver Arrival Process Steps for Verification
Step

Donor Liver Arrival Processing Steps

1

Ensure the Donor Liver Arrival process is performed once with deltaMELD and once without delta-MELD.

2

Ensure that the day of liver arrival is based on the current day and the
number of days computed by the Poisson process.

3

Ensure the correct computation of DRI and SOFT derived data.

4

Ensure patient statuses are translated correctly when processing the
UNOS patient data.

5

Ensure the correct processing of winning patient based on AHP score,
blood type, and DM indicator is performed.

6

Ensure that upon patient selection, the patient is not a candidate for later
liver donor arrivals.

As shown in Figure 8, I performed verification steps 1 and 2 of Table 11 by
showing that the scenarios, without and with delta-MELD, were performed and the livers
randomly arrived (by the C++ random function) between the days 1-180. In Figure 9, I
performed verification steps 3 and 4 of Table 11 by showing the computation of
parameters DRI and SOFT were correct by tracing back to their patient and liver data.
Also in Figure 9, I performed verification steps 5 and 6 of Table 11 by showing that AHP
scores, blood types, and the DM indicator were used to filter the selection of patients,
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determining best patient match, and ensuring that patients were taken off of the waitlist
after transplant.

Figure 8. Donor Liver Arrival process-1.
Figure 8 shows that both scenarios, without and with delta-MELD, always shared
the same liver arrival day, liver ID, and initial pool of patients. Patient selection in each
scenario may have varied for the same liver arrival, but may sometimes have resulted in
the same patient selection. When there was no patient selected for an arriving liver, it
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was due to “no match” of patient blood type to donor liver blood type. Often, these
donor livers would be transferred to another region.

Figure 9. Donor Liver Arrival process-2.
Figure 9 shows that on Day 109, Patient ID 41 was matched with Liver 396. The
candidate and donor liver blood types were both “O”. On Day 114, Patient ID 57 was
matched with Liver 236. Patient ID 41 was not listed again for the same blood type as
Patient 41 had received a liver transplanted already on Day 109. On both days, 109 and
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114, the patients with the highest AHP score were matched for the arriving liver. Also,
ECD acceptance may have affected whether a patient was listed on the candidate list.
Weekly Reports
The response variables from the simulation were verified to ensure that
computations were performed from weekly statuses. The MELDmean and
Total_Patients_Removed were captured in two scenarios, one with and one without deltaMELD.

Figure 10. Weekly reports: Disease progression.
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Figure 10 shows the weekly Average_MELD and
Patients_Dropped_From_Waitlist. Patients who received liver transplants were removed
from the waitlist and were not included in the weekly count. The simulation interval for
viewing weekly Average_MELD and Patients_Dropped_From_Waitlist values is userselectable.
Statistics from One Simulation Run

Figure 11. Statistics from one simulation run.
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Figure 11 shows the statistics from only one simulation run, with and without
delta-MELD, which included 10 intervals covering the years 2008-2012. This simulation
run was conducted to verify that the simulation would properly provide statistics of the
MELDmean and Total_Patients_Removed response variables and that a simulation can run
correctly to completion. The number of intervals for the experiment was 10 x 7 = 70.
The experiment was conducted from 7 replications of simulation runs.
Experimental Outcome
Figure 11 shows the simulation results from running through all 10 intervals, of
only one simulation run for review of the Total_Patients_Removed and MELDmean
statistics. Figure 11 also shows that there was no difference in Total_Patients_Removed
between the scenarios using and not using the delta-MELD parameter as criterion for
patient selection. This is because the average MELD scores from the weekly report did
not vary by much between the two scenarios with and without delta-MELD; and hence,
the chances of death for the patients did not change between the two scenarios.
Therefore, the simulation removed patients off of the waitlist with the same probability
based on Table 4 within the two scenarios, yielding identical numbers of patients
removed.
For the simulation experiment, Figure 12 captured the Total_Patients_Removed
and MELDmean values from 7 simulation runs, 70 intervals runs, which the experiment
covers from the beginning to the end of 2008-2012 time span, seven times.
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Figure 12. Experimental outcome.
Figure 12 shows the response variables of two independent populations from
running 70 (180-day) intervals (Figure 12 shows an excerpt of interval runs 47-70).
Table 12 and Table 13 contain the MELDmean without delta-MELD and with delta-MELD
as criteria. There was no difference in patients removed between the two scenarios
because the MELDmean in the two scenarios did not differ significantly, and probabilities
referenced from Table 4 resulted in the same number of patients who dropped off of the
waitlist.
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Table 12
MELDmean without delta-MELD
15.8438
14.2018
14.1635
15.1035
14.0263
13.4543
15.5249
13.6922
13.4043
15.2507

16.1996
13.6028
13.2521
16.8286
13.7512
13.2394
14.8552
15.4811
14.9186
14.0098

15.9228
14.2833
12.7992
15.7062
15.3257
14.5611
13.8493
14.9557
13.3764
13.4606

15.1181
15.5608
14.3478
13.9185
15.9791
13.3201
13.5476
15.5131
14.3921
13.1959

13.6869
16.3485
13.2947
13.2357
16.7212
14.0769
13.3461
15.7917
14.5505
14.6224

13.5392
16.6443
13.7007
13.2084
16.3308
15.1372
14.4549
13.6374
15.8038
12.8331

13.7071
16.7870
15.8071
14.4254
13.9717
15.6286
13.9029
13.7224
15.3231
14.1951

Table 12 contains response values of MELDmean from 70 sample interval scenarios
not using delta-MELD as criterion. Its standard deviation was 1.093 and the mean of the
MELDmean values was 14.5467.
Table 13
MELDmean with delta-MELD
15.5884
14.1556
14.0139
15.1584
13.9046
13.2952
15.7462
13.4068
13.2501
14.3009

15.6231
13.6045
13.1232
16.6119
13.6221
13.1861
14.5906
15.5278
14.6899
13.8084

16.4457
14.1657
12.7618
15.5911
15.5583
14.3737
13.7309
14.8153
13.7787
13.3675

15.3546
15.7969
14.2003
14.0714
15.6571
13.4701
13.1515
16.0105
14.1981
13.0653

13.6629
16.6854
13.2199
13.4139
16.9211
13.9819
13.0595
15.4416
14.5525
14.6666

13.5124
17.6333
13.6131
13.2076
16.0705
15.1675
14.1815
13.6918
15.5066
12.6397

13.7133
17.3875
15.8623
14.3658
13.8258
15.7436
13.5878
13.5289
16.4584
14.2691

Table 13 contains response values of MELDmean from 70 sample interval scenarios

142
that used delta-MELD as criterion. Its standard deviation was 1.2010, and the mean of
the MELDmean values was 14.5192.
The values for the t-statistic are as follows.
%= = 70

(32)

,= = 14.5467

(34)

%[ = 70

(33)

,[ = 14.5192

(35)

*[ = 1.2010

(37)

*= = 1.0930

(36)

These values were applied to the formula for the t-statistic described in Chapter 3.
= (14.5467 − 14.5192)/‹(1.0930[ /70) + (1.2010[ /70))

= 0.02750/0.1940

= 0.1417

(38)
(39)
(40)

The critical t value for 69 degrees of freedom is 1.995. The 95% confidence interval was
computed according to the formula,
( 9= – 9[ ) ±

k/[

∗ ‹(•= [ /%= ) + (•[ [ /%[ )

(41)

(Aczel & Sounderpandian, 2008). Applying the appropriate values,
9= = 14.5467,

9[ = 14.5192,
k/[

= 1.995,

(42)
(43)
(44)
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•=[ = (1.0930)[ ,

(45)

%= = 70,

(47)

•[[ = (1.2010)[ ,

(46)

%[ = 70.

(48)

= 0.0275 ± 1.995 ∗ ‹1.1946/70 + 1.4424/70

(49)

= 0.0275 ± 0.3872

(51)

95% confidence interval is

= 0.0275 ± 1.995 ∗ (0.1940)
= (−0.3597, 0.4147).

(50)

(52)

Since t = 0.1417 is not greater than 1.995, or less than -1.995, the null hypothesis
for MELDmean is not rejected. Thus there is insufficient evidence to conclude that there is
a difference in the average MELD score (MELDmean) among pretransplant patients
between simulation models with and without delta-MELD where MELD score is the
primary criteria for patient selection in donor liver allocation.
Results
I can conclude that from the data gathered, there was not enough evidence to say
there was a difference in MELDmean between simulation scenarios with and without using
delta-MELD as decision-making criterion for liver transplant patient selection. Based on
the experimental outcome, I can answer the two research questions.
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Research Question One
Does a simulation model using the additional parameter of delta-MELD as a
patient selection criterion reduce the number of pretransplant patients who dropped off
the waiting list?
There is not enough evidence to say there is a difference in
Total_Patients_Removed between the simulation scenarios with and without delta-MELD
since that difference is 0. Therefore, to answer the research question of whether a
simulation model using the additional parameter of delta-MELD as a patient selection
criterion would reduce the number of pretransplant patients who dropped off of the
waiting list, the answer is no.
Research Question Two
Does a simulation model using the additional parameter of delta-MELD as a
patient selection criterion lower the average MELD score among pretransplant patients?
To answer the research question of whether a simulation model using the
additional parameter of delta-MELD as a patient selection criterion would lower the
average MELD score among pretransplant patients, the answer is also no.
Summary
Based on the simulation results, we conclude that there is no difference in
outcomes whether or not I used delta-MELD as a decision criterion for the liver
allocation system. In Chapter 5, I interpret my experimental results, provide detailed
insights from the results, and provide new ideas for refining the donor liver allocation
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system. These suggestions were based on the observations and limitations of the
simulation data.
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Chapter 5: Research Conclusion
In Chapter 5, I offer my interpretation of the simulation results which leads to
some recommended future studies that would complement this research. These
recommended future studies were based on observations of the OPTN/UNOS data and
limitations of the OPTN/UNOS data for the simulation model. Chapter 5 includes four
sections: A Summary of the Research, Explanation of Simulation Results,
Recommendations for Future Studies, and Conclusion.
A Summary of the Research
I investigated whether the U.S. donor liver allocation system could be improved
upon by including the delta-MELD parameter into the decision-making process for
patient selection. More specifically, I evaluated the influence of the delta-MELD
parameter on the MELDmean and Total_Patients_Removed response variables in a
simulation model. The model was based on Kalman estimation of missing MELD scores
for the computation of delta-MELD values, and the AHP algorithm for decision-making.
The main objective was to compare the outcome of the decision-making using deltaMELD against the decision-making not using delta-MELD as a criterion for patient
selection. I used t tests for two independent populations to determine whether the
postulated improvement in decision-making was significant enough to justify adding
delta-MELD into the decision-making process for patient selection to refine the liver
allocation system.
As detailed in Chapter 4, Pilot Testing and Verification of the Simulation Model, I
verified the simulation model’s four processes through pilot testing and verified that the
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simulation processed the UNOS STAR data correctly and as intended. From the
simulation, I learned that the UNOS STAR data used in the simulation, such as the
MELD average, the limitation of data to only OPO Region 9, and the exclusion of HCC
and status 1 patients can make a difference in the simulation outcome. As a result of a
rigorous verification and validation process, I believe the simulation model can be used in
future research, particularly with data from other OPO regions that have higher MELD
averages than OPO Region 9.
The simulation results showed that given the limitation of data from OPO Region
9, exclusion of HCC and status 1 patients, and sample intervals of 180-days, the results
were not enough to be statistically significant given my sample size, level of significance,
and hypothesis tests. From the simulation results based on the UNOS STAR data that I
used, there was insufficient statistical evidence to conclude that including the deltaMELD parameter for decision-making could improve the liver allocation system. The
simulation results showed that there was a slight improvement in the liver allocation
system, a small drop in average MELD, and this may be operationally significant. Even a
modest improvement to the donor liver allocation system, like a 1% reduction of patients
removed from waitlist or lowering of the average MELD, could mean saving additional
lives when refining the allocation system. Freeman (2009) explained that the deltaMELD parameter may have more variability near the end-stage of patients’ liver disease.
This suggests that an evaluation of the delta-MELD of patients who dropped off the
waitlist should be analyzed against patients who remained on the waitlist, while
extending the simulation sample interval from 180 to 360 days in future research. The
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duration of the simulation sample intervals may not have been long enough when
evaluating the influence of delta-MELD up to 180 days, as the median wait time for liver
transplant is 11 months (Gift of Life Donor Program, 2014). Hence, future research
should be performed by updating the simulation sample intervals from 180 to 360 days to
ensure that the duration of simulation intervals would be sufficient for all expected
outcomes to occur in its due time.
Explanation of Simulation Results
The simulation results failed to provide sufficient statistical evidence to reject the
null hypothesis and to then conclude that the use of delta-MELD values were influential
on the simulation’s response variables. Looking more closely at the UNOS STAR data
and the simulation results to explain this outcome, I observed that for most patients, their
delta-MELD scores did not change by much within a short timeframe such as within a
month; and when their delta-MELD scores did change, their MELD scores did not always
increase. Many times the MELD scores decreased. There were not many patient cases
where the delta-MELD increased significantly along with a high MELD score. This may
be because when such cases occur, the statuses of these patients are changed to status 1,
where these patients are then removed from the waitlist. Status 1 patients are normally in
ICU with less than 7 days to live (Cherkassky, 2011). Status 1 and HCC patients undergo
additional decision-making based on physicians’ knowledge and experience, such as
exception MELD point assignment or deciding whether a status 1 patient should undergo
transplant after all, that are outside of the decision-making of the OPO’s hierarchy of
priority levels for liver allocation. The additional decision-making for these patients
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should be researched and implemented in an updated simulation model, and these
patients should be included in future study.
In my research, I replicated the decision-making process of the OPO’s hierarchy
of priority levels into the simulation, used actual MELD data of patients and donor livers
from OPO Region 9 of the United States from 2008-2012, and used Kalman estimation to
get uniformed and unbiased delta-MELD values. While the simulation reflected OPO’s
hierarchy of priority levels of the liver allocation system and I used actual donor liver and
patient data, I excluded status 1 and HCC patients, as these subgroups go through
additional decision-making for patient selection. However, when Young et al. (2006)
concluded that there was value in using both MELD and delta-MELD in decision-making
regarding donor liver allocation, all patients listed for liver transplant between July 1998
and June 2003 from St. James University Hospital in the U.K. of their study were
included. Young et al. explained that their data included all patients who were removed
from or died on the waiting list during this period. Data collected included demographic,
clinical, survival, and donor data that had been prospectively recorded in the U.K.
transplant database (p. 332). This means that patients who were the equivalent of status 1
and HCC patients of the United States were included. Freeman (2009) explained that
delta-MELD has been associated with increased waiting list mortality and the most
significant changes in delta-MELD tend to occur late in the course of the disease. This
leads me to conclude that the delta-MELD should be studied among status 1 and HCC
patients with simulation sample intervals extending to 360 days, as well as analyzing the
utility and survivability aspects of liver transplants of these patients.
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On the other hand, in my study, the MELD average from OPO Region 9 is 20,
which is much lower compared to the MELD averages from other studies in the literature
review. Quante et al (2012) explained that in Germany, there has been a steady increase
in the MELD average. In 2010, the MELD average for standard liver allocation was 34
points, without standard exceptions and without high-urgency status. This is 14 MELD
points higher than the MELD average in OPO Region 9 of the United States for a similar
time frame of 2008-2012. A higher MELD score reflects a more urgent need of a liver
transplant and a condition closer to the end-stage of liver failure, which is accompanied
by more variability in the delta-MELD (Freeman, 2009). Hence, other OPO regions and
other countries that use the MELD system that have higher MELD averages than OPO
Region 9 are also suitable for future studies regarding the use of the delta-MELD
parameter.
Another observation to note regarding the simulation results was that there were
instances where donor livers could not be matched to patients on the waitlist. The
simulation model did not handle the occurrence of the case where an available donor liver
needs to be transferred to another OPO. This suggests that there could be benefits for
patients to enroll into another OPO in order to increase their chances of getting an earlier
transplant. A study should be conducted to evaluate the decision-making of patients
deciding on whether to stay in the current waitlist or enrolling into another or nearby
OPO that has a shorter wait time.
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Recommendations for Future Studies
Myers et al. (2013) explained that multiple studies used the UNOS STAR
database for refining the liver allocation system. Similarly, in this study, the UNOS
STAR database was referenced to identify patients registered on the liver transplant
waiting list in the United States. In fact, the data inclusion and exclusion criteria of this
study were similar to the study of Myers et al. These criteria excluded patients listed for
multiple organs and live donor liver recipients, and status 1, temporarily inactive, and
HCC patients. Patients with missing laboratory data necessary for calculation of MELD
were excluded as well (p. 2). A more complete model would have included a separate
study for some of these subgroups as these subgroups were excluded from this deltaMELD study.
Additionally, applying a modeling perspective into a research topic such as this
one matters because it provided a basis on how to extend this research. Expanding this
research could mean going beyond the limitations of pretransplant data such as to include
posttransplant data for the study of survivability. Young et al. (2006) explained that the
usefulness of MELD can be enhanced if it could also predict posttransplant outcomes in
some way. Predicting posttransplant outcome could enable a more rational utilization of
scarce resources to achieve the maximum benefit. Also, a modeling perspective could
provide a basis for the analysis of donor liver allocation beyond the geographical location
of UNOS Region 9 which covers New York and western Vermont to a geographical
expanded region covering all of continental United States.
Pidd (2010) explained that some models are intended for routine use on a frequent
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basis, with little or no human intervention. Other models provide assistance to the human
decision process. Model validation and data requirements can add value or provide
insights to possible pitfalls that can lead to a theory. But most importantly, modeling is
grouped into four categories. These four categories of decision modeling are decision
automation, routine decision support, investigation and improvement, and generation of
insights for debate (p. 14). The models of AHP and Kalman estimation models can be
extended into new and future research for the study of posttransplant survivors, for
patients that were in the exception subgroups, and for an expanded geographical UNOS
region, for the purpose of decision support, and investigation and improvement to the
allocation system, as well and generation of insights for discussion.
Schaubel et al. (2009) explained that currently, patients awaiting deceased-donor
liver transplantation were primarily prioritized by medical urgency. More specifically,
waitlist chronic liver failure patients are sequenced in decreasing order of MELD scores.
In order to maximize lifetime gain through liver transplantation, posttransplant survival
should also be considered in the prioritization of liver allocation for patients on the
waiting list. Schaubel et al. evaluated that a survival benefit-based system should be
applied for allocation of deceased-donor livers to chronic liver failure patients. Under
this proposed system, the transplant survival benefit score would be computed for each
patient active on the waiting list (p. 1). Schaubel et al. also explained that this proposed
score should be based on the difference in 5-year mean lifetime (with vs. without a liver
transplant) and should account for patient and donor characteristics. There is an overlap
in the distribution of benefit score across MELD categories, since waiting list mortality is
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significantly affected by several factors (p. 1). Schaubel et al. further argued that their
simulation study results indicated that over 2,000 life-years could be saved if benefitbased allocation was implemented. Schaubel et al. explained that while the shortage of
donor livers increases, the need to maximize the life-saving capacity of procured livers
has become more pressing. Allocation of deceased-donor livers to chronic liver failure
patient efficiency could make the liver allocation system more effective by also
prioritizing patients based on transplant survival benefit (p. 1).
Schaubel et al. (2009) further explained that one can envision an extreme case
where medical urgency-based allocation does not result in fewer deaths, but merely shifts
mortality from the pretransplant to the posttransplant side. Conversely, a utility-based
allocation system would ensure that transplanted organs are received by patients with
lowered posttransplant mortality. However, patients with the best posttransplant
outcomes may also have the best waiting list outcomes. In an extreme case, an ordering
that is based on utility could also result in transplantation having no effect on the
mortality experience of the patient population, since the low death rate faced by the lowrisk patients is merely traded for a low posttransplant death rate. In both cases, the
lifetime experienced by the patient population is equal to that in the absence of access to
transplantation (p. 2).
Pidd (2010) also explained that operations research/ management science
modeling is an external and explicit representation of a part of reality that is seen by
people who use models to understand, change, manage, and control that part of reality (p.
10). It is not really so important whether a model is based on a sophisticated
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mathematical formulation or whether it is just a simple flow diagram showing how
entities are believed to relate to one another. It is more important to recognize that
models are approximations, built with intended use in mind and that models are the
product of human thought and ingenuity (p. 14). Therefore, specific and additional
models can be built for that part of the allocation model that deals specifically on
exception subgroups or status 1 patients where different sets of decision-making criteria
are usually implemented.
Regarding exception patient groups, Bernal et al. (2010) explained that acute liver
failure which is one of the major exception groups within status 1 patients is the clinical
manifestation of sudden and severe hepatic injury which can arise from many causes.
After abrupt loss of hepatic metabolic and immunological function, it leads to hepatic
encephalopathy, coagulopathy, and in many cases progressive multi-organ failure.
Although uncommon, this illness occurs mostly in young adults and is associated with
high mortality and resource cost. In many countries, it is the most frequent indication for
emergency liver transplantation. In the past 10 years, there have been major changes in
the understanding of the cause and pathogenesis of this disease.
Bernal et al. (2010) further explained that the main causal agents for the hepatic
injury that triggers the onset of liver failure show wide geographical variation, and is
normally dependent on the prevalent hepatotoxic virus infections and patterns of drug
use. In the developing world, viral causes predominate, with infection by hepatitis A, B,
and E viruses accounting for most cases. By contrast, acute viral infection is an
uncommon cause in the United States and much of Western Europe, where drug induced
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liver injury instead, predominates (p. 190). Bernal et al. further explained that druginduced injury is the second main cause of acute liver failure and predominates in much
of the developed world. In the United States and northern Europe, non-prescription
paracetamol (acetaminophen) is the analgesic that is most commonly consumed in
overdose, either inadvertently or with intent for deliberate self-harm. Paracetamolinduced hepatoxicity is characteristically hyper-acute from of acute liver failure (p. 3).
Perhaps this subgroup could be a candidate group for future research simulation of deltaMELD.
For these cases of acute liver failure, survival has been transformed by the
introduction of emergency transplantation, which is now part of routine care in many
countries for those patients with acute liver failure who meet criteria indicative of a poor
prognosis. However, emergency transplantation outcomes are consistently lower than
those of elective surgery, with high early posttransplant mortality. Surgical outcomes
have shown progressive and substantial improvement, where 1 year survival exceeds
80% (Bernal et al, 2010). However, the ideal means for identification and selection of
patients who are likely to benefit from emergency liver transplantation remains
controversial. Inaccurate selection will have serious effects where a patient who would
otherwise have survived with medical management and who has incorrectly received a
transplant will be subjected to an unnecessary surgical procedure and lifelong
immunosuppression, which is associated with major resource cost and increased risk of
death. But more significantly, a graft that could have been used for a more suitable
candidate would have been lost. The result of failure to identify a patient with acute liver
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failure who would have survived only with emergency liver transplantation is of equal
magnitude, because of a potentially preventable death (p. 196). This suggests that the
delta-MELD parameter could be an area of focus for these subgroups in future research.
Finally, Pidd (2010) argued that the view of complexity can be the property of a
real-world system that has manifested from the inability to apply any one formal method
as being adequate to capture all its properties. A single approach may not be sufficient to
capture the rich behavior of real-world systems. Hence, a single model may not be
sufficient to fully represent its behavior. This is not based on the view that different
interpretations are due to cognitive limitations, but that different interpretations may be
necessary to provide clarity and understanding to the problem (p. 15).
Pidd (2010) argued that in many simulation studies, complexity is a function of
the number of elements in a system and of the number of interactions between the
elements. This definition treats complexity as an issue of scale and is better regarded as
being concerned with complicated, rather than complex, systems (p. 15). In the context
of complexity, Feglar and Levy (2005) explained that methods of AHP and ANP are
powerful for combatting complex system requiring decision-making with tradeoff
considerations. At the same time, design of an appropriate hierarchical structure (AHP)
can help in setting up the control structure (ANP). An additional application of these
methods could be significantly simplified when integrated with decision models such as
benefits, opportunities, cost, and risk (BOCR) models, to a simulation framework. Feglar
and Levy suggested using AHP and ANP methods while synthesizing BOCR models.
Future studies of the donor liver allocation system can be applied in a nation-wide scope
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by covering the continental United States while integrating the BOCR model into
multiple AHP regional decision-making models. This would enable various decisionmaking considerations to be taken into account, such as meeting survivability, travelling
time that add risks to the donor liver’s cold ischemia time, and the number of patients on
the waitlist.
Finally, the social change implication of this research is that donor liver allocation
systems in the United States, Europe, and Brazil can continuously be made more efficient
to save more lives through liver transplant. The MELD and MELD-based modeling has
been studied world-wide, and the MELD and MELD-based modeling has continued to
attract researchers from the areas of medicine, health science, and decision-science
management disciplines. As new research and additional findings help to refine the liver
allocation system, the opportunity to effect social change of the liver transplant
community through the discipline of operation research techniques and modeling
continues to be a crucial role.
Conclusion
In this study, I investigated whether the donor liver allocation system could be
improved by including the delta-MELD parameter into decision-making for selecting a
matching recipient. The variables for analysis in the simulation were the average MELD
scores and the number of patients who dropped off the waitlist. In this study, I created a
simulation that mimics the actual U.S. donor liver allocation system. The simulation
model was based on Kalman estimation of MELD score progression and the AHP, an
operations research technique for decision-making. The main objective was to compare
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the outcome of decision-making using delta-MELD against decision-making not using
delta-MELD as a criterion for patient selection. Statistical t tests were used for statistical
analysis and comparison. This simulation did not result in an improvement in patient
average MELD scores or patient wait time after reviewing the data and final results of the
simulation. Although a gap in literature in determining the usefulness of the delta-MELD
parameter towards a significant improvement in the donor liver simulation system is
closed, there are still unanswered cases of whether, due to the research scope, deltaMELD could have been an effective criterion for excluded subgroups.
While this research did not show a significant impact from using delta-MELD in
decision-making in a simulation, this research led to the recommendations for future
research to study decision-making using delta-MELD for status 1 patients with acute liver
failure, analyze the survivability objective with posttransplant data, and study the
different dynamics of integrating regional OPOs into a nation-wide study.
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Appendix A: Kalman Filter and Error Ellipse
A state space model consists of two equations: the state equation and the
observation equation. The essential difference between the state-space model and the
conventional linear model representation is that the state space nature is not assumed to
be constant but can change with time. This dynamic feature is incorporated and reflected
in the transition equation.
In the example of Kalman filter, the state vector is (MELD, deltaMELD). The
state space nature is not assumed to be constant but can change with time. This dynamic
feature is reflected in the transition equation. The transition equation would project the
current MELD and the delta-MELD values, patient’s progression of liver disease to a
specific time. In a state space system, the state vector can be propagated to the specific
time when a donor liver is made available and upon a change in a patients’ health status.
The covariance matrix can also be propagated to the time when an available liver is made
available or upon a patient’s health status is updated. The eignenvalues of the
corresponding covariance matrix are computed and use these eigenvalues are used to
derive an error ellipse. The state vector is propagated to an instance in time as follows

where x is MELD and y is deltaMELD.
∆9 = ∆ ∗ 9
∆6 = ∆ ∗ 6
’ℎ

,

,

∆ = N“”•V7 − N†V–
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Tval is the last valid time of state vector, and Tupdate is the time of current update.

9 =

6 =

,

(A4)

,

(A5)

Xdot is the rate of X, and Ydot is the rate of Y. Tupdate is the time of current update,
and Xdot and Ydot are the X and Y rates of change of the MELD score progress.
The covariance matrix is computed to propagate the covariance matrix to time
tupdate, where TMELD is the current MELD score and TdeltaMELD is the current deltaMELD.
The 4 x 4 covariance matrix is computed from the patients’ last health update.
The covariance matrix use the matrix equation,
`^z= = —`^ ψ™

(A6)

to propagate the 4 x 4 covariance matrix of MELD score update.

Pk+1 is the covariance matrix valid at time t + 1,
ψ is the transition matrix,

Pk is the covariance matrix from the matrix valid at time t, and
ψT is the transpose of the transition matrix.

Using matrix equation, Pk+1 = ψPkψT, we calculate this into its final algebraic form.
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where Pk+1 is the covariance matrix valid at time tupdate. ψ is the transition matrix Pk is

the covariance matrix from the MELD score update matrix valid blood work at time Tval.

ψT is the transpose of the transition matrix.
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The algebra for the covariance propagation is computed as follows.
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The elements of the 2 x 2 covariance matrix needed for the error ellipse

calculation are as follows.
(•,)[ = •s[

(A20)

(•®)[ = •¯[ .

(A22)

•,® = •s¯ ,

(A21)
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To calculate the eigenvalues of the 2 x 2 covariance matrix, the eigenvalues and
the roots of the characteristic equation of a matrix are calculated by determining the
following.
B

,=

N(H − °$) = 0
,

(A23)

®=

.

In the case of our 2 x 2 covariance matrix, we get the following.
[
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The following steps calculate out the following.
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When in its equation into its quadratic form, we have,
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Then λ1 and λ2 are as follows, and they would be used to formulate our error ellipse.
°= = (−H + √H[ + 4ª)/2

°[ = (−H − √H[ + 4ª)/2
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The elements of a covariance matrix include σ2x , σ2y , and σ2xy , where the
eigenvalues of λ1 and λ1 are derived to provide the axes for the Error Ellipse. The aspect
ratio of the ellipse,

(∆®/®) / (∆,/,)

(A36)

is computed which is the counter-clockwise rotation angle of the ellipse as follows.
H

=½∗
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((1/ EJ

) ∗ 2•s¯ /(•s[ − •¯[ ))

(A37)

Since σx and σy represent the standard deviations of stochastically independent

random variables, additional theorem for the chi-square distribution can be used to show
that the probability associated with a confidence ellipse is given by p = 1 – e –(1/2)k^2.
Conversely, the semimajor (k * σx) and semiminor (k * σy) axes of a confidence ellipse
having specified probability p can be calculated from (σx, σy).
P = ‹(−2 ∗

(1 − J))

(A38)

Hence, the error ellipse is a confidence ellipse with elliptical scale factor k = 1

and probability approximately p = 0.3935. The 50% and 95% confidence ellipses have
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elliptical scale factors approximately 1.1774 and 2.4477, respectively (Hoover, 1984).
If σx > σy, then the semi-axis length parallel to the x-axis is equal to
wmax(eigenvalues) *

scalefactor is computed. Then the semi-axis length parallel to the

y-axis is equal to wmin(eigenvalues) * scalefactor.

If σy > σx, then the semi-axis length parallel to the x-axis is equal to
wmin(eigenvalues) *

scalefactor is computed. The semi-axis length parallel to the y

axis is equal to wmax(eigenvalues) * scalefactor. The ellipse can now be rotated

counter clock-wise from this orientation (angle).

174
Appendix B: Analytic Hierarchy Process (AHP)
Saaty (1996) developed the analytic hierarchy process (AHP) and stated that AHP
is a general measurement that derives ratio scaled values from both discrete and
continuous paired comparisons of multilevel hierarchy structures. These comparisons
can be taken from actual measurements or from a fundamental scale that reflects the
relative strength of preferences and feelings. AHP is widely used for multiple criteria
decision-making in planning, resource allocation, and conflict resolution. In using the
AHP to model a problem, one would need a hierarchy or a network structure to represent
the problem. Pairwise comparisons are used to establish relations within the hierarchy or
network structure.
Saaty (1996) explained that the AHP is a heuristic algorithm for scoring multiple
criteria and alternatives in decision-making. AHP is best demonstrated by reviewing its
step with an example. The details of the three major AHP algorithm steps are as follows.
1. Develop the weights for the criteria.
a. Develop a single pair-wise comparison matrix for the criteria.
b. Multiply the values in each row together and calculate the nth root of the
product.
c. Normalize the nth root of products to get the appropriate weights.
d. Calculate and check the Consistency Ratio.
2. Develop the ratings for each decision alternative for each criterion.
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a. Develop a pair-wise comparison matrix for each criterion, with each matrix
containing the pair-wise comparisons of the performance of decision
alternatives on each criterion.
b. Multiply the values in each row together and calculate the nth root of the
product.
c. Normalize the nth root of product to gate the corresponding ratings.
d. Calculate and check the Consistency Ratio.
3. Calculate the weighted average rating for each alternative. Then choose the one
with the highest score.
The following demonstrates the above steps with an example of decision-making
for selecting a liver transplant recipient. The criteria of the example are MELD score,
blood type, and body structure. Furthermore, the decision alternatives are three possible
alternatives (patients). Pair-wise comparison is used to establish the relative priority of
each criterion against every other criterion. Then the relative priority of the alternatives
is pair-wise compared against every other alternative for each criterion.
The main element to the AHP technique is the use of pair-comparisons. The pairwise comparisons use a scale that ranges from equally preferred to extremely preferred.
The following illustrates the values associated with the level of preference used to scale
the results of pair-comparisons.
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Table B1
Paired Comparison: Value-Description
Value
1
2
3
4
5
6
7
8
9

Description
Equally preferred
Equally to moderately preferred
Moderately preferred
Moderately to strongly preferred
Strongly preferred
Strongly preferred to very strongly preferred
Very strongly preferred
Very strong
Extremely preferred

In the example below, the value “9” is used to denote that the preference of MELD score
is “extremely preferred” over body structure. Also, as indicated in the example the
MELD score is “moderately preferred” over blood type. When comparing blood type to
body structure, the paired comparison shows that blood type is “strongly preferred”
(number 5) over body structure.
Table B2
AHP Table of Weights of the Criteria
MELD
MELD
Blood Type
Body Structure
Sum
Sum*PV
LambaMax
CI
CR

1
0.33333333
0.11111111
1.44444444
0.97012565
3.02906377
0.02906377
0.05019004

Blood Type
3
1
0.2
4.2
1.11482004
NA
NA
NA

Additional notes on Table B2 are as follows.

Body
Structure
9
5
1
15
0.94411808
NA
NA
NA

3rd root of
product
3
1.1856311
0.2811442
4.4667753
3.0290637
NA
NA
NA

Priority
Vector
0.67162545
0.26543334
0.06294121
1
NA
NA
NA
NA
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1. The “Sum” row is the value of the sum of the criteria column (Ex: MELD
Column = 1 + 0.33333333 + 0.11111111).
2. The “3rd Product Root” is the product of the row of criteria (Ex: MELD row = 1 *
3 * 9) taken to the 3rd root divided by the sum of all 3rd Product Root.
3. The “Sum * PV” row is the value of the sum of the previous row times the
corresponding “Priority Vector”.
4. The “LambdaMax” value is the sum of all “Sum*PV” values.
5. The “Consistency Index” is the value of “LambdaMax” minus 3. 3 is the number
of criteria.
6. The “Consistency Ratio” is computed by taking the “Consistency Index” and
dividing by 0.58. 0.58 is the value to divide for three criteria.
Now suppose that there are three alternatives (three types of patients). And these
three types of patient are the AHP alternatives that have the highest MELD score within a
Transplant Center (TC), an alternative whose MELD score is the next highest within the
same Transplant Center, and an alternative of highest MELD score outside of the
Transplant Center where the donor is. In this example, the hierarchy of priority is such
that the highest priority is the alternative with the highest MELD score within the same
Transplant Center. The next in priority is the next highest MELD scoring alternative
outside of the Transplant Center but within the same OPO. If there are no suitable
recipients within the OPO, then the highest MELD scoring alternative outside of the OPO
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is selected. We now develop the ratings for the each alternative with respect to each
criterion (MELD, blood type, and body structure).

Table B3
AHP Table of Weights of Alternatives according to MELD
Highest
MELD in
TC
Highest
MELD in
same TC
Next Highest
MELD in TC
Highest
MELD out of
TC but within
OPO
Outside of
OPO
Sum
Sum*PV
LambaMax
CI
CR

1

Next
Highest
MELD in
TC
5

Highest
MELD out
of TC but
within OPO
5

Outside
of OPO

4rd root
of
product

Priority
Vector

7

3.63713

0.62248

0.2

1

3

5

1.44225

0.246835

0.2

0.2

1

5

0.58480

0.100086

0.1428571

0.2

0.2

1

0.17878

0.030597

1.5428571
0.9603987
4.011670
0.0116969
0.0129966

0.2
1.579744
NA
NA
NA

0.2
0.92079
NA
NA
NA

1
0.55076
NA
NA
NA

1.78781
4.01169
NA
NA
NA

0.030597
NA
NA
NA
NA

Additional notes on Table B3 are as follows.
1. The “Sum” row is the value of the sum of the criteria column (Ex: Column = 1 +
0.2 + 0.2 + 0.1428571).
2. The “4th Product Root” is the product of the row of criteria (Ex: Row = 1* 5 * 5 *
7) taken to the 4th root divided by the sum of all 4th Product Root.
3. The “Sum * PV” row is the value of the sum of the previous row times the
corresponding “Priority Vector”.
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4. The “LambdaMax” value is the sum of all “Sum*PV” values.
5. The Consistency Index (CI) above is the value of “LambdaMax” minus 4. 4 is the
number of criteria.
6. The Consistency Ratio above is computed by taking the Consistency Index (CI)
divided by 0.90. 0.90 is the value to divide by for four criteria.
Table B4
AHP Table of Weights of Alternatives according to Blood Type
Highest
MELD in
same TC
Highest
MELD in
same TC
Next Highest
MELD in TC
Highest
MELD out of
TC but within
OPO
Outside of
OPO
Sum
Sum*PV
LambaMax
CI
CR

1

Next
Highest
MELD in
TC
1

Highest
MELD out
of TC but
within OPO
1

Outside
of OPO

4rd root
of
product

Priority
Vector

1

1

0.25

1

1

1

1

1

0.25

1

1

1

1

1

0.25

1

1

1

1

1

0.25

4
1
4
0
0

4
1
NA
NA
NA

4
1
NA
NA
NA

4
1
NA
NA
NA

4
4
NA
NA
NA

1
NA
NA
NA
NA

The values on Table B5 are similarly derived as the values from Table B4. The
paired comparisons of the alternatives are all identically preferred over each other.
Hence the Priority Vectors are 0.25 each for all four alternatives.
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Table B5
AHP Table of Weights of Alternatives according to Body Structure
Highest
MELD in
TC
Highest
MELD in
same TC
Next Highest
MELD in TC
Highest
MELD out of
TC but within
OPO
Outside of
OPO
Sum
Sum*PV
LambaMax
CI
CR

1

Next
Highest
MELD in
TC
1

Highest
MELD
score within
OPO
1

Outside
of OPO

4rd root
of
product

Priority
Vector

1

1

0.25

1

1

1

1

1

0.25

1

1

1

1

1

0.25

1

1

1

1

1

0.25

4
1
4
0
0

4
1
NA
NA
NA

4
1
NA
NA
NA

4
1
NA
NA
NA

4
4
NA
NA
NA

1
NA
NA
NA
NA

Similar to Table B4, the values in Table B5 are similarly derived by paired
comparisons. The paired comparisons of the alternatives are all identically preferred over
each other. Hence the Priority Vectors are 0.25 each for all four alternatives. Finally,
Table B6 shows the calculations of the weighted average rating for each decision
alternative. The highest weighted average rating is selected as the “Winner”.
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Table B6
AHP Table Ranking of Alternatives
Criteria
and
Alternatives
Highest
MELD in
same TC
Next Highest
MELD in TC
Highest
MELD out of
TC but within
OPO
Outside of
OPO

MELD

Blood
Type

Body
Structure

Sum

Multiplier

0.671624

0.265433

0.062941

1.12248

0.50016

0.2468350

0.25

0.25

0.74683

0.24787

0.1000867

0.25

0.25

0.60008

0.14931

0.030597

0.25

0.25

0.53059

0.10264

Winner
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Appendix C: Simulation Programming Notes
The simulation Graphical User Interface (GUI) panels allow the simulation
experiments to be broken into logical steps. The simulation allows the user to choose the
interval data or pilot test to run, and provides simulation GUI panels and output file for
simulation verification and data analysis of scenario and pilot runs. Below are the
simulation GUI panels and their corresponding programming notes.
Initialize Data Panel

Figure C1. Initialize data panel.
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Programming Notes:
1. Upon selection of Select Data push button, Patient data that include age group,
gender, race, primary cause of disease, transplant history, blood type, MELD
scores, date of MELD scores, time on wait list, and status are initialized. This
Patient data are translated from the UNOS STAR database depending on the
interval selection or pilot dataset.
2. Donor Liver data that include donor age, donor height, donation after cardiac death
donors, split liver donors, race, donor’s cause of death by cerebrovascular accident,
regional sharing, local sharing, and cold ischemia time are initialized. This data are
translated from the UNOS STAR database depending on the interval selection or
pilot dataset.
3. Patient data also include the additional initialized fields of patient ID, interval ID,
and Day_# fields.
4. Donor Liver data also include the additional initialized fields of Donor ID,
interval ID, ECD/ECD-1 year/SCD status fields. Day_# is cleared here and set by
the Setup Scenario(s) panel.
5. Patient data processing is prescreened for Waitlist Entry processing of new
patients by ensuring new patients have multiple MELD scores and that their
waitlist start dates exist.
6. Patient data processing is prescreened for patients with non-HCC disease, nonstatus 1 patients, and having completed laboratory or survival data. Hence, there
are 100 patient records per user defined interval and 130 donor liver records
annually.
7. Patient data processing include prescreening for MELD scores on the day of
transplant as well as at least 30 days prior to medical transplant.
8. The AHP decision table parameters are initialized for the simulation of decisionmaking where the delta-MELD is not used as a criterion according to AHP
Weights and Ranking without delta-MELD table.
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9. The AHP decision table parameters are initialized for the simulation of decisionmaking where the delta-MELD is used as a criterion according to AHP Weights
and Ranking with delta-MELD.
10. Initialize the Recipient and Donor Risk factor tables.
11. Patient data, Donor Liver data, and Disease Progression data updated into the
Initialize Data panel are also updated onto the Simulation Progress panel for data
analysis of scenario runs and simulation verification of pilot runs.
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Setup Scenario(s) Panel

Figure C2. Setup scenario(s) panel.
Programming Notes:
1. Upon selection of (Pilot Test Setup radio button or Patient Data Setup radio button),
and Set up Scenario / Pilot push button, perform the following steps.
2. Upon selection of the Patient Data Setup radio button and Set up Scenario / Pilot
push button, the program ensures that the scenarios for including and not including
delta-MELD are setup consistently in patient data regarding the patients’ arrival
times (day_#s) into the simulation event queue.
3. Upon selection of the Patient Data Setup radio button and Set up Scenario / Pilot
push button, the program ensures that the corresponding Donor Liver data are set up
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consistently regarding the interarrival times and donor liver parameters for both
scenarios including and not including delta-MELD into the event queue. The day_#
is processed randomly by a Poisson function.
4. Once Patient and Donor Liver data for a specified time interval are setup, that
specified scenario can be run. A new setup would override an existing setup.
5. Upon selection of Patient Data Setup radio button and selection of a 180-day
interval, the liver quality of type SCD, ECD 1-year, or ECD is determined.
6. The programming of both Patient and Donor Liver data are setup up consistently,
such that patient and donor liver arrival times (day_#s) for both without and with
delta-MELD scenarios are the same.
7. The programming of donor liver types are setup randomly but consistently in both
scenarios with and without delta-MELD, and the liver types are based on the
proportion of OPTN data.
8. The Patient Entry, Donor Arrival Liver, and Waitlist Patient Management simulation
process data are setup as event messages queued for the Run Scenario(s) panel to be
processed.
9. Compute the derived parameter DRI based on the Donor Livers’ donor risk factors.
10. The Patient Entry, Donor Arrival Liver, and Waitlist Patient Management event
messages are updated onto the Simulation Progress panel for data analysis in
scenario runs and simulation verification in pilot runs.
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Run Scenario(s) Panel

Figure C3. Run scenario(s) panel.
Programming Notes:
1. The Run Scenario(s) panel takes scenario event messages (Patient, Liver, or
Waitlist Patient Mgmt. messages) and their day_# setup by Setup Scenario(s), and
run the simulation processes of Waitlist Entry, Donor Liver Arrival, and Waitlist
Patient Management processes.
2. Each message processed are updated in the Scenario Runs / Pilot Test Event
Message(s) text area and Simulation Progress text area.
3. The Run Scenario(s) panel also processes the simulation Disease Progression
process for 180 days (iterations).
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Programming Notes (Waitlist Entry):
1. A patient is entered into the waitlist by the day_# (there are 180 days in each
scenario and pilot run).
2. Upon patient’s waitlist entry, the program ensures that the number of patients
entering into the waitlist is being tallied at the end of each week.
3. Patient’s waitlist entry along with initial MELD and MELD dates are updated into
the Simulation Progress text area for data analysis of scenario runs and simulation
verification of pilot runs. The Simulation Progress panel would tag this data as
from the Waitlist Entry process.
Programming Notes (Donor Liver Arrival):
1. The Donor Liver Arrival’s output data includes the ECD/SCD status, DRI score,
whether a patient has accepted an ECD liver if donor liver is an ECD, patient
MELD, AHP scores, and the number of SCD and ECD livers.
2. Upon arrival of an ECD or ECD 1-year, the simulation would determine whether
a patient would accept an ECD 1-year or ECD by a random function with a
chance of 25% or 15%.
3. The Donor Liver Arrival process computes the AHP scores for all the patients on
the waitlist.
4. The parameters of DRI and SOFT scores are computed upon the arrival of a donor
liver according to the formula that is based on donor risks and recipient risks.
Compute the AHP scores for decision-making where the delta-MELD is not used
as a criterion.
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5. Compute the AHP scores for decision-making where the delta-MELD is used as a
criterion and where delta-MELD and AHP scores are calculated as follows.
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(C2)

(C3)

6. Patients are prioritized on the waitlist according to blood type by descending AHP
scores. The livers are offered to the waitlist patient with the highest AHP score,
patient consent to accept ECD liver if liver is ECD or ECD 1-year, and blood type
identical to the patient. To avoid an inequitable distribution of organs, blood type
O livers are only assigned to blood type O patients. If there is a note indicating
the patient is a very small size adult patients or AB-type, that patient would be
listed for more than one blood type.
7. The Simulation Progress panel would be updated of successful patient selection
along with patient ID, liver ID, blood-type, liver type, AHP score, MELD, and
delta-MELD score for data analysis of scenario runs and simulation verification
of pilot runs. This update would be tagged as from the Waitlist Entry process.
Programming Notes (Disease Progression):
1. This Disease Progression process computes the Kalman estimation of MELD and
delta-MELD parameters based on the patients’ MELD parameters, and patients’
covariance matrices.
2. This process references Disease Progression data updated from the Initialization
Data panel and performs a Kalman propagation for every patient.
3. Every patient’s MELD and delta-MELD (Kalman estimation of MELD and deltaMELD) are output into the Simulation Progress text area for data analysis of
scenario runs and simulation verification of pilot runs. The Simulation Progress
panel would tag this data as coming from the Disease Progression process along
with the day_#.
4. The Disease Progression outputs include patient MELDs, delta-MELDs, and
waitlist statuses. Additional outputs include the average MELD scores of patients
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on waitlist and the counts of patients removed from the waitlist,
Patients_Dropped_From_Waitlist, updated at the end of each week for 26 weeks.
5. The risks based on patient risk factors are tallied up and patients with the highest
risks are considered removal based on MELD scores and survival rates. The
survival rates are based on the Hazard Ratios based on MELD Table.
6. The patient waitlist status would be updated indicating whether the patient is still
on the waitlist awaiting for an available donor liver, or who has dropped off from
the waitlist due to being too sick, death, or other reasons.
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8. The Average_MELD(n) and Patients_Dropped_From_Waitlist(n) are updated into
the Simulation Progress text area for data analysis of scenario runs and simulation
verification of pilot runs for week n = 1 through 26. The Simulation Progress
panel would tag this data as coming from the Disease Progression process along
with the week_#s and patient IDs of patients removed.
Programming Notes (Waitlist Patient Management):
1. The Waitlist Patient Management processes the messages indicating patient
statuses have been updated which may require these patients to be removed from
the waitlist depending on the reason description.
2. The patient IDs and the patient statuses are updated into the Simulation Progress
panel for data analysis of scenario runs and simulation verification of pilot runs.
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View Disease Progression Panel

Figure C4. View disease progression panel.
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Programming Notes:
1. Disease Progression output data include interval_#, week ID, patients who
dropped from the waitlist, and average MELD. These fields are tagged “(wo)” for
the scenario without delta-MELD, and “(w/)” for the scenario with delta-MELD.
2. The two dependent variables: Average_MELD for “Avg MELD” and
Patients_Dropped_From_Waitlist for “# Rem” are updated into the View Disease
Progression panel at the end of each week from the Disease Progression process.
3. The dependent variables from scenario or pilot runs are used to compute response
variables MELDmean and Total_Patients_Removed, and are updated as the last
entry of the View Disease Progression panel.
4. Both “Avg_MELD” and “# Rem” dependent variables updated into the View
Disease Progression panel are also updated into the Simulation Progress panel
for data analysis of scenario runs and simulation verification of pilot runs.
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View Liver Arrival Panel

Figure C5. View liver arrival panel.
Programming Notes:
1. To differentiate the data between the scenarios without delta-MELD and with
delta-MELD, the Liver ID field is tagged either with “(wo)” or “(w/)”. “(wo)”
indicates the output is from the scenario without delta-MELD. “(w/)” indicates
the output is from the scenario with delta-MELD.
2. The data fields for scenarios with and without delta-MELD include Liver ID,
Patient ID, blood type, interval #, and Arrival Day and it is updated upon
successful patient selections for transplant from the Donor Liver Arrival process.
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3. The data updated into the View Liver Arrival panel are also updated into the
Simulation Progress panel’s text area where the data can be updated into a log file
for data analysis of scenario runs and simulation verification of pilot runs.
View t tests of two independent populations Parameter Panel

Figure C6. View t test of two independent populations’ parameters panel.
Programming Notes:
1. Statistical tests are computed upon completion of scenario run.
2. The t test of two independent populations parameters for average MELD scores
are computed;

t(MELDmean) =
U VW
U VW
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n = 1 to 10 for pilot test, n = 1 to 70 for experimental run.

x1 is the MELDmean in scenario without delta-MELD,
x2 is the MELDmean in scenario with delta-MELD,
S1 is the standard deviation of MELDmean in scenario without delta-MELD,
S2 is the standard deviation of MELDmean in scenario with delta-MELD,
S12 is the variance of MELDmean in scenario without delta-MELD,
S22 is the variance of MELDmean in scenario with delta-MELD, and
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n = 1 to 70 in experimental run supporting Figure 12.

The t test of two independent populations parameters are computed
for the Total_Patients_Removed response variable;
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i = 1 to 10 for pilot test, i = 1 to 70 for experimental run.
x1 is the Total_Patients_Removed in scenario without delta-MELD,
x2 is the Total_Patients_Removed in scenario with delta-MELD,
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S1 is the standard deviation of Total_Patients_Removed without
delta- MELD,
S2 is the standard deviation of Total_Patients_Removed with delta-MELD,
and
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( ), n is the interval index,
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n = 1 to 10 in pilot test supporting Figure 11,

G s” = ‹(1⁄69) ∑WY= 7Z ~e [N( ) − NV†‡ ][
n = 1 to 70 in experimental run supporting Figure 12.

(C17)

S12 is the variance of Total_Patients_Removed without delta-MELD,
S22 is the variance of Total_Patients_Removed with delta-MELD,
3. The data updated onto the View t test of two independent populations panel are
also updated into the Simulation Progress text area for data analysis of scenario
runs and simulation verification of pilot runs.
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Simulation Progress Panel

Figure C7. Simulation progress panel.
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Programming Notes:
1. Each messages updated into the Simulation Progress panel have the tag of
Initialize Data, Setup Scenarios(s), Run Scenario(s), View Liver Arrival, View
Disease Progression depending on the source of panel output.
2. When messages are generated as a result of the Run Scenario(s), the simulation
process names are also tagged (Waitlist Entry, Disease Progression, Donor Liver
Arrival, and Waitlist Patient Management).
3. The selection of Save to File push button logs all messages from startup of the
simulation GUI into the designated output file.
4. The Message Area text area allows the user to view completion statuses of user
requests and of any simulation’s informational, warning, or error messages.
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Appendix D: Statistics Notes
The F-ratio test was used for testing homogeneity of variances. From an example
of running the pilot test, the standard deviations were computed from Figure D1. These
standard deviations were squared to yield their variances and these variances were set
into an F-ratio, where the smaller of the two variances is the denominator, and the larger
of the two variances is the numerator. The critical value for 25 degrees of freedom for
both variances is 1.35 according to the F distribution critical values table provided by
Aczel and Sounderpandian (2008). From Figure D1, the variances were computed from
the 2008 1st 180 days interval into an F-ratio. The F-ratio is (1.5363)2 / (1.3861)2 =
1.228 and is below the critical value of 1.35. Since the F-ratio of 1.228 is not greater
than the critical value of 1.35, this indicates the variances of the average MELD scores
are homogeneous.
Aczel and Sounderpandian (2008, p. 311) provided the formula for the test
statistic Z, for the comparison of two populations, where the hypothesized value for the
difference in the two population means is (μ1 – μ2).

t=

(st <su )<(vt <vu )
wxtu ⁄yt zxuu ⁄yu

(D1)

The research experiment was about a comparison of MELD scores based on the
same set of arriving donor livers that were applied to the same pool of 100 patients, one
scenario without delta-MELD, one scenario with delta-MELD. The MELD scores were
normally distributed according to a similar study of Kanwal, Dulai, Speigel, Yee, and
Gralnek. (2005). Aczel and Sounderpandian (2008) stated that in the case where X1 and
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X2 each follows a normal distribution, (X1 - X2) would also follow a normal distribution.
It can be verified whether (X1 - X2) assumed a normal distribution (p. 311).
Regarding whether the difference in average MELD scores between the scenarios
with and without delta-MELD is normally distributed, the chi-square test for normality
was utilized. Aczel and Sounderpandian (2008) explained that a chi-square goodness of
fit method requires hypothesizing about the sample set with null and alternative
hypotheses, computing frequencies of where the null hypothesis is expected, providing
the expected counts of data points into different chi-square bins, and computing the
difference between the observed and expected data leading to the chi-square statistics (p.
662). Aczel and Sounderpandian (2008) further explained that a goodness of fit test is a
statistical test that tells whether data would support an assumption relating to a
distribution or random variable. The simulation computed the difference in MELD
averages against its mean, the mean and standard deviation of these differences, and the
z-values that would provide the bin values for the goodness of fit chi-square bins. The
following formula is the chi-square statistics.
¸ [ = ∑(+ˆ –
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for i= 1 to k, where k is the number of fit cells.
The chi-square hypotheses are as follows:
Ho: The differences of average MELD scores are normally distributed.
Ha: The differences of average MELD scores are not normally distributed.
The differences of average MELD means, standard deviations, and variances are
computed. With 26 weeks of average MELD scores, 5 bins are set up, where each bin
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would have 1/5 = 0.20 probability. The bin boundaries of 0.20 probability are translated
to their corresponding z-values which then provide the z value intervals of < -0.84,
(-0.84, -0.255), (-0.255, 0.255), (0.255, 0.84), and >0.84. From the formula of
² = (, – ,

)/E

(D3)

Where s is the standard deviation, and x-bar is the mean, the formula is rewritten in terms
of x,

, = E ∗ ² + ,

(D4)

Table D1 supports the computation of chi-square value based on the differences of
average MELD scores falling into the appropriate bins.
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Figure D1. Goodness of fit-test for normality.
In Figure D1 example, the differences in MELD averages were computed and
they were counted and allocated into Table D1. Table D1 was set up to determine the
chi-square goodness of fit for the normal distribution. The differences of average
MELDs were computed, along with their mean and standard deviation. These values
were utilized to support a Goodness of Fitness computation by setting up bin boundary
values for each of the five bins. Once these boundary values were computed for each bin,
a count of the differences of average MELDs can be performed and be grouped into their
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appropriate bins. Table D1 identifies the computational steps necessary to carry out the
chi-square Goodness of Fit test for normality.
Table D1
Chi-square Goodness of Fit test for Normality
Bin #

Interval

1

<-0.249998

2
3
4
5

Observed
Frequency
(f)
7

Expected
Frequency
(e)
5

(-0.249998,
-0.119605)
(-0.119605,
-0.005940)

6

(-0.005940,
0.124440)
>0.124440

(B –

)

(B –

)[

(B –

2

4

4/5

5

1

1

1/5

1

5

-4

16

16/5

7

5

2

4

4/5

4

5

-1

1

1/5

)[ ⁄

The intervals were computed, with
,

= −0.062773,

E = 0.222873,

² = −0.84, −0.255, −0.255, 0.84.

,ˆ = E ∗ ² + ,

,

(D5)
(D6)
(D7)
(D8)

where i is the interval boundary index,

,= = (0.222873) (−0.84) + (−0.062773) = −0.249998

(D9)

,g = (0.222873) (0.255) + (−0.062773) = −0.005940

(D11)

,[ = (0.222873) (−0.255) + (−0.062773) = −0.119605
,h = (0.222873) (0.84) + (−0.062773) = 0.124440

(D10)

(D12)
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¸ [ = ((7 − 5)[ + (6 − 5)[ + (1 − 5)[ (7 − 5)[ + (4 − 5)[ )/ 5
= (2[ + 1[ + 4[ + 2[ + 1) / 5
= (4 + 1 + 16 + 4 + 1) / 5
= (21 + 5) / 5 = 26 / 5

= 5.2

(D13)

For this example, with 4 degrees of freedom, the chi-square value of 5.2 lies
between the 0.05 and .95 confidence level of the chi-square region, where the
corresponding chi-square value is between 1.06336 and 7.779. The goodness of fit test
did not suggest rejecting the chi-square null hypothesis. Hence, one can conclude that
there is not enough evidence to claim that the MELD scores are not normally distributed.

